,Product,EU Designation,Designated Orphan Indication,Sponsor,Designation date,TradenameEU Centralised NrImplemented on,drug_qid,indication,doid,hpo,ordo,mesh,indication_qid_doid,indication_qid_ordo,indication_qid_mesh
0,"11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",EU/3/10/767,Treatment of post-essential thrombocythaemia myelofibrosis,CTI Life Sciences Ltd,25/08/2010,,,postessential thrombocythemia myelofibrosis,,,,,,,
1,"11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",EU/3/10/768,Treatment of primary myelofibrosis,CTI Life Sciences Ltd,25/08/2010,,,primary myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,,http://www.orpha.net/ORDO/Orphanet_824,D055728,Q1752571,,Q1752571
2,"11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",EU/3/10/769,Treatment of post-polycythaemia vera myelofibrosis,CTI Life Sciences Ltd,25/08/2010,,,postpolycythemia vera myelofibrosis,,,,,,,
3,"11-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-aza-cyclopentadecane-13,15-dione",EU/3/14/1239,Treatment of cystic fibrosis,Synovo GmbH,19/02/2014,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
4,"1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamide",EU/3/14/1281,Treatment of cystic fibrosis,Vertex Pharmaceuticals (Europe) Limited,04/07/2014,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
5,"1,2:5,6-Dianhydrogalactitol",EU/3/12/1093,Treatment of glioma,IDIS Ltd,24/01/2013,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
6,"1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine",EU/3/05/332,Treatment of acute myeloid leukaemia,"Vion (UK) Limited, ℅ i3 Research",14/12/2005,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
7,"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene",EU/3/12/1021,Prevention of poliomyelitis in patients with immunodeficiencies deemed at risk,ViroDefense Ltd,17/07/2012,,,poliomyelitis in patients with immunodeficiencies deemed at risk,,,,,,,
8,"1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one",EU/3/14/1404,Treatment of multiple system atrophy,AstraZeneca AB,16/12/2014,,,multiple system atrophy,http://purl.obolibrary.org/obo/DOID_4752,,http://www.orpha.net/ORDO/Orphanet_102,D019578,Q1541975,,Q1541975
9,"1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride",EU/3/07/459,Treatment of narcolepsy,Bioprojet Pharma,10/07/2007,WakixEU/1/15/106804/04/2016,,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
10,"1,3-Propanedisulfonic acid, disodium salt",EU/3/01/051,Treatment of Systemic Secondary Amyloidosis,C.T. Phinco S.à.r.l.,31/07/2001,,,systemic secondary amyloidosis,,,,,,,
11,"1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one",EU/3/12/984,Treatment of chronic lymphocytic leukaemia,Janssen-Cilag International NV,26/04/2012,IMBRUVICAEU/1/14/94523/10/2014,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
12,"1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one",EU/3/13/1115,Treatment of mantle cell lymphoma,Janssen-Cilag International NV,12/03/2013,IMBRUVICAEU/1/14/94523/10/2014,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
13,1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride,EU/3/15/1475,Treatment of cryptococcosis,"Arno Therapeutics UK, Limited",24/04/2015,,,cryptococcosis,http://purl.obolibrary.org/obo/DOID_12053,,http://www.orpha.net/ORDO/Orphanet_1546,D003453,Q1470140,,Q1470140
14,1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride,EU/3/15/1476,Treatment of tularaemia,"Arno Therapeutics UK, Limited",24/04/2015,,,tularemia,http://purl.obolibrary.org/obo/DOID_2123,,http://www.orpha.net/ORDO/Orphanet_3392,D014406,Q153861,,Q153861
15,16-base single-stranded peptide nucleic acid oligonucleotide linked to 7-amino acid peptide,EU/3/10/789,Treatment of medulloblastoma,Biogenera SpA,01/10/2010,,,medulloblastoma,http://purl.obolibrary.org/obo/DOID_0050902,http://purl.obolibrary.org/obo/HP_0002885,http://www.orpha.net/ORDO/Orphanet_616,D008527,Q1333608,,Q18556102
16,16-base single-stranded peptide nucleic acid oligonucleotide linked to 7-amino acid peptide,EU/3/12/1016,Treatment of neuroblastoma,Biogenera SpA,04/07/2012,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
17,16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7 aminoacid peptide,EU/3/16/1690,Treatment of soft tissue sarcoma,Biogenera SpA,14/07/2016,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
18,16-base single-stranded PNA oligonucleotide linked to a 7-aminoacid peptide,EU/3/09/692,Treatment of neuroblastoma,Biogenera SpA,25/11/2009,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
19,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid,EU/3/14/1361,Treatment of systemic sclerosis,Inventiva,19/11/2014,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
20,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid,EU/3/14/1362,Treatment of idiopathic pulmonary fibrosis,Inventiva,19/11/2014,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
21,177Lu-tetraxetan-tetulomab,EU/3/14/1271,Treatment of follicular lymphoma,Nordic Nanovector AS,04/06/2014,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
22,"(-)-17-(cyclopropylmethyl)-3,14 ß-dihydroxy-4,5 a-epoxy-6ß-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan hydrochloride",EU/3/02/115,Treatment of uremic pruritus,Toray International Europe GmbH,11/09/2002,,,uremic pruritus,,,,,,,
23,"17a,21-dihydroxy-16a-methyl-pregna-1,4,9(11)-triene-3,20-dione",EU/3/14/1309,Treatment of Duchenne muscular dystrophy,ReveraGen BioPharma Limited,22/08/2014,,Q27270940,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
24,1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,EU/3/09/693,Treatment of acute myeloid leukaemia,Astex Therapeutics Limited,26/11/2009,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
25,1-deoxygalactonojirimycin hydrochloride,EU/3/06/368,Treatment of Fabry disease,Amicus Therapeutics UK Ltd,22/05/2006,GalafoldEU/1/15/108231/05/2016,Q27291314,fabry disease,http://purl.obolibrary.org/obo/DOID_14499,,http://www.orpha.net/ORDO/Orphanet_324,D000795,Q615645,,Q615645
26,"(1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione",EU/3/16/1639,Treatment of X-linked spinal and bulbar muscular atrophy (Kennedy's disease),Coté Orphan Consulting UK Limited,28/04/2016,,,xlinked spinal and bulbar muscular atrophy (kennedys disease),,,,,,,
27,"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N’-bis(2-bromoethyl)diamidophosphate",EU/3/13/1152,Treatment of pancreatic cancer,Chiltern International Limited,17/07/2013,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
28,"(1R, 2R)-Octanoic acid [2-(2’,3’-dihydro-benzo [1,4] dioxin-6’-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt",EU/3/07/514,Treatment of Gaucher Disease,Genzyme Europe B.V.,04/12/2007,CerdelgaEU/1/14/97421/01/2015,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
29,"(1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol",EU/3/05/314,Treatment of tuberculosis,Janssen-Cilag International NV,26/08/2005,SirturoEU/1/13/90107/03/2014,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
30,"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-2-yl)-ß-D-galactopyranosyl]-4-O-(a-L-fucopyranosyl)-5-orothylamido-cyclohexane-1-carboxylic acid ethyl-2-amidyl-ethyloxy-2-acetyl-(8-amino-1,3,6-naphthalene-tris sodium sulfonate) amide",EU/3/13/1184,Treatment of sickle cell disease,Pfizer Limited,05/08/2013,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
31,"(1S,3S)-3-amino-4-(difluoromethylene) cyclopentanecarboxylic acid hydrochloride",EU/3/12/953,Treatment of West syndrome,Catalent Pharma Solutions Limited,09/02/2012,,,west syndrome,http://purl.obolibrary.org/obo/DOID_0050562,http://purl.obolibrary.org/obo/HP_0011097,http://www.orpha.net/ORDO/Orphanet_3451,D013036,Q1041258,,Q18555095
32,"(1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine",EU/3/14/1400,Treatment of neurotrophic keratitis,MIMETECH S.r.l.,16/12/2014,,Q418123,neurotrophic keratitis,,,http://www.orpha.net/ORDO/Orphanet_137596,,,,
33,"20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate",EU/3/11/900,Treatment of ovarian cancer,Nektar Therapeutics UK Ltd,27/09/2011,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
34,"2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide",EU/3/16/1713,Treatment of scedosporiosis,F2G Ltd,29/08/2016,,,scedosporiosis,,,http://www.orpha.net/ORDO/Orphanet_449280,,,,
35,"2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide",EU/3/16/1738,Treatment of invasive aspergillosis,F2G Ltd,14/10/2016,,,invasive aspergillosis,http://purl.obolibrary.org/obo/DOID_0050073,,,,Q18553203,,
36,"2,2'-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid",EU/3/11/899,Treatment of multiple myeloma,Takeda Pharma A/S,27/09/2011,NinlaroEU/1/16/109423/11/2016,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
37,2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate,EU/3/15/1598,Treatment of Charcot-Marie-Tooth disease,Inflectis Bioscience,14/12/2015,,,charcotmarietooth disease,http://purl.obolibrary.org/obo/DOID_10595,,http://www.orpha.net/ORDO/Orphanet_166,D002607,Q1052687,Q1052687,Q1052687
38,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",EU/3/10/802,Treatment of idiopathic pulmonary fibrosis,GenKyoTex Innovation S.A.S,26/11/2010,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
39,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",EU/3/15/1559,Treatment of systemic sclerosis,GenKyoTex Innovation S.A.S,09/10/2015,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
40,"2,2-dimethylbutyric acid, sodium salt",EU/3/09/617,Treatment of beta-thalassaemia intermedia and major,Isabelle Ramirez,27/02/2009,,Q5984881,betathalassemia intermedia and major,,,,,,,
41,"2,2-dimethylbutyric acid, sodium salt",EU/3/09/621,Treatment of sickle cell disease,Isabelle Ramirez,18/03/2009,,Q5984881,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
42,"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile",EU/3/16/1712,Treatment of idiopathic pulmonary fibrosis,Galapagos NV,29/08/2016,,Q407204,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
43,2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide,EU/3/14/1324,Treatment of small cell lung cancer,DualTpharma B.V.,22/08/2014,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
44,2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,EU/3/15/1544,Treatment of hepatocellular carcinoma,Dr Ulrich Granzer,10/08/2015,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
45,"2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride",EU/3/15/1517,Treatment of acute myeloid leukaemia,Pierre Fabre Médicament,28/07/2015,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
46,"2',3',5'-tri-O-acetyluridine",EU/3/09/637,Treatment of 5-fluorouracil overdose,Wellstat Therapeutics EU Limited,15/05/2009,,,5fluororacil overdose,,,,,,,
47,2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid,EU/3/16/1691,Treatment of Huntington's disease,Pfizer Limited,14/07/2016,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
48,2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid,EU/3/13/1108,Treatment of systemic sclerosis,Sanofi-Aventis groupe,12/03/2013,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
49,2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide,EU/3/15/1498,Treatment of cystic fibrosis,Clinical Network Services (UK) Ltd,21/05/2015,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
50,"2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one",EU/3/12/989,Treatment of ovarian cancer,AstraZeneca UK Limited,26/04/2012,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
51,"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy)phenyl]thio]phenyl]ethyl]-1,3-propanediol hydrochloride",EU/3/15/1583,Prevention of graft-versus-host disease,Novartis Europharm Limited,14/12/2015,,,graftversushost disease,,,,D006086,,,Q1194520
52,"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]-(3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide",EU/3/15/1488,Treatment of ovarian cancer,Right Track Regulatory Limited,21/05/2015,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
53,"((2-aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxy benzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosuccinic acid] salt",EU/3/04/200,Treatment of functional gastro-entero-pancreatic endocrine tumours,Novartis Europharm Limited,08/06/2004,,,functional gastroenteropancreatic endocrine tumors,,,,,,,
54,2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide,EU/3/15/1565,Treatment of hepatocellular carcinoma,PBS Regulatory Consulting Group Limited,09/10/2015,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
55,[2-Cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-trifluoromethylphenyl)prop-2-enamide],EU/3/12/1050,Treatment of traumatic spinal cord injury,Algiax Pharmaceuticals GmbH,10/10/2012,,,traumatic spinal cord injury,,,,,,,
56,"2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate",EU/3/16/1615,Treatment of Ebola virus disease,Gilead Sciences International Ltd,17/02/2016,,,ebola virus disease,http://purl.obolibrary.org/obo/DOID_4325,,http://www.orpha.net/ORDO/Orphanet_319218,D019142,Q51993,,Q8064876
57,2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,EU/3/16/1769,Treatment of sickle cell disease,SynteractHCR Deutschland GmbH,18/11/2016,,Q1959945,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
58,"2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one",EU/3/14/1386,Treatment of ovarian cancer,Aprea AB,16/12/2014,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
59,2-hydroxyoleic acid,EU/3/11/916,Treatment of glioma,Lipopharma Therapeutics SL,27/10/2011,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
60,2-hydroxypropyl-ß-cyclodextrin,EU/3/13/1124,"Treatment of Niemann-Pick disease, type C",Vtesse Europe Limited,26/04/2013,,,"niemannpick disease, type c",,,,D052556,,,Q2067267
61,2-iminobiotin,EU/3/09/701,Treatment of perinatal asphyxia,Neurophyxia B.V.,28/01/2010,,Q27094295,perinatal asphyxia,,,,,,,
62,"2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol",EU/3/04/195,Treatment of anaplastic thyroid cancer,Diamond BioPharm Limited,14/04/2004,,,anaplastic thyroid cancer,,,,D065646,,,
63,"2-methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one",EU/3/10/742,Treatment of acute myeloid leukaemia,Aprea AB,10/06/2010,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
64,"2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate",EU/3/16/1640,Treatment of acute myeloid leukaemia,Celgene Europe Limited,28/04/2016,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
65,2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide targeting the growth hormone receptor,EU/3/16/1671,Treatment of acromegaly,Coté Orphan Consulting UK Limited,27/06/2016,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
66,"2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'",EU/3/15/1432,Treatment of Huntington's disease,BioMarin International Limited,18/02/2015,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
67,"(-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate",EU/3/08/560,Treatment of moderate and severe closed traumatic brain injury,KeyNeurotek Pharmaceuticals AG,05/09/2008,,,moderate and severe closed traumatic brain injury,,,,,,,
68,"(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol",EU/3/13/1230,Treatment of acute myeloid leukaemia,Voisin Consulting S.A.R.L.,16/01/2014,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
69,"(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol",EU/3/13/1231,Treatment of acute lymphoblastic leukaemia,Voisin Consulting S.A.R.L.,16/01/2014,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
70,"(2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide",EU/3/14/1372,Treatment of microscopic polyangiitis,ChemoCentryx Limited,19/11/2014,,,microscopic polyangiitis,,,http://www.orpha.net/ORDO/Orphanet_727,D055953,,Q1934069,Q1934069
71,"(2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide",EU/3/14/1373,Treatment of granulomatosis with polyangiitis,ChemoCentryx Limited,19/11/2014,,,granulomatosis with polyangiitis,,,http://www.orpha.net/ORDO/Orphanet_900,D014890,,,Q1161568
72,"2S, 4R ketoconazole",EU/3/12/1012,Treatment of Cushing&#8217;s syndrome,Cortendo AB,04/07/2012,,,cushings syndrome,http://purl.obolibrary.org/obo/DOID_12252,,http://www.orpha.net/ORDO/Orphanet_553,D003480,Q219102,,Q219102
73,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",EU/3/12/1028,Treatment of progressive familial intrahepatic cholestasis,Albireo AB,17/07/2012,,,progressive familial intrahepatic cholestasis,,,http://www.orpha.net/ORDO/Orphanet_172,,,Q6058436,
74,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",EU/3/12/1040,Treatment of Alagille syndrome,Albireo AB,09/08/2012,,,alagille syndrome,http://purl.obolibrary.org/obo/DOID_9245,,http://www.orpha.net/ORDO/Orphanet_52,D016738,Q1544408,,Q1544408
75,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",EU/3/12/1041,Treatment of primary biliary cirrhosis,Albireo AB,09/08/2012,,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
76,(2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl] butanamide,EU/3/05/315,Treatment of progressive myoclonic epilepsies,UCB Pharma S.A.,26/08/2005,,,progressive myoclonic epilepsies,,,,D020191,,,Q7248853
77,"3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid",EU/3/15/1507,Treatment of non-infectious uveitis,Panoptes Pharma Ges.m.b.H,19/06/2015,,,noninfectios uveitis,,,,,,,
78,3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid,EU/3/15/1431,Treatment of hereditary angioedema,BioCryst UK Ltd.,12/02/2015,,,hereditary angioedema,http://purl.obolibrary.org/obo/DOID_14735,,http://www.orpha.net/ORDO/Orphanet_91378,D054179,Q2096745,,Q2096745
79,3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt,EU/3/16/1692,Treatment of idiopathic pulmonary fibrosis,Vicore Pharma AB,14/07/2016,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
80,"3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione",EU/3/03/177,Treatment of multiple myeloma,Celgene Europe Limited,12/12/2003,RevlimidEU/1/07/39119/06/2007,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
81,"3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione",EU/3/04/192,Treatment of myelodysplastic syndromes,Celgene Europe Limited,08/03/2004,RevlimidEU/1/07/39117/06/2013,,myelodysplastic syndromes,,,,D009190,,,Q954625
82,"3,4-diaminopyridine phosphate",EU/3/02/124,Treatment of Lambert-Eaton myasthenic syndrome,BioMarin Europe Ltd.,18/12/2002,FirdapseEU/1/09/60128/12/2009,,lamberteaton myasthenic syndrome,http://purl.obolibrary.org/obo/DOID_0050214,,http://www.orpha.net/ORDO/Orphanet_43393,D015624,Q1756898,,Q1756898
83,"(3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid",EU/3/05/277,Treatment of cystic fibrosis,PTC Therapeutics International Limited,27/05/2005,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
84,"(3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid",EU/3/05/278,Treatment of Duchenne muscular dystrophy,PTC Therapeutics International Limited,27/05/2005,TranslarnaEU/1/13/90205/08/2014,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
85,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",EU/3/16/1672,Treatment of diffuse large B-cell lymphoma,Celgene Europe Limited,27/06/2016,,,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
86,"3,5-diiodothyropropionic acid",EU/3/13/1193,Treatment of Allan-Herndon-Dudley syndrome,CATS Consultants GmbH,07/10/2013,,Q27252433,allanherndondudley syndrome,http://purl.obolibrary.org/obo/DOID_0050631,,http://www.orpha.net/ORDO/Orphanet_59,,Q4731121,Q4731121,
87,"3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid",EU/3/10/761,Treatment of cystic fibrosis,Vertex Pharmaceuticals (Europe) Limited,04/08/2010,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
88,3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone,EU/3/14/1242,Treatment of Rett syndrome,Neurolixis UK Ltd.,19/02/2014,,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
89,3-methoxy-pregnenolone,EU/3/07/511,Treatment of spinal cord injury,MAPREG SAS,04/12/2007,,Q27270371,spinal cord injury,,,,D013119,,,Q1415275
90,3-pentylbenzeneacetic acid sodium salt,EU/3/15/1550,Treatment of idiopathic pulmonary fibrosis,ProMetic Pharma SMT Limited,09/10/2015,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
91,3-pentylbenzeneacetic acid sodium salt,EU/3/16/1810,Treatment of Alstr&ouml;m syndrome,ProMetic Pharma SMT Limited,12/01/2017,,,alstr&oml;m syndrome,,,,,,,
92,"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one",EU/3/14/1334,Treatment of fragile X syndrome,Centre National de la Recherche Scientifique (CNRS),15/10/2014,,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
93,"(3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate",EU/3/14/1310,Treatment of Fabry disease,Genzyme Europe B.V.,22/08/2014,,Q27077129,fabry disease,http://purl.obolibrary.org/obo/DOID_14499,,http://www.orpha.net/ORDO/Orphanet_324,D000795,Q615645,,Q615645
94,"(3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate",EU/3/14/1374,Treatment of Gaucher disease,Genzyme Europe B.V.,19/11/2014,,Q27077129,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
95,(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt,EU/3/10/760,Treatment of ovarian cancer,TESARO U.K. Limited,04/08/2010,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
96,(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt,EU/3/10/787,Treatment of mantle cell lymphoma,TESARO U.K. Limited,01/10/2010,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
97,4-[123I]iodo-L-phenylalanine,EU/3/06/386,Diagnosis of glioma,Therapeia GmbH & Co. KG,25/07/2006,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
98,4-[131I]iodo-L-phenylalanine,EU/3/06/363,Treatment of glioma,Therapeia GmbH & Co. KG,11/04/2006,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
99,"4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid",EU/3/14/1363,Treatment of cystic fibrosis,Coté Orphan Consulting UK Limited,19/11/2014,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
100,"4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate",EU/3/13/1109,Treatment of hepatocellular carcinoma,Eli Lilly Nederland B.V.,13/03/2013,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
101,"4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate",EU/3/13/1120,Treatment of glioma,Eli Lilly Nederland B.V.,26/04/2013,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
102,"4’-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2’-(ethoxymethyl)-[1,1’-biphenyl]-2-sulfonamide",EU/3/15/1574,Treatment of focal segmental glomerulosclerosis,Retrophin Europe Limited,11/11/2015,,Q27896056,focal segmental glomerulosclerosis,http://purl.obolibrary.org/obo/DOID_1312,http://purl.obolibrary.org/obo/HP_0000097,,D005923,Q1435223,,Q1435223
103,"4-[(2E)-1-oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide",EU/3/16/1658,Treatment of retinitis pigmentosa,Shire Pharmaceuticals Ireland Limited,30/05/2016,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
104,"4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid",EU/3/14/1328,Treatment of acute myeloid leukaemia,Roche Registration Limited,22/08/2014,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
105,4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine x HCl,EU/3/05/288,Treatment of Huntington's disease,Teva GmbH,20/06/2005,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
106,"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",EU/3/12/1080,Treatment of chronic lymphocytic leukaemia,AbbVie Ltd,06/12/2012,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
107,4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid,EU/3/14/1279,Prevention of scarring post glaucoma filtration surgery,Clanotech AB,04/06/2014,,,scarring post glaucoma filtration surgery,,,,,,,
108,"4,6,4’–trimethylangelicin",EU/3/13/1137,Treatment of cystic fibrosis,Rare Partners srl Impresa Sociale,19/06/2013,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
109,"4,7,10,13,16,19-docosahexaenoic acid",EU/3/06/412,Treatment of retinitis pigmentosa,Natac Pharma S.L.,03/11/2006,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
110,"4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol",EU/3/11/934,Treatment of idiopathic pulmonary fibrosis,Celgene Europe Limited,09/12/2011,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
111,"4-Amino-1-[5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-ß-D-arabinofuranosyl]-2(1H)-pyrimidinone",EU/3/07/477,Treatment of hepatocellular carcinoma,Interface International Consultancy Limited,14/09/2007,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
112,4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline,EU/3/06/356,Treatment of renal cell carcinoma,Prodimed S.A.,16/02/2006,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
113,"4-amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride",EU/3/06/390,Treatment of moderate and severe traumatic brain injury,vasopharm GmbH,28/08/2006,,,moderate and severe traumatic brain injury,,,,,,,
114,[4-aminobutanoic acid-glycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-L-aspartyl](cyclo 1-Dgamma17),EU/3/15/1592,Treatment of pseudohypoaldosteronism type 1B,Apeptico Forschung und Entwicklung GmbH,14/12/2015,,,pseudohypoaldosteronism type 1b,,,,,,,
115,"4-ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indol",EU/3/07/487,Treatment of chronic lymphocytic leukaemia,BlackSwan Pharma GmbH,14/11/2007,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
116,"4-imino-1, 3-diazobicyclo-[3.1.0]-hexan-2-one",EU/3/05/299,Treatment of pancreatic cancer,ICON Clinical Research (U.K.) Limited,27/07/2005,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
117,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride",EU/3/13/1214,Treatment of Alagille syndrome,Shire Pharmaceutical Ireland limited,18/12/2013,,,alagille syndrome,http://purl.obolibrary.org/obo/DOID_9245,,http://www.orpha.net/ORDO/Orphanet_52,D016738,Q1544408,,Q1544408
118,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride",EU/3/13/1215,Treatment of primary biliary cirrhosis,Shire Pharmaceutical Ireland limited,18/12/2013,,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
119,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride",EU/3/13/1216,Treatment of progressive familial intrahepatic cholestasis,Shire Pharmaceutical Ireland limited,18/12/2013,,,progressive familial intrahepatic cholestasis,,,http://www.orpha.net/ORDO/Orphanet_172,,,Q6058436,
120,"(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride",EU/3/13/1217,Treatment of primary sclerosing cholangitis,Shire Pharmaceutical Ireland limited,18/12/2013,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
121,"505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase",EU/3/15/1448,Treatment of facioscapulohumeral muscular dystrophy,Voisin Consulting S.A.R.L.,12/02/2015,,,facioscapulohumeral muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11727,,http://www.orpha.net/ORDO/Orphanet_269,D020391,Q1399182,,Q1399182
122,"5,10,15,20-tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl)bacteriochlorin",EU/3/15/1470,Treatment of biliary tract cancer,Luzitin S.A,19/03/2015,,,biliary tract cancer,http://purl.obolibrary.org/obo/DOID_4607,,,D001661,Q18556397,,Q18556397
123,"[5,10,15,20-tetrakis(4-carboxyphenyl)-21H,23H-porphine]manganese(III) chloride",EU/3/16/1809,Treatment of Cockayne syndrome,Institut Pasteur,12/01/2017,,,cockayne syndrome,http://purl.obolibrary.org/obo/DOID_2962,,http://www.orpha.net/ORDO/Orphanet_132271,D003057,Q914389,,Q914389
124,"5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride",EU/3/11/892,Treatment of 5q spinal muscular atrophy,Repligen Europe Limited,30/08/2011,,,5q spinal muscular atrophy,,,,,,,
125,"5-[1-(2,6-dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride",EU/3/13/1136,Treatment of 5q spinal muscular atrophy,Sirius Regulatory Consulting Limited,07/06/2013,,,5q spinal muscular atrophy,,,,,,,
126,"5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride",EU/3/16/1770,Treatment of adrenoleukodystrophy,Minoryx Therapeutics S.L.,18/11/2016,,,adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_117677,D000326,Q366964,,Q366964
127,"5,5'-(4-(trifluromethyl)benzylazanediyl)bis(methylene)diquinolin-8-ol",EU/3/14/1408,Treatment of glioma,Prof. Olivier Blin,16/12/2014,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
128,"[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride",EU/3/15/1457,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",Daiichi Sankyo Europe GmbH,19/03/2015,,,"tenosynovial giant cell tumor, localised and diffuse type",,,,,,,
129,"5,6,7,8-Tetrahydrobiopterin",EU/3/03/163,Treatment of hyperphenylalaninemia,Orphanetics Pharma Entwicklungs GmbH,02/10/2003,,Q419808,hyperphenylalaninemia,,http://purl.obolibrary.org/obo/HP_0004923,http://www.orpha.net/ORDO/Orphanet_238583,D010661,,Q7706537,Q5958471
130,"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride",EU/3/15/1497,Treatment of Huntington&#8217;s disease,Prana Biotechnology UK Limited,21/05/2015,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
131,5'-ASCSASTSCSASGSTSCSTSGSASUSASASGSCSTSA-3',EU/3/15/1451,Treatment of Alport syndrome,CTI Clinical Trial and Consulting Services Europe GmbH,19/03/2015,,,alport syndrome,http://purl.obolibrary.org/obo/DOID_10983,,http://www.orpha.net/ORDO/Orphanet_63,D009394,Q1331116,,Q1331116
132,"[5-amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone",EU/3/14/1323,Treatment of pancreatic cancer,Synovo GmbH,22/08/2014,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
133,5-aminolevulinic acid,EU/3/16/1811,Treatment of glioma,Centre Hospitalier Universitaire de Lille,12/01/2017,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
135,"5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidine-4,6-diamine",EU/3/14/1392,Treatment of Huntington&#8217;s disease,Palobiofarma S.L.,16/12/2014,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
136,5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole,EU/3/08/591,Treatment of Duchenne muscular dystrophy,Summit (Oxford) Limited,04/12/2008,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
137,5-methyl-pyridine-2-sulfonic acid {6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt,EU/3/03/182,Treatment of aneurysmal subarachnoid haemorrhage,Actelion Registration Ltd,12/12/2003,,,aneurysmal subarachnoid hemorrhage,,,,D013345,,,Q693442
138,5'-O-(trans-9'-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine,EU/3/07/476,Treatment of acute myleoid leukaemia,Aqualis ASA,14/09/2007,,,acute myleoid leukemia,,,,,,,
139,"(5R,5aR,8aR,9S)-9-[[4,6-O-[(R)-Ethylidene]-(-D-glucopyranosyl]-oxy]-5-(4-({[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]carbonyl}oxy)-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydroisobenzofuro[5,6-f][1,3]benzodioxol-6(5aH)-one",EU/3/14/1270,Treatment of biliary tract cancer,CellAct Pharma GmbH,04/06/2014,,,biliary tract cancer,http://purl.obolibrary.org/obo/DOID_4607,,,D001661,Q18556397,,Q18556397
140,5(S)-(2'-hydroxy ethoxy)-20(S)- camptothecin,EU/3/07/450,Treatment of osteosarcoma,Dr Reddy's Laboratories (UK) Limited,08/06/2007,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
141,"(5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide",EU/3/15/1576,Treatment of ovarian cancer,"ASPHALION, SL",11/11/2015,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
142,"68Ga-2,2'-(7-(4-((S)-1-((4S,7S,10S,13R,16S,19R)-4-((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-ylcarbamoyl)-10-(4-aminobutyl)-16-(4-((S)-2,6-dioxohexahydropyrimidine-4-carboxamido)benzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-ylamino)-3-(4-chlorophenyl)-1-oxopropan-2-ylamino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid",EU/3/14/1246,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,Ipsen Pharma,19/02/2014,,,gastroenteropancreatic neuroendocrine tumors,,,,,,,
143,68Ga-DOTA-pABzA-DIG-dPhe-Gln-Trp-Ala-Val-Gly-His-NHCH[(CH2-CH(CH3)2]2,EU/3/16/1794,Diagnosis of gastrointestinal stromal tumours,Advanced Accelerator Applications,12/12/2016,,,gastrointestinal stromal tumors,,http://purl.obolibrary.org/obo/HP_0100723,,D046152,,,Q1495661
144,6alpha-ethyl-chenodeoxycholic acid,EU/3/10/753,Treatment of primary biliary cirrhosis,Intercept Pharma Ltd,27/07/2010,,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
145,"(6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic acid",EU/3/16/1808,Treatment of systemic sclerosis,TMC Pharma Services Ltd,12/01/2017,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
146,"(6aR,10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydrocannabinol-9-carboxylic acid",EU/3/16/1736,Treatment of cystic fibrosis,TMC Pharma Services Ltd,14/10/2016,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
147,"(6aS)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol",EU/3/13/1226,Treatment of dystrophic myotonia,Valentia BioPharma S.L,16/01/2014,,,dystrophic myotonia,,,,,,,
148,"6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide",EU/3/09/681,Treatment of Huntington's disease,Siena Biotech SpA,28/10/2009,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
149,"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one",EU/3/15/1454,Treatment of Netherton syndrome,Sixera Pharma AB,19/03/2015,,,netherton syndrome,http://purl.obolibrary.org/obo/DOID_0050474,,http://www.orpha.net/ORDO/Orphanet_634,D056770,Q9390284,Q9390284,Q9390284
150,"6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one",EU/3/12/970,Treatment of amyotrophic lateral sclerosis,Pharma Gateway AB,05/03/2012,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
151,"(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine dihydrochloride monohydrate",EU/3/09/616,Treatment of amyotrophic lateral sclerosis,Knopp Neurosciences Sub Ltd,27/02/2009,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
152,"6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate",EU/3/16/1714,Treatment of mucopolysaccharidosis type I,Coté Orphan Consulting UK Limited,29/08/2016,,,mucopolysaccharidosis type i,,,http://www.orpha.net/ORDO/Orphanet_579,D008059,,,Q1906054
153,6-thioguanine (oral liquid),EU/3/09/694,Treatment of acute lymphoblastic leukaemia,Only for Children Pharmaceuticals,26/11/2009,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
154,7-beta-hydroxycholesteryl-3-beta-oleate,EU/3/10/816,Treatment of glioma,Intsel Chimos SA,17/12/2010,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
155,"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one mono-hydrochloride",EU/3/09/695,Treatment of ovarian cancer,Merck Sharp & Dohme Limited,30/11/2009,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
156,9-cis-Retinyl acetate,EU/3/11/861,Treatment of Leber's congenital amaurosis,"QLT Ophthalmics (UK), Ltd",13/05/2011,,,lebers congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,,,Q1811132,,
157,9-cis-Retinyl acetate,EU/3/11/865,Treatment of retinitis pigmentosa,"QLT Ophthalmics (UK), Ltd",13/05/2011,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
158,A combination of H-Lys-Lys-Gly-Pro-Arg-Cys(SH)-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys-OH and H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH,EU/3/14/1360,Treatment of haemophilia A,Apitope International NV,19/11/2014,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
159,A highly purified formulation of Staphylococcus aureus protein A,EU/3/15/1562,Treatment of immune thrombocytopenia,Coté Orphan Consulting UK Limited,09/10/2015,,,immune thrombocytopenia,,http://purl.obolibrary.org/obo/HP_0001973,http://www.orpha.net/ORDO/Orphanet_3002,D016553,,Q3410984,Q638729
160,"A lentiviral vector pseudotyped by the Indiana serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins",EU/3/14/1417,Treatment of adult T-cell leukaemia/lymphoma,THERAVECTYS,15/01/2015,,,adult tcell leukemia/lymphoma,http://purl.obolibrary.org/obo/DOID_0050523,,http://www.orpha.net/ORDO/Orphanet_86875,,Q379054,Q379054,
161,"A lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins",EU/3/14/1418,Treatment of adult T-cell leukaemia/lymphoma,THERAVECTYS,15/01/2015,,,adult tcell leukemia/lymphoma,http://purl.obolibrary.org/obo/DOID_0050523,,http://www.orpha.net/ORDO/Orphanet_86875,,Q379054,Q379054,
162,A mixture of anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein,EU/3/05/317,Treatment of graft-versus-host disease,Xenikos B.V.,26/08/2005,,,graftversushost disease,,,,D006086,,,Q1194520
163,A non-covalent trimer of tumour necrosis factor fused to an antibody specific to the extra-domain B of fibronectin in single-chain variable fragment format,EU/3/16/1739,Treatment of soft tissue sarcoma,Philogen S.p.A.,14/10/2016,,Q27074566,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
164,AASSGVSTPGSAGHDIITEQPRS,EU/3/15/1492,Treatment of Huntington&#8217;s disease,Centre National de la Recherche Scientifique (CNRS),21/05/2015,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
165,Acadesine,EU/3/05/280,Treatment of B-cell chronic lymphocytic leukemia (B-CLL),Advancell - Advanced In Vitro Cell Technologies S.A.,27/05/2005,,Q4671562,bcell chronic lymphocytic leukemia (bcll),,,,,,,
166,Acadesine,EU/3/11/881,Treatment of multiple myeloma,Advancell - Advanced In Vitro Cell Technologies S.A.,05/08/2011,,Q4671562,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
167,Acalabrutinib,EU/3/16/1624,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,"Acerta Pharma, BV",21/03/2016,,Q27074143,chronic lymphocytic leukemia / small lymphocytic lymphoma,,,,,,,
168,Acalabrutinib,EU/3/16/1625,Treatment of mantle cell lymphoma,"Acerta Pharma, BV",21/03/2016,,Q27074143,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
169,Acalabrutinib,EU/3/16/1626,Treatment of lymphoplasmacytic lymphoma,"Acerta Pharma, BV",21/03/2016,,Q27074143,lymphoplasmacytic lymphoma,http://purl.obolibrary.org/obo/DOID_0050747,,,,Q1778287,,
170,Acamprosate calcium,EU/3/14/1337,Treatment of fragile X syndrome,Real Regulatory Limited,15/10/2014,,Q27122289,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
171,Acebutolol hydrochloride,EU/3/16/1742,Treatment of Smith-Magenis syndrome,Therapicon Srl,14/10/2016,,Q27105651,smithmagenis syndrome,http://purl.obolibrary.org/obo/DOID_0060768,,http://www.orpha.net/ORDO/Orphanet_819,D058496,Q2295338,,
172,Acetylsalicylic acid,EU/3/04/208,Treatment of polycythemia vera,Bayer HealthCare AG,29/07/2004,,Q18216,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
173,Adeno-associated viral vector containing a modified U7-snRNA gene,EU/3/05/297,Treatment of Duchenne muscular dystrophy,Généthon,27/07/2005,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
174,Adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin / adeno-associated viral vector containing a rhodopsin gene,EU/3/10/817,Treatment of rhodopsin-linked retinitis pigmentosa,Genable Technologies Ltd,17/12/2010,,Q23671272,rhodopsinlinked retinitis pigmentosa,,,,,,,
175,Adeno-associated viral vector containing modified U1 snRNA,EU/3/09/663,Treatment of Duchenne muscular dystrophy,uniQure biopharma B.V.,08/10/2009,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
176,Adeno-associated viral vector containing porphobilinogen deaminase gene,EU/3/09/632,Treatment of acute intermittent porphyria,uniQure biopharma B.V.,29/04/2009,,,acute intermittent porphyria,http://purl.obolibrary.org/obo/DOID_3890,,http://www.orpha.net/ORDO/Orphanet_79276,D017118,Q424247,,Q424247
177,Adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene,EU/3/11/917,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),Institut Pasteur,27/10/2011,,,mucopolysaccharidosis type iiib (sanfilippo b syndrome),,,,,,,
178,Adeno-associated viral vector containing the human ARSB gene,EU/3/11/864,Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome),Fondazione Telethon,13/05/2011,,,mucopolysaccharidosis type vi (maroteauxlamy syndrome),,,,,,,
179,Adeno-associated viral vector containing the human factor IX gene,EU/3/11/938,Treatment of haemophilia B,uniQure biopharma B.V.,11/01/2012,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
180,Adeno-associated viral vector containing the human factor IX gene,EU/3/15/1501,Treatment of haemophilia B,Baxalta Innovations GmbH,19/06/2015,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
181,Adeno-associated viral vector containing the human NADH dehydrogenase 4 gene,EU/3/11/860,Treatment of Leber's hereditary optic neuropathy,GenSight- Biologics,13/05/2011,,,lebers hereditary optic neuropathy,http://purl.obolibrary.org/obo/DOID_705,,,D029242,Q1262161,,Q1262161
182,Adeno-associated viral vector expressing lipoprotein lipase,EU/3/04/194,Treatment of lipoprotein lipase deficiency,uniQure biopharma B.V.,08/03/2004,GlyberaEU/1/12/79129/10/2012,,lipoprotein lipase deficiency,,,,D008072,,,Q2349695
183,Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene,EU/3/12/974,Treatment of primary hyperoxaluria type 1,uniQure biopharma B.V.,21/03/2012,,,primary hyperoxaluria type 1,,,http://www.orpha.net/ORDO/Orphanet_119538,,,,
184,Adeno-associated viral vector serotype 2/2 containing a gene encoding the channelrhodopsin-2 protein,EU/3/16/1740,Treatment of retinitis pigmentosa,Alacrita LLP,14/10/2016,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
186,Adeno-associated viral vector serotype 2 containing the human REP1 gene,EU/3/14/1290,Treatment of choroideremia,NightstaRx Ltd.,04/07/2014,,,choroideremia,http://purl.obolibrary.org/obo/DOID_9821,http://purl.obolibrary.org/obo/HP_0001139,http://www.orpha.net/ORDO/Orphanet_180,D015794,Q2397009,,Q2397009
187,Adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene,EU/3/16/1693,Treatment of retinitis pigmentosa,GenSight- Biologics,14/07/2016,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
188,Adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene,EU/3/16/1622,Treatment of haemophilia A,BioMarin Europe Ltd,21/03/2016,,Q27280697,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
189,Adeno-associated viral vector serotype 5 containing the human CHM gene,EU/3/15/1482,Treatment of choroideremia,HORAMA SA,24/04/2015,,,choroideremia,http://purl.obolibrary.org/obo/DOID_9821,http://purl.obolibrary.org/obo/HP_0001139,http://www.orpha.net/ORDO/Orphanet_180,D015794,Q2397009,,Q2397009
190,Adeno-associated viral vector serotype 5 containing the human RLBP1 gene,EU/3/16/1741,Treatment of retinitis pigmentosa,HORAMA SA,14/10/2016,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
191,Adeno-associated viral vector serotype 8 containing the human CNGA3 gene under the control of a cone arrestin promoter,EU/3/16/1795,Treatment of achromatopsia caused by mutations in the CNGA3 gene,Universitätsklinikum Tübingen (UKT),12/12/2016,,,achromatopsia caused by mutations in the cnga3 gene,,,,,,,
192,Adeno-associated viral vector serotype 8 containing the human factor VII gene,EU/3/14/1430,Treatment of congenital factor VII deficiency,Professor Edward G. Tuddenham,15/01/2015,,,congenital factor vii deficiency,,,http://www.orpha.net/ORDO/Orphanet_327,,,,
193,Adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene,EU/3/16/1771,Treatment of glycogen storage disease type Ia,Pharma Gateway AB,18/11/2016,,Q27291628,glycogen storage disease type ia,,,,,,,
194,Adeno-associated viral vector serotype 8 containing the human GUCY2D gene,EU/3/14/1256,Treatment of Leber&#8217;s congenital amaurosis,Fondazione Telethon,26/03/2014,,,lebers congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,,,Q1811132,,
195,Adeno-associated viral vector serotype 8 containing the human MD1 gene,EU/3/14/1381,Treatment of Duchenne muscular dystrophy,Généthon,19/11/2014,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
196,Adeno-associated viral vector serotype 8 containing the human MTM1 gene,EU/3/15/1539,Treatment of X-linked myotubular myopathy,Audentes Therapeutics UK Limited,10/08/2015,,Q27258209,xlinked myotubular myopathy,,,,D020914,,,Q18556238
197,Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene,EU/3/14/1321,Treatment of Crigler-Najjar syndrome,Fondazione Telethon,22/08/2014,,,criglernajjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,http://www.orpha.net/ORDO/Orphanet_205,D003414,Q1140000,Q1140000,Q1140000
198,Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene,EU/3/14/1338,Treatment of Crigler-Najjar syndrome,Généthon,15/10/2014,,,criglernajjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,http://www.orpha.net/ORDO/Orphanet_205,D003414,Q1140000,Q1140000,Q1140000
199,Adeno-associated viral vector serotype 8 containing the human UGT1A1 gene,EU/3/16/1772,Treatment of Crigler-Najjar syndrome,Audentes Therapeutics UK Limited,18/11/2016,,,criglernajjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,http://www.orpha.net/ORDO/Orphanet_205,D003414,Q1140000,Q1140000,Q1140000
200,Adeno-associated viral vector serotype 8 encoding engineered rhodopsin DNA-binding repressor and human rhodopsin expression cassettes,EU/3/16/1796,Treatment of retinitis pigmentosa,Fondazione Telethon,12/12/2016,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
201,Adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase,EU/3/16/1623,Treatment of ornithine transcarbamylase deficiency,Pharma Gateway AB,21/03/2016,,Q27896091,ornithine transcarbamylase deficiency,http://purl.obolibrary.org/obo/DOID_9271,,http://www.orpha.net/ORDO/Orphanet_664,D020163,Q3043161,,Q3043161
202,Adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter,EU/3/15/1573,Treatment of Wilson's disease,Aligen Therapeutics S.L.,11/11/2015,,,wilsons disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
203,Adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene,EU/3/14/1296,Treatment of catecholaminergic polymorphic ventricular tachycardia,Audentes Therapeutics UK Limited,29/07/2014,,,catecholaminergic polymorphic ventricular tachycardia,http://purl.obolibrary.org/obo/DOID_0060674,,http://www.orpha.net/ORDO/Orphanet_3286,,Q28024493,,
204,Adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene,EU/3/15/1468,Treatment of Gaucher disease,Gauchers Association,19/03/2015,,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
205,Adeno-associated viral vector serotype 9 containing the human HGSNAT gene,EU/3/15/1491,Treatment of mucopolysaccharidosis IIIC (Sanfilippo C syndrome),Cochamo Systems Ltd,21/05/2015,,,mucopolysaccharidosis iiic (sanfilippo c syndrome),,,,,,,
206,Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene,EU/3/15/1540,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),"Laboratorios del Dr Esteve, S.A.",10/08/2015,,,mucopolysaccharidosis type ii (hunters syndrome),,,,,,,
207,Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene,EU/3/16/1716,Treatment of Duchenne muscular dystrophy,Advanced Biotherapeutics Consulting SARL,29/08/2016,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
208,Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene,EU/3/12/1095,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),"Laboratorios del Dr Esteve, S.A.",24/01/2013,,,mucopolysaccharidosis type iiib (sanfilippo b syndrome),,,,,,,
209,Adeno-associated viral vector serotype 9 containing the human SMN gene,EU/3/15/1509,Treatment of spinal muscular atrophy,"AveXis EU, Ltd",19/06/2015,,,spinal muscular atrophy,http://purl.obolibrary.org/obo/DOID_12377,http://purl.obolibrary.org/obo/HP_0007269,,D009134,Q580290,,Q7577466
210,Adeno-associated viral vector serotype 9 containing the human sulfamidase gene,EU/3/11/877,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),"Laboratorios del Dr Esteve, S.A.",21/06/2011,,Q22075857,mucopolysaccharidosis type iiia (sanfilippo a syndrome),,,,,,,
211,Adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA,EU/3/14/1389,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),LYSOGENE,16/12/2014,,,mucopolysaccharidosis type iiia (sanfilippo a syndrome),,,,,,,
212,Adeno-associated viral vector serotype rh10 containing the human factor IX gene,EU/3/15/1599,Treatment of haemophilia B,Pharma Gateway AB,14/12/2015,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
213,Adenoviral vector containing human p53 gene,EU/3/06/404,Treatment of Li Fraumeni Syndrome,Gendux Molecular Limited,23/10/2006,,,li fraumeni syndrome,,,,D016864,,,Q187542
214,Adenoviral vector serotype 5 containing the vascular endothelial growth factor D isoform (preprocessed short form) from a CMV promoter,EU/3/14/1415,Treatment of placental insufficiency,Magnus Invention Management Ltd,15/01/2015,,,placental insufficiency,http://purl.obolibrary.org/obo/DOID_3891,,http://www.orpha.net/ORDO/Orphanet_439167,D010927,Q2099138,,Q2099138
215,Adenovirus associated viral vector serotype 2 containing the human RPE65 gene,EU/3/12/981,Treatment of Leber&#8217;s congenital amaurosis,Alan Boyd Consultants Ltd,02/04/2012,,,lebers congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,,,Q1811132,,
216,Adenovirus associated viral vector serotype 4 containing the human RPE65 gene,EU/3/07/484,Treatment of Leber's congenital amaurosis,HORAMA SA,22/10/2007,,,lebers congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,,,Q1811132,,
217,Adenovirus associated viral vector serotype 4 containing the human RPE65 gene,EU/3/07/486,Treatment of retinitis pigmentosa,HORAMA SA,14/11/2007,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
218,Adenovirus associated viral vector serotype 5 containing the human pde6ß gene,EU/3/13/1142,Treatment of retinitis pigmentosa,HORAMA SA,19/06/2013,,Q27270104,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
219,Adenovirus associated viral vector serotype 5 containing the human RPE65 gene,EU/3/15/1577,Treatment of Leber&#8217;s congenital amaurosis,MeiraGTx UK II Limited,11/11/2015,,,lebers congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,,,Q1811132,,
220,Adenovirus associated viral vector serotype 5 containing the human RPGR gene,EU/3/16/1715,Treatment of retinitis pigmentosa,MeiraGTx UK II Limited,29/08/2016,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
221,Adenovirus associated viral vector serotype 8 containing the human CNGB3 gene,EU/3/15/1578,Treatment of achromatopsia caused by mutations in the CNGB3,MeiraGTx UK II Limited,11/11/2015,,,achromatopsia caused by mutations in the cngb3,,,,,,,
222,Adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain,EU/3/14/1396,Treatment of glioma,Alan Boyd Consultants Ltd,16/12/2014,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
223,Adenovirus-associated vector containing human Fas-c gene,EU/3/12/1002,Treatment of glioma,Envigo Pharma Consulting Ltd,06/06/2012,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
224,Adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs,EU/3/10/772,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",LYSOGENE,20/09/2010,,Q27087722,"mucopolysaccharidosis, type iiia (sanfilippo a syndrome)",,,,,,,
225,Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene,EU/3/15/1518,Treatment of retinitis pigmentosa,Alan Boyd Consultants Ltd,28/07/2015,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
226,Adenovirus-mediated Herpes simplex Virus-thymidine kinase gene,EU/3/01/083,Treatment of high-grade glioma with subsequent use of ganciclovir sodium,Gliotherapy Limited,06/02/2002,,,highgrade glioma with subsequent use of ganciclovir sodium,,,,,,,
227,"Adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo",EU/3/13/1227,Treatment of adenovirus infection in allogeneic haematopoietic stem-cell transplant recipients,Cell Medica Ltd,16/01/2014,,,adenovirus infection in allogeneic hematopoietic stemcell transplant recipients,,,,,,,
228,Adrenomedullin,EU/3/10/744,Treatment of acute lung injury,mondoBIOTECH Laboratories AG,09/06/2010,,,acute lung injury,,,http://www.orpha.net/ORDO/Orphanet_178320,D055371,,,
229,"Adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells",EU/3/15/1499,Treatment of thromboangiitis obliterans (Buerger's disease),Regulatory Resources Group Ltd,21/05/2015,,,thromboangiitis obliterans (buergers disease),,,,,,,
230,Afamelanotide,EU/3/09/648,Treatment of solar urticaria,Clinuvel UK Limited,24/07/2009,,Q410794,solar urticaria,,,http://www.orpha.net/ORDO/Orphanet_97230,,,Q959383,
231,Afamelanotide,EU/3/14/1285,Treatment of familial benign chronic pemphigus (Hailey-Hailey disease),Clinuvel UK Limited,04/07/2014,,Q410794,familial benign chronic pemphigus (haileyhailey disease),,,,,,,
232,Aganirsen,EU/3/14/1275,Treatment of central retinal vein occlusion,Gene Signal SAS,10/06/2014,,Q15633943,central retinal vein occlusion,http://purl.obolibrary.org/obo/DOID_2450,,,,Q190831,,
233,Alginate oligosaccharide (G-block) fragment,EU/3/07/475,Treatment of cystic fibrosis,AlgiPharma AS,14/09/2007,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
234,Alicaforsen,EU/3/09/641,Treatment of pouchitis,Atlantic Healthcare plc,15/05/2009,,Q17147922,pochitis,,,,D019449,,,
235,Allantoin,EU/3/13/1232,Treatment of epidermolysis bullosa,Amicus Therapeutics UK Ltd,16/01/2014,,Q409804,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
236,Allogeneic adipose-derived adult mesenchymal stem cells contained in a fibrin-based bioengineered dermis,EU/3/14/1407,Treatment of epidermolysis bullosa,Biodan Yelah S.L.,16/12/2014,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
237,Allogeneic and autologous haptenised and irradiated cells and cell lysates derived from glioma,EU/3/13/1211,Treatment of glioma,ERC Belgium,18/12/2013,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
238,Allogeneic aortic endothelial cells cultured in a porcine gelatin matrix,EU/3/10/843,Prevention of arteriovenous access failure in haemodialysis patients,Shire Pharmaceuticals Ireland Limited,23/02/2011,,,arteriovenos access failure in hemodialysis patients,,,,,,,
239,Allogeneic bone marrow derived mesenchymal cells expanded ex vivo in synthetic media,EU/3/13/1129,Treatment of graft-versus-host disease,"Cell2B Advanced Therapeutics, SA",07/06/2013,,,graftversushost disease,,,,D006086,,,Q1194520
240,Allogeneic bone marrow derived mesenchymal cells expanded ex vivo in synthetic media,EU/3/14/1388,Prevention of graft-versus-host disease,"Cell2B Advanced Therapeutics, SA",16/12/2014,,,graftversushost disease,,,,D006086,,,Q1194520
241,Allogeneic bone-marrow derived ex-vivo expanded multipotent adult progenitor cells,EU/3/13/1233,Prevention of graft-versus-host disease,ReGenesys BVBA,16/01/2014,,,graftversushost disease,,,,D006086,,,Q1194520
242,Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist,EU/3/14/1382,Treatment of acute lymphoblastic leukaemia,Novartis Europharm Limited,16/12/2014,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
243,"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",EU/3/15/1438,Treatment of adenovirus infection following haematopoietic stem cell transplantation,Miltenyi Biotec GmbH,19/03/2015,,,adenovirus infection following hematopoietic stem cell transplantation,,,,,,,
244,"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",EU/3/15/1439,Treatment of cytomegalovirus infection following haematopoietic stem cell transplantation,Miltenyi Biotec GmbH,12/02/2015,,,cytomegalovirus infection following hematopoietic stem cell transplantation,,,,,,,
245,"Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",EU/3/15/1440,Treatment of Epstein-Barr virus infection following haematopoietic stem cell transplantation,Miltenyi Biotec GmbH,19/03/2015,,,epsteinbarr virus infection following hematopoietic stem cell transplantation,,,,,,,
246,Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes,EU/3/16/1773,Treatment of cytomegalovirus infection in patients with impaired cell-mediated immunity,Atara Biotherapeutics Ireland Limited,18/11/2016,,,cytomegalovirus infection in patients with impaired cellmediated immunity,,,,,,,
247,Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19,EU/3/16/1674,Treatment in haematopoietic stem cell transplantation,QRC Consultants Ltd,27/06/2016,,,hematopoietic stem cell transplantation,,,,D018380,,,
248,Allogeneic Epstein-Barr virus specific cytotoxic T lymphocytes,EU/3/16/1627,Treatment of post-transplant lymphoproliferative disorder,Atara Biotherapeutics Ireland Limited,21/03/2016,,,posttransplant lymphoproliferative disorder,,,,,,,
249,Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells,EU/3/14/1395,Treatment of acute myeloid leukaemia,IPD - Therapeutics BV,16/12/2014,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
250,Allogeneic ex-vivo-expanded human umbilical cord blood-derived mesenchymal stem cells,EU/3/15/1503,Prevention of bronchopulmonary dysplasia,PSR Group B.V.,19/06/2015,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
251,Allogeneic fetal human retinal progenitor cells expanded ex vivo,EU/3/16/1620,Treatment of retinitis pigmentosa,Voisin Consulting S.A.R.L.,17/02/2016,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
252,"Allogeneic human adult stem cells, isolated from skeletal muscle and expanded ex vivo",EU/3/15/1519,Treatment of Duchenne muscular dystrophy,Karl Rouger,28/07/2015,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
253,Allogeneic human dendritic cells derived from a CD34+ progenitor cell line,EU/3/12/969,Treatment of acute myeloid leukaemia,DCPrime BV,22/05/2012,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
254,Allogeneic human dermal fibroblasts,EU/3/10/774,Treatment of epidermolysis bullosa,Intercytex Ltd,20/09/2010,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
255,Allogeneic motor neuron progenitor cells derived from human embryonic stem cells,EU/3/12/1088,Treatment of 5q spinal muscular atrophy,California Stem Cell (UK) Ltd,24/01/2013,,,5q spinal muscular atrophy,,,,,,,
256,Allogeneic motor neuron progenitor cells derived from human embryonic stem cells,EU/3/13/1155,Treatment of amyotrophic lateral sclerosis,California Stem Cell (UK) Ltd,17/07/2013,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
257,"Allogeneic peripheral blood mononuclear cells incubated ex vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone",EU/3/16/1774,Treatment in haematopoietic stem cell transplantation,"Fate Therapeutics, LTD",18/11/2016,,,hematopoietic stem cell transplantation,,,,D018380,,,
258,Allogeneic peripheral blood mononuclear cells induced to an early apoptotic state,EU/3/14/1426,Prevention of graft-versus-host disease,Richardson Associates Regulatory Affairs Ltd,15/01/2015,,,graftversushost disease,,,,D006086,,,Q1194520
259,Allogeneic T cells encoding an exogenous TK gene,EU/3/10/773,Treatment of acute myeloid leukaemia,LTKFarma,20/09/2010,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
260,Allogeneic T cells encoding an exogenous TK gene,EU/3/11/878,Treatment of acute lymphoblastic leukaemia,LTKFarma,21/06/2011,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
261,"Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells",EU/3/14/1413,Treatment of acute myeloid leukaemia,Regulatory Resources Group Ltd,15/01/2015,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
262,Allopurinol sodium,EU/3/12/1076,Treatment of perinatal asphyxia,Pharmathen S.A.,06/12/2012,,Q27258510,perinatal asphyxia,,,,,,,
263,Allopurinol sodium,EU/3/15/1493,Treatment of perinatal asphyxia,ACE Pharmaceuticals BV,21/05/2015,,Q27258510,perinatal asphyxia,,,,,,,
264,Alpha-1 antitrypsin (inhalation use),EU/3/04/243,Treatment of cystic fibrosis,Triskel EU Services Ltd,16/11/2004,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
265,Alpha-1 antitrypsin (inhalation use),EU/3/04/244,Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency,Kamada BioPharma Limited,16/11/2004,,,emphysema secondary to congenital alpha1 antitrypsin deficiency,,,,,,,
266,Alpha-1 proteinase inhibitor,EU/3/06/350,Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency,Octapharma (IP) Limited,16/02/2006,,,emphysema secondary to congenital alpha1 antitrypsin deficiency,,,,,,,
267,Alpha-1 proteinase inhibitor (for inhalation use),EU/3/12/1045,Treatment of cystic fibrosis,Grifols Deutschland GmbH,10/10/2012,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
268,Alpha-1 proteinase inhibitor (inhalation use),EU/3/07/474,Treatment of cystic fibrosis,CSL Behring GmbH,14/09/2007,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
269,Alpha-1 proteinase inhibitor (inhalation use),EU/3/08/546,Treatment of congenital alpha-1 antitrypsin deficiency,Grifols Deutschland GmbH,03/06/2008,,,congenital alpha1 antitrypsin deficiency,,,,,,,
270,Alpha-tocopherol,EU/3/16/1775,Treatment of facioscapulohumeral muscular dystrophy,Université de Montpellier,18/11/2016,,Q158348,facioscapulohumeral muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11727,,http://www.orpha.net/ORDO/Orphanet_269,D020391,Q1399182,,Q1399182
271,Alpha-tocotrienol quinone,EU/3/11/937,Treatment of Leigh syndrome,Edison Orphan Pharma BV,09/12/2011,,,leigh syndrome,http://purl.obolibrary.org/obo/DOID_3652,,http://www.orpha.net/ORDO/Orphanet_506,D007888,Q1815019,Q1815019,Q1815019
272,Alvocidib,EU/3/07/485,Treatment of chronic lymphocytic leukaemia,Theorem Clinical Research GmbH,23/10/2007,,Q4063441,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
273,Alvocidib,EU/3/15/1437,Treatment of acute myeloid leukaemia,Theorem Clinical Research GmbH,12/02/2015,,Q4063441,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
274,Amatuximab,EU/3/13/1222,Treatment of malignant mesothelioma,Eisai Europe Limited,16/01/2014,,Q4740637,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
275,Ambrisentan,EU/3/05/273,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,Glaxo Group Ltd,11/04/2005,VolibrisEU/1/08/45124/04/2008,Q410789,pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,,,,,,,
276,Amikacin sulfate,EU/3/14/1259,Treatment of nontuberculous mycobacterial lung disease,Insmed Limited,08/04/2014,,Q27105754,nontuberculos mycobacterial lung disease,,,http://www.orpha.net/ORDO/Orphanet_411703,,,,
277,Amikacin sulfate,EU/3/14/1397,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,PlumeStars s.r.l.,16/12/2014,,Q27105754,pseudomonas eruginosa lung infection in cystic fibrosis,,,,,,,
278,Amikacin sulfate (liposomal),EU/3/06/387,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,Insmed Limited,25/07/2006,,,pseudomonas eruginosa lung infection in cystic fibrosis,,,,,,,
279,Ammonium tetrathiomolybdate,EU/3/08/539,Treatment of Wilson's disease,JJGConsultancy Ltd,01/04/2008,,,wilsons disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
280,Amphotericin B (for inhalation use),EU/3/06/391,Prevention of pulmonary fungal infection in patients deemed at risk,Novartis Europharm Limited,28/08/2006,,,pulmonary fungal infection in patients deemed at risk,,,,,,,
281,Anti epidermal growth factor receptor antibody h-R3,EU/3/04/220,Treatment of glioma,Oncoscience AG,02/09/2004,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
282,Anti-epithelial cell adhesion molecule / anti-CD3 monoclonal antibody,EU/3/04/193,Treatment of ovarian cancer,Neovii Biotech GmbH,08/03/2004,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
283,Anti-H5N1 equine immunoglobulin F(ab')2 fragments,EU/3/15/1512,Treatment of avian influenza,Fab'entech,28/07/2015,,,avian influenza,http://purl.obolibrary.org/obo/DOID_4492,,http://www.orpha.net/ORDO/Orphanet_454836,D005585,Q43987,,Q43987
284,Antisense NF-Kß p65 Oligonucleotide,EU/3/02/106,Treatment of active ulcerative colitis,InDex Pharmaceuticals AB,30/07/2002,,,active ulcerative colitis,,,,,,,
285,Antisense oligonucleotide 5'-d[P-Thio](CCCTG CTCCC CCCTG GCTCC)-3',EU/3/06/416,Treatment of acute myeloid leukaemia,EleosInc Limited,03/11/2006,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
286,Antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA,EU/3/16/1641,Treatment of Leber&#8217;s congenital amaurosis,ProQR Therapeutics IV BV,28/04/2016,,,lebers congenital amaurosis,http://purl.obolibrary.org/obo/DOID_14791,,,,Q1811132,,
287,Antisense oligonucleotide directed against TGF-beta2 mRNA,EU/3/15/1506,Prevention of scarring post glaucoma filtration surgery,Isarna Therapeutics GmbH,19/06/2015,,Q199678,scarring post glaucoma filtration surgery,,,,,,,
288,Antisense oligonucleotide targeted to the SMN2 gene,EU/3/12/976,Treatment of 5q spinal muscular atrophy,Biogen Idec Limited,02/04/2012,,,5q spinal muscular atrophy,,,,,,,
289,Antisense oligonucleotide targeting the F508delta mutation of CFTR,EU/3/13/1195,Treatment of cystic fibrosis,ProQR Therapeutics III BV,07/10/2013,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
290,Antisense Oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT),EU/3/03/160,Treatment of retinopathy of prematurity,Gene Signal SAS,02/10/2003,,,retinopathy of prematurity,http://purl.obolibrary.org/obo/DOID_13025,,http://www.orpha.net/ORDO/Orphanet_90050,D012178,Q1423087,,Q1423087
291,Antisense Oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT),EU/3/03/161,Treatment of neovascular glaucoma,Gene Signal SAS,02/10/2003,,,neovascular glaucoma,http://purl.obolibrary.org/obo/DOID_1687,,http://www.orpha.net/ORDO/Orphanet_94058,D015355,Q7885682,,Q7885682
292,Antisense Oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT),EU/3/07/445,Prevention of corneal graft rejection,Gene Signal SAS,17/04/2007,,,corneal graft rejection,,,,,,,
293,Antroquinonol,EU/3/16/1812,Treatment of pancreatic cancer,Biological Consulting Europe Ltd,12/01/2017,,Q27133859,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
294,Aplidine,EU/3/04/245,Treatment of multiple myeloma,Pharma Mar S.A.,16/11/2004,,Q4779975,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
295,Apomorphine hydrochloride,EU/3/11/862,Treatment of moderate and severe traumatic brain injury,Dr Elkan Raphael Gamzu,13/05/2011,,Q27114230,moderate and severe traumatic brain injury,,,,,,,
296,Apomorphine hydrochloride (inhalation use),EU/3/06/349,Treatment of off-periods in Parkinson&#8217;s disease not responding to oral treatment,Vectura Group plc,16/02/2006,,,offperiods in parkinsons disease not responding to oral treatment,,,,,,,
297,Apremilast,EU/3/13/1180,Treatment of Beh&ccedil;et's disease,Celgene Europe Limited,05/08/2013,,Q2858961,beh&ccedil;ets disease,,,,,,,
298,Arimoclomol,EU/3/06/406,Treatment of amyotrophic lateral sclerosis,Orphazyme ApS,26/10/2006,,Q4790694,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
299,Arimoclomol citrate,EU/3/14/1376,"Treatment of Niemann-Pick disease, type C",Orphazyme ApS,19/11/2014,,Q27287107,"niemannpick disease, type c",,,,D052556,,,Q2067267
300,Arimoclomol citrate,EU/3/16/1659,Treatment of inclusion body myositis,Orphazyme ApS,30/05/2016,,Q27287107,inclusion body myositis,http://purl.obolibrary.org/obo/DOID_3429,,http://www.orpha.net/ORDO/Orphanet_611,D018979,Q1848471,,Q1848471
301,Arsenic trioxide,EU/3/16/1610,Treatment of acute myeloid leukaemia,Orsenix Holdings BV,17/02/2016,,Q26841209,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
302,Arsenic trioxide,EU/3/16/1797,Treatment of graft-versus-host disease,Medsenic,12/12/2016,,Q26841209,graftversushost disease,,,,D006086,,,Q1194520
303,artesunate,EU/3/07/430,Treatment of malaria,ACE Pharmaceuticals BV,20/02/2007,,Q707939,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
304,artesunate,EU/3/07/510,Treatment of malaria,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A,06/12/2007,,Q707939,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
305,Artesunate,EU/3/12/1079,Treatment of malaria,Dafra Pharma International NV,06/12/2012,,Q707939,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
306,Artesunate,EU/3/15/1521,Treatment of malaria,Dr Ulrich Granzer,28/07/2015,,Q707939,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
307,ascorbic acid,EU/3/08/531,Treatment of Charcot-Marie-Tooth disease type 1A,Murigenetics SAS,01/04/2008,,Q199678,charcotmarietooth disease type 1a,http://purl.obolibrary.org/obo/DOID_0110148,,http://www.orpha.net/ORDO/Orphanet_101081,,Q27677640,,
308,Ascorbic acid,EU/3/16/1776,Treatment of facioscapulohumeral muscular dystrophy,Université de Montpellier,18/11/2016,,Q199678,facioscapulohumeral muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11727,,http://www.orpha.net/ORDO/Orphanet_269,D020391,Q1399182,,Q1399182
309,Asp-Arg-Val-Tyr-Ile-His-Pro,EU/3/14/1241,Treatment of Duchenne muscular dystrophy,Envigo Pharma Consulting Ltd,19/02/2014,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
310,Ataluren,EU/3/12/1010,Treatment of Becker muscular dystrophy,PTC Therapeutics International Limited,04/07/2012,,Q753330,becker muscular dystrophy,http://purl.obolibrary.org/obo/DOID_9883,,http://www.orpha.net/ORDO/Orphanet_98895,D020388,Q2484592,Q2484592,Q1648484
311,Ataluren,EU/3/14/1380,Treatment of mucopolysaccharidosis type I,PTC Therapeutics International Limited,19/11/2014,,Q753330,mucopolysaccharidosis type i,,,http://www.orpha.net/ORDO/Orphanet_579,D008059,,,Q1906054
312,Ataluren,EU/3/15/1561,Treatment of aniridia,PTC Therapeutics International Limited,09/10/2015,,Q753330,aniridia,http://purl.obolibrary.org/obo/DOID_12271,http://purl.obolibrary.org/obo/HP_0000526,http://www.orpha.net/ORDO/Orphanet_77,D015783,Q548719,,Q548719
313,Autologous adipose tissue-derived stromal vascular fraction cells,EU/3/15/1464,Treatment of systemic sclerosis,Assistance Publique Hôpitaux de Marseille,19/03/2015,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
314,Autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors,EU/3/13/1148,Treatment of amyotrophic lateral sclerosis,Brainstorm Cell Therapeutics UK Ltd,17/07/2013,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
315,Autologous bone marrow-derived mononuclear cell fraction,EU/3/10/775,Treatment of thromboangiitis obliterans (Buerger's disease),t2cure GmbH,20/09/2010,,,thromboangiitis obliterans (buergers disease),,,,,,,
316,Autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene,EU/3/13/1134,Treatment of adenosine deaminase-deficient-severe combined immunodeficiency,Prof. Bobby Gaspar,07/06/2013,,,adenosine deaminasedeficientsevere combined immunodeficiency,,,,,,,
317,Autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene,EU/3/14/1257,Treatment of recombination-activating gene 1 deficient severe combined immunodeficiency,Prof. F.J.T.Staal,26/03/2014,,,recombinationactivating gene 1 deficient severe combined immunodeficiency,,,,,,,
318,Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene,EU/3/14/1280,Treatment of mucopolysaccharidosis IIIA (Sanfilippo A syndrome),Cochamo Systems Ltd,10/06/2014,,,mucopolysaccharidosis iiia (sanfilippo a syndrome),,,,,,,
319,Autologous CD34+ cells transduced with a lentiviral vector containing the human Wiskott-Aldrich syndrome gene,EU/3/13/1196,Treatment of Wiskott-Aldrich-syndrome,Généthon,07/10/2013,,,wiskottaldrichsyndrome,,,,,,,
320,Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene,EU/3/16/1660,Treatment of beta thalassaemia intermedia and major,Fondazione Telethon,30/05/2016,,,beta thalassemia intermedia and major,,,,,,,
321,Autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA,EU/3/07/446,Treatment of metachromatic leukodystrophy,GlaxoSmithKline Trading Services Limited,13/04/2007,,,metachromatic leukodystrophy,http://purl.obolibrary.org/obo/DOID_10581,,http://www.orpha.net/ORDO/Orphanet_512,D007966,Q1120682,Q1120682,Q1120682
322,Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene,EU/3/12/998,Treatment of Wiskott-Aldrich syndrome,GlaxoSmithKline Trading Services Limited,06/06/2012,,,wiskottaldrich syndrome,http://purl.obolibrary.org/obo/DOID_9169,,http://www.orpha.net/ORDO/Orphanet_906,D014923,Q953638,,Q953638
323,Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene,EU/3/05/313,Treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency,GlaxoSmithKline Trading Services Limited,26/08/2005,StrimvelisEU/1/16/109730/05/2016,,severe combined immunodeficiency (scid) due to adenosine deaminase (ada) deficiency,,,,,,,
324,Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene,EU/3/14/1263,Treatment of sickle cell disease,bluebird bio France,29/04/2014,,Q27892746,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
325,Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene,EU/3/12/1091,Treatment of beta-thalassaemia intermedia and major,bluebird bio France,24/01/2013,,,betathalassemia intermedia and major,,,,,,,
326,Autologous CD4+ and CD8+ T-cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1,EU/3/16/1694,Treatment of soft tissue sarcoma,Adaptimmune Limited,14/07/2016,,Q6703005,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
327,Autologous collagen type II-specific regulatory T cells,EU/3/14/1405,Treatment of non-infectious uveitis,TxCell,16/12/2014,,,noninfectios uveitis,,,,,,,
328,Autologous dendritic cells incubated ex vivo with zebularine and factor VIII,EU/3/16/1813,Treatment of haemophilia A,Idogen AB,12/01/2017,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
329,Autologous dendritic cells pulsed with allogeneic tumour cell lysate,EU/3/13/1229,Treatment of malignant mesothelioma,Amphera BV,16/01/2014,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
330,Autologous dendritic cells pulsed with autologous tumour cell lysate,EU/3/07/431,Treatment of glioma,Northwest Biotherapeutics GmbH,15/02/2007,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
331,Autologous dendritic cells pulsed with recombinant human-fusion protein (mucin 1 - glutathione S transferase) coupled to oxidised polymannose,EU/3/10/776,Treatment of ovarian cancer,Prima Biomed GmbH,20/09/2010,,Q27288045,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
332,Autologous dendritic cells pulsed with RNA from glioma stem cells,EU/3/14/1273,Treatment of glioma,Epitarget AS,04/06/2014,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
333,"Autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha)",EU/3/14/1247,Treatment of glioma,Diamond BioPharm Limited,19/02/2014,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
334,Autologous dermal fibroblasts genetically modified ex vivo with a lentiviral vector containing the human COL7A1 gene,EU/3/16/1642,Treatment of epidermolysis bullosa,Intrexon Actobiotics N.V.,28/04/2016,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
335,"Autologous Epstein-Barr virus specific T-cells derived from peripheral blood mononuclear cells, expanded ex vivo",EU/3/16/1695,"Treatment of extranodal NK/T-cell lymphoma, nasal type",Cell Medica Ltd.,14/07/2016,,,"extranodal nk/tcell lymphoma, nasal type",,,,,,,
336,"Autologous Epstein-Barr virus specific T-cells derived from peripheral blood mononuclear cells, expanded ex vivo",EU/3/16/1696,Treatment of post-transplant lymphoproliferative disorder,Cell Medica Ltd.,14/07/2016,,,posttransplant lymphoproliferative disorder,,,,,,,
337,Autologous ex-vivo-expanded leucocytes treated with 5-aza-2’-deoxycytidine,EU/3/13/1197,Treatment of glioma,CytoVac A/S,13/11/2013,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
338,Autologous haematopoietic cells genetically modified with a lentiviral vector containing the human gp91(phox) gene,EU/3/12/957,Treatment of X-linked chronic granulomatous disease,Généthon,09/02/2012,,,xlinked chronic granulomatos disease,,,,D006105,,,Q2165663
339,Autologous haematopoietic stem cells transduced with lentiviral vector encoding the human beta-globin gene,EU/3/09/623,Treatment of beta-thalassaemia intermedia and major,EGT San Rocco Italia SRL,29/04/2009,,,betathalassemia intermedia and major,,,,,,,
340,Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA,EU/3/12/1003,Treatment of adrenoleukodystrophy,bluebird bio France,06/06/2012,,Q5772985,adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_117677,D000326,Q366964,,Q366964
341,Autologous human peripheral blood Vdelta1+ T lymphocytes activated in vitro by cytokine and monoclonal antibody treatment,EU/3/15/1566,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,Lymphact - Lymphocyte Activation Technologies S.A.,09/10/2015,,,chronic lymphocytic leukemia / small lymphocytic lymphoma,,,,,,,
342,Autologous mesenchymal stromal cells on a decellularised tracheal scaffold from a cadaveric donor,EU/3/16/1717,Treatment of tracheal stenosis,Videregen Ltd,29/08/2016,,,tracheal stenosis,http://purl.obolibrary.org/obo/DOID_3227,http://purl.obolibrary.org/obo/HP_0002777,,D014135,Q4116448,,Q4116448
343,Autologous mononuclear cells derived from human cord blood,EU/3/16/1743,Treatment of neonatal encephalopathy,BrainRepair UG (haftungsbeschränkt),14/10/2016,,,neonatal encephalopathy,,,,,,,
344,Autologous mononuclear cells derived from human cord blood,EU/3/16/1744,Treatment of periventricular leukomalacia,BrainRepair UG (haftungsbeschränkt),14/10/2016,,,periventricular leukomalacia,http://purl.obolibrary.org/obo/DOID_13088,http://purl.obolibrary.org/obo/HP_0006970,http://www.orpha.net/ORDO/Orphanet_171676,D007969,Q469490,,Q469490
345,Autologous regulatory T cells with an immunophenotype of CD4+CD25hiFoxP3+,EU/3/13/1171,Prevention of graft rejection following solid organ transplantation,iReg Medical AB,07/10/2013,,,graft rejection following solid organ transplantation,,,,,,,
346,Autologous renal cell tumor vaccine,EU/3/02/116,Treatment of renal cell carcinoma,Liponova GmbH,21/10/2002,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
347,Autologous stromal vascular cell fraction from adipose tissue,EU/3/16/1643,Treatment of systemic sclerosis,Cytori Ltd,28/04/2016,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
348,Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,EU/3/14/1266,Treatment of B-lymphoblastic leukaemia/lymphoma,Novartis Europharm Limited,29/04/2014,,,blymphoblastic leukemia/lymphoma,,,,,,,
349,Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,EU/3/16/1745,Treatment of diffuse large B-cell lymphoma,Novartis Europharm Limited,14/10/2016,,,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
350,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor,EU/3/14/1393,Treatment of diffuse large B cell lymphoma,"Kite Pharma UK, Ltd",16/12/2014,,,diffuse large b cell lymphoma,,,,,,,
351,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,EU/3/15/1552,Treatment of mantle cell lymphoma,"Kite Pharma UK, Ltd",09/10/2015,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
352,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,EU/3/15/1553,Treatment of primary mediastinal large B-cell lymphoma,"Kite Pharma UK, Ltd",09/10/2015,,,primary mediastinal large bcell lymphoma,,,http://www.orpha.net/ORDO/Orphanet_98838,,,,
353,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,EU/3/15/1571,Treatment of acute lymphoblastic leukaemia,"Kite Pharma UK, Ltd",11/11/2015,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
354,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,EU/3/15/1572,Treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma,"Kite Pharma UK, Ltd",11/11/2015,,,chronic lymphocytic leukemia/small lymphocytic lymphoma,http://purl.obolibrary.org/obo/DOID_6354,,,,Q18557229,,
355,Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor,EU/3/15/1579,Treatment of follicular lymphoma,"Kite Pharma UK, Ltd",11/11/2015,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
356,Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex,EU/3/05/270,Treatment of renal cell carcinoma,Antigenics Therapeutics Limited,11/04/2005,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
357,Autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin,EU/3/06/394,Treatment of follicular lymphoma,Biovest Europe Limited,28/08/2006,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
358,Autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin,EU/3/10/831,Treatment of mantle cell lymphoma,Biovest Europe Limited,23/02/2011,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
359,Autologous tumour-derived gp96 heat shock protein-peptide complex,EU/3/09/624,Treatment of glioma,Antigenics Therapeutics Limited,29/04/2009,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
360,Avelumab,EU/3/16/1798,Treatment of gastric cancer,Merck Serono Europe Limited,12/12/2016,,Q21083261,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
361,Avian polyclonal IgY antibody against Pseudomonas aeruginosa,EU/3/08/564,Treatment of cystic fibrosis,Immunsystem I.M.S. AB,23/09/2008,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
362,Aviptadil,EU/3/06/395,Treatment of acute lung injury,mondoBIOTECH Laboratories Anstalt,28/08/2006,,Q4828930,acute lung injury,,,http://www.orpha.net/ORDO/Orphanet_178320,D055371,,,
363,Aviptadil,EU/3/07/473,Treatment of sarcoidosis,mondoBIOTECH Laboratories Anstalt,14/09/2007,,Q4828930,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
364,Azacitidine,EU/3/01/084,Treatment of myelodysplastic syndromes,Celgene Europe Limited,06/02/2002,VidazaEU/1/08/48822/12/2008,Q416451,myelodysplastic syndromes,,,,D009190,,,Q954625
365,Azacitidine,EU/3/07/509,Treatment of acute myeloid leukaemia,Celgene Europe Limited,29/11/2007,VidazaEU/1/08/48822/12/2008,Q416451,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
366,Aztreonam lysinate (inhalation use),EU/3/04/204,Treatment of gram negative bacteria lung infections in cystic fibrosis,Gilead Sciences International Ltd,21/06/2004,CaystonEU/1/09/54323/09/2009,,gram negative bacteria lung infections in cystic fibrosis,,,,,,,
367,Bacterial lipase,EU/3/05/323,Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency,Nordmark Arzneimittel GmbH u. Co. KG,07/11/2005,,,malabsorption due to exocrine pancreatic enzyme insufficiency,,,,,,,
368,Bazedoxifene acetate,EU/3/14/1367,Treatment of hereditary haemorrhagic telangiectasia,Consejo Superior de Investigaciones Cientificas (CSIC),19/11/2014,,Q27281282,hereditary hemorrhagic telangiectasia,http://purl.obolibrary.org/obo/DOID_1270,,http://www.orpha.net/ORDO/Orphanet_774,D013683,Q776881,Q776881,Q776881
369,Becatecarin,EU/3/06/388,Treatment of cancers of the biliary tree,Helsinn Birex Pharmaceuticals Ltd,25/07/2006,,Q27273671,cancers of the biliary tree,,,,,,,
370,"Beclomethasone 17, 21-dipropionate (oral use)",EU/3/02/093,Treatment of intestinal graft-versus-host disease,Soligenix UK Ltd,13/03/2002,,,intestinal graftversushost disease,,,,,,,
371,Belinostat,EU/3/12/1055,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)","Onxeo DK, Filial af Onxeo S.A., Frankrig",10/10/2012,,Q4882925,"peripheral tcell lymphoma (nodal, other extranodal and leukemic/disseminated)",,,,,,,
372,Belinostat,EU/3/13/1151,Treatment of malignant thymoma,"Onxeo DK, Filial af Onxeo S.A., Frankrig",17/07/2013,,Q4882925,malignant thymoma,http://purl.obolibrary.org/obo/DOID_3284,,http://www.orpha.net/ORDO/Orphanet_99868,,Q7799620,Q7799620,
373,Beloranib,EU/3/14/1287,Treatment of Prader-Willi syndrome,FGK Representative Service GmbH,04/07/2014,,Q4884554,praderwilli syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
374,Beloranib,EU/3/15/1530,Treatment of craniopharyngioma,FGK Representative Service GmbH,28/07/2015,,Q4884554,craniopharyngioma,http://purl.obolibrary.org/obo/DOID_3840,http://purl.obolibrary.org/obo/HP_0030062,http://www.orpha.net/ORDO/Orphanet_54595,D003397,Q1786513,,Q18556089
375,Benserazide hydrochloride,EU/3/14/1402,Treatment of beta-thalassaemia intermedia and major,Isabelle Ramirez,16/12/2014,,Q27114249,betathalassemia intermedia and major,,,,,,,
376,"Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]",EU/3/09/715,Treatment of acute lymphoblastic leukaemia,Incyte Biosciences UK Ltd,02/02/2010,IclusigEU/1/13/83903/07/2013,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
377,"Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]",EU/3/09/716,Treatment of chronic myeloid leukaemia,Incyte Biosciences UK Ltd,02/02/2010,IclusigEU/1/13/83903/07/2013,,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
378,"Benzoic acid, sodium salt",EU/3/02/111,Treatment of non-ketotic hyperglycinaemia,Lucane Pharma SA,11/09/2002,,Q423971,nonketotic hyperglycinemia,http://purl.obolibrary.org/obo/DOID_9268,http://purl.obolibrary.org/obo/HP_0008288,http://www.orpha.net/ORDO/Orphanet_407,D020158,Q3053945,Q3053945,Q3053945
379,Beraprost sodium (modified release tablet),EU/3/08/554,Treatment of pulmonary arterial hypertension,IDEA Innovative Drug European Associates Limited,10/07/2008,,,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
380,Beta-artemether / lumefantrine (powder for oral suspension),EU/3/09/702,Treatment of malaria,Dafra Pharma International NV,28/01/2010,,,malaria,http://purl.obolibrary.org/obo/DOID_12365,,http://www.orpha.net/ORDO/Orphanet_673,D008288,Q12156,,Q12156
381,Betaine anhydrous,EU/3/01/045,Treatment of homocystinuria,Orphan Europe S.A.R.L.,09/07/2001,CystadaneEU/1/06/37919/02/2007,,homocystinuria,http://purl.obolibrary.org/obo/DOID_9263,http://purl.obolibrary.org/obo/HP_0002156,,D006712,Q994859,,Q994859
382,Bevacizumab,EU/3/14/1390,Treatment of hereditary haemorrhagic telangiectasia,Dr Sophie Dupuis-Girod,16/12/2014,,Q413299,hereditary hemorrhagic telangiectasia,http://purl.obolibrary.org/obo/DOID_1270,,http://www.orpha.net/ORDO/Orphanet_774,D013683,Q776881,Q776881,Q776881
383,Bilayer engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts,EU/3/15/1596,Treatment of partial deep dermal and full thickness burns,Voisin Consulting S.A.R.L.,14/12/2015,,,partial deep dermal and full thickness burns,,,,,,,
384,Bilayer engineered skin composed of keratinocytes from the patient (autologous) and fibroblasts from a donor (allogeneic) embedded in a plasma matrix,EU/3/06/369,Treatment of epidermolysis bullosa,Biodan Yelah S.L.,22/05/2006,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
385,Bimosiamose disodium,EU/3/05/285,Treatment of acute lung injury,Revotar Biopharmaceuticals AG,27/05/2005,,Q27266838,acute lung injury,,,http://www.orpha.net/ORDO/Orphanet_178320,D055371,,,
386,Biotinylated anti-tenascin monoclonal antibody for use with 90-Yttrium,EU/3/04/232,Treatment of glioma,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A,20/10/2004,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
387,Blinatumomab,EU/3/09/650,Treatment of acute lymphoblastic leukaemia,Amgen Europe B.V.,24/07/2009,BlincytoEU/1/15/104725/11/2015,Q410189,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
388,Bosutinib,EU/3/10/762,Treatment of chronic myeloid leukaemia,Pfizer Limited,04/08/2010,BosulifEU/1/13/81802/04/2013,Q894611,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
389,Bovine bile extract,EU/3/05/287,Treatment of pancreatic cancer,Dr Ulrich Granzer,20/06/2005,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
390,Brentuximab vedotin,EU/3/11/939,Treatment of cutaneous T-cell lymphoma,Takeda Pharma A/S,11/01/2012,,Q422324,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
391,Brincidofovir,EU/3/16/1644,Prevention of cytomegalovirus disease,Chimerix UK Ltd,28/04/2016,,Q15411004,cytomegalovirus disease,,,,,,,
392,Brincidofovir,EU/3/16/1697,Treatment of adenovirus infection in immunocompromised patients,Chimerix UK Ltd,14/07/2016,,Q15411004,adenovirus infection in immunocompromised patients,,,,,,,
393,Brincidofovir,EU/3/16/1777,Treatment of smallpox,Chimerix UK Ltd,18/11/2016,,Q15411004,smallpox,http://purl.obolibrary.org/obo/DOID_8736,,,D012899,Q12214,,Q18558071
394,Brivudine,EU/3/09/703,Treatment of pancreatic cancer,RESprotect GmbH,28/01/2010,,Q904107,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
395,Budesonide,EU/3/13/1181,Treatment of eosinophilic oesophagitis,Dr Falk Pharma GmbH,05/08/2013,,Q422212,eosinophilic oesophagitis,,,,,,,
396,Budesonide,EU/3/16/1778,Treatment of primary IgA nephropathy,Pharmalink AB,18/11/2016,,Q422212,primary iga nephropathy,http://purl.obolibrary.org/obo/DOID_2986,,,,Q1146454,,
397,Budesonide (oral use),EU/3/06/413,Treatment of Graft-versus-Host disease,Dr Falk Pharma GmbH,03/11/2006,,Q27252075,graftversushost disease,,,,D006086,,,Q1194520
398,Cabiralizumab,EU/3/16/1799,"Treatment of tenosynovial giant cell tumour, localised and diffuse type",Albany Regulatory Consulting Limited,12/12/2016,,,"tenosynovial giant cell tumor, localised and diffuse type",,,,,,,
399,Caffeine citrate,EU/3/03/132,Treatment of primary apnoea of premature newborns,Chiesi Farmaceutici S.P.A.,17/02/2003,PeyonaEU/1/09/52806/07/2009,Q2974480,primary apnoea of premature newborns,,,,,,,
400,Caffeine citrate,EU/3/14/1261,Prevention of bronchopulmonary dysplasia,Viridian Pharma Ltd,11/04/2014,,Q2974480,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
401,Cannabidiol,EU/3/14/1339,Treatment of Dravet syndrome,GW Pharma Ltd,15/10/2014,,Q422917,dravet syndrome,http://purl.obolibrary.org/obo/DOID_0060171,,http://www.orpha.net/ORDO/Orphanet_33069,D004831,Q1255956,Q1255956,Q17147280
402,Cannabidiol,EU/3/15/1520,Treatment of perinatal asphyxia,GW Pharma Ltd,28/07/2015,,Q422917,perinatal asphyxia,,,,,,,
403,Cannabidiol,EU/3/16/1645,Prevention of graft-versus-host disease,Richardson Associates Regulatory Affairs Ltd,28/04/2016,,Q422917,graftversushost disease,,,,D006086,,,Q1194520
404,Cannabidiol,EU/3/16/1718,Treatment of graft-versus-host disease,Richardson Associates Regulatory Affairs Ltd,29/08/2016,,Q422917,graftversushost disease,,,,D006086,,,Q1194520
405,Carbamazepine,EU/3/16/1746,"Treatment of metaphyseal chondrodysplasia, Schmid type",University of Newcastle upon Tyne,14/10/2016,,Q410412,"metaphyseal chondrodysplasia, schmid type",,,http://www.orpha.net/ORDO/Orphanet_174,,,,
406,Carbetocin,EU/3/12/975,Treatment of Prader-Willi syndrome,Ferring Pharmaceuticals A/S,21/03/2012,,Q5037853,praderwilli syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
407,Carboxy pyrrolidine hexanoyl pyrrolidine carboxylate,EU/3/14/1292,Treatment of AL amyloidosis,GlaxoSmithKline Trading Services Limited,30/07/2014,,,al amyloidosis,,,http://www.orpha.net/ORDO/Orphanet_85443,,,,
409,Cardiotrophin-1,EU/3/06/396,Prevention of the ischemia/reperfusion injury associated with solid organ transplantation,Digna Biotech S.L.,28/08/2006,,Q339975,the ischemia/reperfusion injury associated with solid organ transplantation,,,,,,,
410,Cardiotrophin-1,EU/3/11/893,Treatment of acute liver failure,Digna Biotech S.L.,30/08/2011,,Q339975,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
411,Carfilzomib,EU/3/08/548,Treatment of multiple myeloma,Amgen Europe B.V.,03/06/2008,KyprolisEU/1/15/106023/11/2015,Q15366934,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
412,Carglumic acid,EU/3/08/575,Treatment of isovaleric acidaemia,Orphan Europe S.A.R.L.,07/11/2008,CarbagluEU/1/02/24601/06/2011,Q822884,isovaleric acidemia,http://purl.obolibrary.org/obo/DOID_14753,,http://www.orpha.net/ORDO/Orphanet_33,,Q3278042,Q3278042,
413,Carglumic acid,EU/3/08/576,Treatment of methylmalonic acidaemia,Orphan Europe S.A.R.L.,07/11/2008,CarbagluEU/1/02/24601/06/2011,Q822884,methylmalonic acidemia,http://purl.obolibrary.org/obo/DOID_14749,http://purl.obolibrary.org/obo/HP_0002912,,,Q742500,,
414,Carglumic acid,EU/3/08/577,Treatment of propionic acidaemia,Orphan Europe S.A.R.L.,07/11/2008,CarbagluEU/1/02/24601/06/2011,Q822884,propionic acidemia,http://purl.obolibrary.org/obo/DOID_14701,,http://www.orpha.net/ORDO/Orphanet_35,D056693,Q7250337,Q7250337,Q7250337
415,Catumaxomab,EU/3/06/414,Treatment of gastric cancer,Neovii Biotech GmbH,03/11/2006,,Q408155,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
416,CD33-directed antibody-drug conjugate consisting of an antibody conjugated to a DNA cross-linking pyrrolobenzodiazepine dimer drug,EU/3/15/1545,Treatment of acute myeloid leukaemia,"Seattle Genetics UK, Limited",10/08/2015,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
417,Cediranib,EU/3/14/1303,Treatment of ovarian cancer,AstraZeneca AB,29/07/2014,,Q5057052,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
418,Ceftriaxone,EU/3/14/1425,Treatment of spinocerebellar ataxia,Ospedale San Raffaele s.r.l.,15/01/2015,,Q421713,spinocerebellar ataxia,,,,D020754,,,Q899726
419,Celecoxib,EU/3/01/070,Treatment of Familial Adenomatous Polyposis,Pfizer Limited,20/11/2001,OnsenalEU/1/03/25922/10/2003,Q408801,familial adenomatos polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
420,Cenersen,EU/3/08/587,Treatment of chronic lymphocytic leukaemia,EleosInc Limited,03/12/2008,,Q27282015,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
421,Chemically modified human recombinant sulfamidase,EU/3/16/1747,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),Swedish Orphan Biovitrum AB (publ),14/10/2016,,,mucopolysaccharidosis type iiia (sanfilippo a syndrome),,,,,,,
422,Chenodeoxycholic acid,EU/3/14/1406,Treatment of inborn errors of primary bile acid synthesis,sigma-tau Arzneimittel GmbH,16/12/2014,,Q419028,inborn errors of primary bile acid synthesis,,,,,,,
423,Chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA,EU/3/15/1453,Treatment of Huntington&#8217;s disease,Ionis USA Limited,19/03/2015,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
424,Chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2,EU/3/14/1422,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),BioMarin Europe Ltd.,15/01/2015,,,mucopolysaccharidosis type iiib (sanfilippo b syndrome),,,,,,,
425,Chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions,EU/3/15/1434,Treatment of ovarian cancer,PsiOxus Therapeutics Ltd,12/02/2015,,Q423971,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
426,Chimeric IgG monoclonal antibody cG250,EU/3/02/094,Treatment of renal cell carcinoma,Wilex AG,19/03/2002,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
427,Chimeric locked nucleic acid-deoxynucleoside phosphorothioate-linked oligonucleotide directed against microRNA-451,EU/3/11/940,Treatment of polycythaemia vera,Miragen Therapeutics Europe Ltd,11/01/2012,,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
428,Chimeric monoclonal antibody against claudin 6,EU/3/12/1092,Treatment of ovarian cancer,GANYMED Pharmaceuticals AG,24/01/2013,,Q1106,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
429,Chimeric monoclonal antibody against claudin-18 splice variant 2,EU/3/10/803,Treatment of gastric cancer,GANYMED Pharmaceuticals AG,26/11/2010,,,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
430,Chimeric monoclonal antibody against claudin-18 splice variant 2,EU/3/13/1177,Treatment of pancreatic cancer,GANYMED Pharmaceuticals AG,05/08/2013,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
431,Chimeric monoclonal antibody against GD2,EU/3/11/879,Treatment of neuroblastoma,United Therapeutics Europe Ltd,21/06/2011,UnituxinEU/1/15/102218/08/2015,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
432,Chimeric monoclonal antibody against GD2,EU/3/12/1062,Treatment of neuroblastoma,APEIRON Biologics AG,08/11/2012,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
433,Chimeric monoclonal antibody to O-acetyl-GD2 antigen,EU/3/14/1416,Treatment of neuroblastoma,OGD2 Pharma,15/01/2015,,Q27089127,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
434,Chimeric monoclonal antibody to shiga-toxin 1 and 2,EU/3/05/301,Treatment of shiga-toxin producing bacterial infection.,Albany Regulatory Consulting Limited,26/08/2005,,,shigatoxin producing bacterial infection.,,,,,,,
435,Chimeric-anti-interleukin-6 monoclonal antibody,EU/3/07/508,Treatment of Castleman&#8217;s disease,Janssen-Cilag International NV,30/11/2007,SylvantEU/1/14/92827/05/2014,,castlemans disease,,,,D005871,,,
436,Chlormethine,EU/3/12/963,Treatment of cutaneous T-cell lymphoma,Actelion Registration Ltd,22/05/2012,,Q418011,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
437,Chloroquine,EU/3/14/1377,Treatment of glioma,DualTpharma B.V.,19/11/2014,,Q422438,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
438,"Cholest-4-en-3-one, oxime",EU/3/05/264,Treatment of 5q spinal muscular atrophy,Roche Registration Limited,10/03/2005,,Q7086437,5q spinal muscular atrophy,,,,,,,
439,Cholic acid,EU/3/02/127,Treatment of inborn errors in primary bile acid synthesis,Laboratoires CTRS,18/12/2002,OrphacolEU/1/13/87016/09/2013,Q287415,inborn errors in primary bile acid synthesis,,,,,,,
440,Cholic acid,EU/3/09/683,Treatment of inborn errors of primary bile acid synthesis responsive to treatment with cholic acid,Retrophin Europe Limited,28/10/2009,KolbamEU/1/13/89508/04/2014,Q287415,inborn errors of primary bile acid synthesis responsive to treatment with cholic acid,,,,,,,
441,Choline tetrathiomolybdate,EU/3/12/1089,Treatment of Wilson&#8217;s disease,Wilson Therapeutics AB,24/01/2013,,,wilsons disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
442,Ciclosporin,EU/3/06/360,Treatment of vernal keratoconjunctivitis,Santen Oy,06/04/2006,,Q367700,vernal keratoconjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_70476,D003233,,Q4119259,Q18555085
443,Ciclosporin,EU/3/07/455,Prevention of corneal graft rejection,SANTEN SAS,22/10/2007,,Q367700,corneal graft rejection,,,,,,,
444,Ciclosporin,EU/3/07/489,Treatment of Herpes simplex virus stromal keratitis,SANTEN S.A.S.,29/10/2007,,Q367700,herpes simplex virus stromal keratitis,,,,,,,
445,Ciclosporin,EU/3/10/791,Treatment of moderate and severe closed traumatic brain injury,NeuroVive Pharmaceutical AB,01/10/2010,,Q367700,moderate and severe closed traumatic brain injury,,,,,,,
446,"Ciclosporin (eye drops, solution)",EU/3/09/651,Treatment of atopic keratoconjunctivitis,Allergan Pharmaceuticals Ireland,24/07/2009,,Q4347890,atopic keratoconjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_163934,,,,
447,Ciclosporin (inhalation use),EU/3/04/209,Prevention of graft rejection after lung transplantation,PARI Pharma GmbH,29/07/2004,,,graft rejection after lung transplantation,,,http://www.orpha.net/ORDO/Orphanet_91128,,,,
448,Ciclosporin (inhalation use),EU/3/04/210,Treatment of graft rejection after lung transplantation,PARI Pharma GmbH,29/07/2004,,,graft rejection after lung transplantation,,,http://www.orpha.net/ORDO/Orphanet_91128,,,,
449,Ciprofloxacin (inhalation use),EU/3/07/469,Treatment of cystic fibrosis,Bayer Pharma AG,03/08/2007,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
450,Ciprofloxacin (liposomal),EU/3/09/652,Treatment of cystic fibrosis,Aradigm Limited,24/07/2009,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
451,Cisplatin,EU/3/16/1719,Treatment of malignant mesothelioma,PlumeStars s.r.l.,29/08/2016,,Q412415,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
452,Cisplatin (liposomal),EU/3/07/451,Treatment of pancreatic cancer,Regulon AE,08/06/2007,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
453,Citric acid monohydrate,EU/3/16/1675,Treatment of acute liver failure,CATS Consultants GmbH,27/06/2016,,Q27114303,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
454,Cladribine,EU/3/13/1182,Treatment of mastocytosis,Lipomed GmbH,05/08/2013,,Q414030,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
455,Clonidine hydrochloride,EU/3/11/919,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,Onxeo,27/10/2011,,Q27292429,oral mucositis in head and neck cancer patients undergoing radiation therapy,,,,,,,
456,"Combination of 4-hydroxyandrostenedione, Serenoa serrulata fruit extract and alpha lipoic acid",EU/3/16/1646,Treatment of multiple symmetric lipomatosis,Dr Regenold GmbH Development·Regulatory·Market Access,28/04/2016,,,multiple symmetric lipomatosis,http://purl.obolibrary.org/obo/DOID_14116,,http://www.orpha.net/ORDO/Orphanet_2398,D008069,Q4887975,,Q18555303
457,Combretastatin A1 diphosphate,EU/3/15/1587,Treatment of acute myeloid leukaemia,Diamond BioPharm Limited,14/12/2015,,Q27095572,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
458,"Copper meso-5,15-bis[3-[(1,2-dicarba-closo-dodecaboranyl)methoxy]phenyl]-meso-10,20-dinitroporphyrin",EU/3/13/1138,Treatment of squamous cell carcinoma of the head and neck in patients undergoing radiotherapy,MorEx Development Partners LLP,27/06/2013,,,squamos cell carcinoma of the head and neck in patients undergoing radiotherapy,,,,,,,
459,Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes,EU/3/12/1042,Prevention of cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk,Astellas Pharma Europe B.V.,09/08/2012,,,cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk,,,,,,,
460,Crenolanib besylate,EU/3/16/1748,Treatment of acute myeloid leukemia,Arog Pharmaceuticals Europe Ltd,14/10/2016,,Q27283841,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
461,Crenolanib besylate,EU/3/16/1749,Treatment of soft tissue sarcoma,Arog Pharmaceuticals Europe Ltd,14/10/2016,,Q27283841,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
462,Cultured allogeneic corneal limbal stem cells,EU/3/14/1340,Treatment of limbal stem cell deficiency,NHS National Services Scotland Trading as Scottish National Blood Transfusion Service,15/10/2014,,,limbal stem cell deficiency,,,,,,,
463,Cyclic pyranopterin monophosphate,EU/3/10/777,Treatment of molybdenum cofactor deficiency type A,Alexion Europe SAS,20/09/2010,,Q27126832,molybdenum cofactor deficiency type a,,,,,,,
464,Cyclocreatine,EU/3/16/1676,Treatment of creatine deficiency syndromes,Pharma Gateway AB,27/06/2016,,Q27076942,creatine deficiency syndromes,,,,,,,
465,Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys,EU/3/13/1102,Treatment of high altitude pulmonary oedema,Apeptico Forschung und Entwicklung GmbH,08/02/2013,,,high altitude pulmonary oedema,,,,,,,
466,"Cyclo(-gamma-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt",EU/3/12/1075,Treatment of acromegaly,Cortendo AB,06/12/2012,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
467,Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt,EU/3/13/1114,Treatment of congenital alpha-1 antitrypsin deficiency,Polyphor UK Ltd,20/03/2013,,,congenital alpha1 antitrypsin deficiency,,,,,,,
468,"Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt",EU/3/08/610,Treatment of medullary thyroid carcinoma,Ipsen Pharma,06/02/2009,CometriqEU/1/13/89026/03/2014,Q27263708,medullary thyroid carcinoma,http://purl.obolibrary.org/obo/DOID_3973,http://purl.obolibrary.org/obo/HP_0002865,http://www.orpha.net/ORDO/Orphanet_1332,,Q3493538,,
469,Cysteamine,EU/3/11/928,Treatment of cystic fibrosis,NovaBiotics Ltd,09/12/2011,,Q617563,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
470,Cysteamine,EU/3/14/1240,Treatment of cystic fibrosis,Horizon Pharma Europe B.V.,19/02/2014,,Q617563,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
471,Cysteamine bitartrate,EU/3/14/1252,Treatment of pancreatic cancer,Horizon Pharma Europe B.V.,26/03/2014,,Q27122045,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
472,Cysteamine bitartrate,EU/3/14/1306,Treatment of Huntington&#8217;s disease,Horizon Pharma Europe B.V.,29/07/2014,,Q27122045,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
473,Cysteamine bitartrate (gastroresistant),EU/3/10/778,Treatment of cystinosis,Horizon Pharma Europe B.V.,20/09/2010,ProcysbiEU/1/13/86110/09/2013,,cystinosis,http://purl.obolibrary.org/obo/DOID_1064,,http://www.orpha.net/ORDO/Orphanet_213,D003554,Q1149042,Q1149042,Q1149042
474,Cysteamine hydrochloride,EU/3/08/578,Treatment of cystinosis,Orphan Europe S.A.R.L.,07/11/2008,,Q27280697,cystinosis,http://purl.obolibrary.org/obo/DOID_1064,,http://www.orpha.net/ORDO/Orphanet_213,D003554,Q1149042,Q1149042,Q1149042
475,Cysteamine hydrochloride,EU/3/14/1341,Treatment of cystinosis,Lucane Pharma SA,15/10/2014,,Q27280697,cystinosis,http://purl.obolibrary.org/obo/DOID_1064,,http://www.orpha.net/ORDO/Orphanet_213,D003554,Q1149042,Q1149042,Q1149042
476,Cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate,EU/3/03/149,Treatment of pancreatic cancer in combination with ifosfamide,Pharmacyte Biotech Europe Limited,30/06/2003,,,pancreatic cancer in combination with ifosfamide,,,,,,,
477,Dantrolene sodium,EU/3/14/1379,Treatment of malignant hyperthermia,Eagle Laboratories Limited,19/11/2014,,Q27225695,malignant hyperthermia,http://purl.obolibrary.org/obo/DOID_8545,http://purl.obolibrary.org/obo/HP_0002047,,D008305,Q1585081,,Q1585081
478,Dantrolene sodium,EU/3/16/1800,Treatment of Wolfram syndrome,Alan Boyd Consultants Ltd,12/12/2016,,Q27225695,wolfram syndrome,http://purl.obolibrary.org/obo/DOID_10632,,http://www.orpha.net/ORDO/Orphanet_3463,D014929,Q1153641,,Q1153641
479,Daratumumab,EU/3/13/1153,Treatment of plasma cell myeloma,Janssen-Cilag International NV,17/07/2013,DarzalexEU/1/16/110124/05/2016,Q5222113,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
480,Darinaparsin,EU/3/11/850,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",IDEA Innovative Drug European Associates Limited,15/04/2011,,Q27166111,"peripheral tcell lymphoma (nodal, other extranodal and leukemic/disseminated)",,,,,,,
481,Daunorubicin (liposomal),EU/3/08/585,Treatment of acute myeloid leukaemia,Diatos S. A.,03/12/2008,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
482,Decitabine,EU/3/03/135,Treatment of myelodysplastic syndromes,Janssen-Cilag International NV,14/02/2003,,Q1181878,myelodysplastic syndromes,,,,D009190,,,Q954625
483,Decitabine,EU/3/06/370,Treatment of acute myeloid leukaemia,Janssen-Cilag International NV,08/06/2006,DacogenEU/1/12/79224/09/2012,Q1181878,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
484,Deferiprone,EU/3/10/832,Treatment of sickle cell disease,Apotex Europe B.V.,23/02/2011,,Q749664,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
485,Defibrotide,EU/3/04/211,Prevention of hepatic veno-occlusive disease,Gentium S.r.I.,29/07/2004,,Q3704725,hepatic venoocclusive disease,,,http://www.orpha.net/ORDO/Orphanet_890,D006504,,,Q5731687
486,Defibrotide,EU/3/04/212,Treatment of hepatic veno-occlusive disease,Gentium S.r.I.,29/07/2004,DefitelioEU/1/13/87822/10/2013,Q3704725,hepatic venoocclusive disease,,,http://www.orpha.net/ORDO/Orphanet_890,D006504,,,Q5731687
487,Defibrotide,EU/3/13/1201,Prevention of graft-versus-host disease,Gentium S.r.I.,13/11/2013,,Q3704725,graftversushost disease,,,,D006086,,,Q1194520
488,Delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant,EU/3/16/1621,Treatment of glioma,GW Research Ltd,17/02/2016,,Q15427841,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
489,Denileukin diftitox,EU/3/01/075,Treatment of cutaneous T-cell lymphoma,Eisai Limited,11/12/2001,,Q1187179,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
490,Desipramine hydrochloride,EU/3/09/643,Treatment of Rett syndrome,ORPHELIA Pharma SA,12/06/2009,,Q27106387,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
491,Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes,EU/3/13/1158,Treatment of ataxia telangiectasia,Erydel S.p.A.,17/07/2013,,,ataxia telangiectasia,http://purl.obolibrary.org/obo/DOID_12704,,,D001260,Q387082,,Q387082
492,Dexamethasone sodium phosphate encapsulated in human erythrocytes,EU/3/04/230,Treatment of cystic fibrosis,Erydel S.p.A.,20/10/2004,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
493,Diacerein,EU/3/14/1236,Treatment of epidermolysis bullosa,Medpace Finland OY,19/02/2014,,Q413178,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
494,Diaspirin cross-linked haemoglobin,EU/3/14/1378,Treatment of hepatocellular carcinoma,New B Innovation (UK) Limited,19/11/2014,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
495,Diaspirin cross-linked haemoglobin,EU/3/16/1628,Treatment of oesophageal cancer,New B Innovation (UK) Limited,21/03/2016,,,oesophageal cancer,,,,,,,
496,Diclofenamide,EU/3/16/1616,Treatment of periodic paralysis,Prof. Michael Hanna,17/02/2016,,Q3706987,periodic paralysis,,http://purl.obolibrary.org/obo/HP_0003768,http://www.orpha.net/ORDO/Orphanet_206976,,,,
497,Diclofenamide,EU/3/16/1677,Treatment of periodic paralysis,Sun Pharmaceutical Industries Europe BV,27/06/2016,,Q3706987,periodic paralysis,,http://purl.obolibrary.org/obo/HP_0003768,http://www.orpha.net/ORDO/Orphanet_206976,,,,
498,Dimethyl fumarate,EU/3/16/1698,Treatment of bullous pemphigoid,Immungenetics AG,14/07/2016,,Q418123,bullos pemphigoid,http://purl.obolibrary.org/obo/DOID_8506,,http://www.orpha.net/ORDO/Orphanet_703,D010391,Q1004647,,Q1004647
499,dimethyl sulfoxide,EU/3/05/263,Treatment of severe closed traumatic brain injury,AOP Orphan Pharmaceuticals AG,03/03/2005,,Q4161663,severe closed traumatic brain injury,,,,,,,
500,Dinaciclib,EU/3/11/901,Treatment of chronic lymphocytic leukaemia,Merck Sharp & Dohme Limited,27/09/2011,,Q15723091,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
501,"Dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, sodium salt, synthetic surfactant protein C analogue and synthetic surfactant protein B analogue",EU/3/12/982,Treatment of respiratory distress syndrome in premature neonates of less than 37 weeks of gestational age,Chiesi Farmaceutici S.P.A.,02/04/2012,,,respiratory distress syndrome in premature neonates of less than 37 weeks of gestational age,,,,,,,
502,DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFa p55 receptor linked to the human IgG1 Fc domain,EU/3/16/1619,Treatment of non-infectious uveitis,Eyevensys SA,17/02/2016,,,noninfectios uveitis,,,,,,,
503,Donor lymphocyte preparation depleted of functional alloreactive T-cells,EU/3/08/561,Prevention of Graft-versus-Host disease,Kiadis Pharma Netherlands B.V.,05/09/2008,,Q162867,graftversushost disease,,,,D006086,,,Q1194520
504,Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment,EU/3/14/1356,Treatment of acute myeloid leukaemia,Kiadis Pharma Netherlands B.V.,19/11/2014,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
505,Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment,EU/3/16/1678,Treatment in haematopoietic stem cell transplantation,Kiadis Pharma Netherlands B.V.,27/06/2016,,,hematopoietic stem cell transplantation,,,,D018380,,,
506,Doxorubicin,EU/3/15/1513,Treatment of hepatoblastoma,Double Bond Pharmaceutical AB,28/07/2015,,Q18936,hepatoblastoma,http://purl.obolibrary.org/obo/DOID_687,http://purl.obolibrary.org/obo/HP_0002884,http://www.orpha.net/ORDO/Orphanet_449,D018197,Q1607658,,Q1607658
507,Doxorubicin (administered after synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine),EU/3/12/1006,Treatment of glioma,Avena Therapeutics Ltd,28/11/2012,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
508,Doxorubicin hydrochloride (drug eluting beads),EU/3/07/507,Treatment of glioma,Biocompatibles UK Limited,29/11/2007,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
509,Doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin,EU/3/16/1814,Treatment of malignant mesothelioma,"TREAT U, S.A.",12/01/2017,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
510,Doxorubicin hydrochloride (in heat-sensitive liposomes),EU/3/10/833,Treatment of hepatocellular carcinoma,Biological Consulting Europe Ltd,23/02/2011,,Q27259647,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
511,Doxorubicin hydrochloride (liposomal),EU/3/06/410,Treatment of soft tissue sarcoma,GP-Pharm S.A.,27/10/2006,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
512,Doxorubicin polyisohexylcyanoacrylate nanoparticles,EU/3/04/229,Treatment of the hepatocellular carcinoma,Onxeo,21/10/2004,,,the hepatocellular carcinoma,,,,,,,
513,Doxorubicin(6-maleimidocaproyl)hydrazone,EU/3/14/1258,Treatment of soft tissue sarcoma,Pharma Gateway AB,26/03/2014,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
514,Doxycycline hyclate,EU/3/12/955,Treatment of familial amyloid polyneuropathy,Giampaolo Merlini,02/04/2012,,Q27116248,familial amyloid polyneuropathy,http://purl.obolibrary.org/obo/DOID_0050638,,,D028227,Q2844603,,
515,Doxycycline hyclate,EU/3/12/961,Treatment of systemic amyloidosis caused by beta-2 microglobulin,Giampaolo Merlini,05/03/2012,,Q27116248,systemic amyloidosis caused by beta2 microglobulin,,,,,,,
516,Drotrecogin alfa (activated),EU/3/08/565,Treatment of acute respiratory distress syndrome,Savara ApS,22/09/2008,,,acute respiratory distress syndrome,,,,D012128,,,Q7315912
517,"Dry extract from birch bark (DER 0.1-0.2:1), extraction solvent n-heptane 95% (V/V)",EU/3/10/845,Treatment of epidermolysis bullosa,Birken AG,23/02/2011,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
518,Duramycin,EU/3/02/120,Treatment of cystic fibrosis,AOP Orphan Pharmaceuticals AG,13/11/2002,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
519,E. Coli heat-shock protein 70 with bovine retinal S-antigen,EU/3/05/346,Treatment of autoimmune uveitis,Biotech Tools SA,24/01/2006,,,autoimmune uveitis,,,,,,,
520,((E)-1-(4'-chlorophenyl)-3-(4-hydroxy-3-metoxyphenyl)prop-2-en-1-one),EU/3/14/1384,Treatment of WHIM syndrome,Centre National de la Recherche Scientifique (CNRS),16/12/2014,,,whim syndrome,http://purl.obolibrary.org/obo/DOID_0060591,,http://www.orpha.net/ORDO/Orphanet_51636,,Q1258463,,
521,"(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone",EU/3/05/279,Treatment of cutaneous T-cell lymphoma,Celgene Europe Limited,27/05/2005,,,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
522,"(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone",EU/3/05/328,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",Celgene Europe Limited,28/10/2005,,,"peripheral tcell lymphoma (nodal, other extranodal and leukemic/disseminated)",,,,,,,
523,"(E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt",EU/3/12/987,Treatment of myelodysplastic syndromes,Onconova Europe GmbH,26/04/2012,,,myelodysplastic syndromes,,,,D009190,,,Q954625
524,"(E)-(6-((N-methyl-((3-methylbenzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl phosphate, bis ethanolamine salt",EU/3/16/1737,Treatment of osteomyelitis,Voisin Consulting S.A.R.L.,14/10/2016,,,osteomyelitis,http://purl.obolibrary.org/obo/DOID_1019,http://purl.obolibrary.org/obo/HP_0002754,,D010019,Q938983,,Q938983
525,Ecopipam,EU/3/09/717,Treatment of Lesch-Nyhan disease,Dr Alain Munoz,03/02/2010,,Q5333851,leschnyhan disease,,,,D007926,,,Q727436
526,Ecothiopate iodide,EU/3/15/1474,Treatment of Stargardt's disease,Dorian Regulatory Affairs BV,24/04/2015,,,stargardts disease,,,,,,,
527,Ecteinascidin 743,EU/3/01/039,Treatment of soft tissue sarcoma,Pharma Mar S.A.,30/05/2001,YondelisEU/1/07/41720/09/2007,Q2637746,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
528,Eculizumab,EU/3/03/166,Treatment of paroxysmal nocturnal haemoglobinuria,Alexion Europe SAS,17/10/2003,SolirisEU/1/07/39322/06/2007,Q421617,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
529,Eculizumab,EU/3/09/653,Treatment of atypical haemolytic uremic syndrome,Alexion Europe SAS,24/07/2009,SolirisEU/1/07/39329/11/2011,Q421617,atypical hemolytic uremic syndrome,,,,D065766,,,Q17165460
530,Eculizumab,EU/3/13/1185,Treatment of neuromyelitis optica,Alexion Europe SAS,05/08/2013,,Q421617,neuromyelitis optica,http://purl.obolibrary.org/obo/DOID_8869,,http://www.orpha.net/ORDO/Orphanet_71211,D009471,Q611458,,Q611458
531,Eculizumab,EU/3/14/1238,Prevention of delayed graft function after solid organ transplantation,Alexion Europe SAS,19/02/2014,,Q421617,delayed graft function after solid organ transplantation,,,,,,,
532,Eculizumab,EU/3/14/1254,Prevention of graft rejection following solid organ transplantation,Alexion Europe SAS,26/03/2014,,Q421617,graft rejection following solid organ transplantation,,,,,,,
533,Eculizumab,EU/3/14/1304,Treatment of myasthenia gravis,Alexion Europe SAS,29/07/2014,,Q421617,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
534,Edaravone,EU/3/14/1399,Treatment of amyotrophic lateral sclerosis,Treeway B.V.,16/12/2014,,Q335099,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
535,Edaravone,EU/3/15/1510,Treatment of amyotrophic lateral sclerosis,Mitsubishi Tanabe Pharma Europe Ltd.,19/06/2015,,Q335099,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
536,Eflornithine,EU/3/10/779,Treatment of familial adenomatous polyposis,Cancer Prevention Pharma Limited,20/09/2010,,Q424751,familial adenomatos polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
537,Eflornithine,EU/3/11/902,Treatment of neuroblastoma,Cancer Prevention Pharma Limited,27/09/2011,,Q424751,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
538,Eflornithine,EU/3/16/1679,Treatment of glioma,Orbus Therapeutics Limited,27/06/2016,,Q424751,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
539,Eflornithine in combination with sulindac,EU/3/12/1086,Treatment of familial adenomatous polyposis,Cancer Prevention Pharma Limited,24/01/2013,,,familial adenomatos polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
540,Eicosapentaenoic acid,EU/3/09/666,Treatment of familial adenomatous polyposis,S.L.A. Pharma (UK) Limited,08/10/2009,,Q409990,familial adenomatos polyposis,http://purl.obolibrary.org/obo/DOID_0050424,,http://www.orpha.net/ORDO/Orphanet_733,D011125,Q1369011,,Q1369011
541,Elafin,EU/3/07/443,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,Proteo Biotech AG,20/03/2007,,,pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,,,,,,,
542,Emtricitabine,EU/3/14/1420,Treatment of Aicardi-Gouti&egrave;res syndrome,Dr Yanick Crow,15/01/2015,,Q422604,aicardigoti&egrave;res syndrome,,,,,,,
543,Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor,EU/3/12/1072,Treatment of macular telangiectasia type 2,Enpharma Ltd,08/11/2012,,,macular telangiectasia type 2,,,,,,,
544,Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor,EU/3/12/1098,Treatment of retinitis pigmentosa,Enpharma Ltd,24/01/2013,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
545,Enoxacin,EU/3/15/1459,Treatment of amyotrophic lateral sclerosis,Dr Regenold GmbH Development·Regulatory·Market Access,19/03/2015,,Q1639616,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
546,Entinostat,EU/3/10/732,Treatment of Hodgkin's lymphoma,Syndax Limited,10/06/2010,,Q1281020,hodgkins lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
547,Entolimod,EU/3/15/1607,Treatment of acute radiation syndrome,TMC Pharma Services Ltd,11/01/2016,,,acute radiation syndrome,,,,D054508,,,Q275459
548,Enzastaurin hydrochloride,EU/3/05/343,Treatment of glioma,Isabelle Ramirez,23/12/2005,,Q27282481,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
549,Enzastaurin hydrochloride,EU/3/07/442,Treatment of diffuse large B cell lymphoma,Isabelle Ramirez,20/03/2007,,Q27282481,diffuse large b cell lymphoma,,,,,,,
550,Eptacog alfa (activated),EU/3/05/333,Treatment of diffuse alveolar haemorrhage,Savara ApS,14/12/2005,,,diffuse alveolar hemorrhage,,,http://www.orpha.net/ORDO/Orphanet_90060,,,,
551,Erdosteine,EU/3/12/1067,Treatment of mercury toxicity,Rafifarm SRL,08/11/2012,,Q3731252,mercury toxicity,,,,,,,
552,Erdosteine,EU/3/12/1084,Treatment of lead toxicity,Rafifarm SRL,06/12/2012,,Q3731252,lead toxicity,,,,,,,
553,Estradiol Hemihydrate and Progesterone,EU/3/05/275,Prevention of bronchopulmonary dysplasia in premature neonates of less than 30 weeks of gestational age,Dr Frank Pohlandt,11/04/2005,,,bronchopulmonary dysplasia in premature neonates of less than 30 weeks of gestational age,,,,,,,
554,Ethyl Eicosopentaenoate,EU/3/00/013,Treatment of Huntington's disease,Amarin Neuroscience Limited,29/12/2000,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
555,Etilefrin,EU/3/02/122,Treatment of low flow priapism,Laboratoires SERB,13/11/2002,,,low flow priapism,,,,,,,
556,Everolimus,EU/3/10/764,Treatment of tuberous sclerosis,Novartis Europharm Limited,04/08/2010,VotubiaEU/1/11/71006/09/2011,Q421052,tuberos sclerosis,http://purl.obolibrary.org/obo/DOID_13515,,http://www.orpha.net/ORDO/Orphanet_805,D014402,Q1362721,,Q1362721
557,Exenatide,EU/3/16/1629,Treatment of idiopathic intracranial hypertension,Alan Boyd Consultants Ltd,21/03/2016,,Q417762,idiopathic intracranial hypertension,http://purl.obolibrary.org/obo/DOID_11459,,http://www.orpha.net/ORDO/Orphanet_238624,D011559,Q741208,,Q741208
558,Exendin (9-39),EU/3/16/1750,Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome,Eiger Biopharmaceuticals Europe Limited,14/10/2016,,Q2070105,noninsulinoma pancreatogenos hypoglycemia syndrome,,,,,,,
559,Exisulind,EU/3/14/1387,Treatment of familial cerebral cavernous malformations,Firc Institute of Molecular Oncology (IFOM),16/12/2014,,Q5420370,familial cerebral cavernos malformations,,,,,,,
560,Exon 44 specific phosphorothioate oligonucleotide,EU/3/08/598,Treatment of Duchenne muscular dystrophy,BioMarin International Limited,27/02/2009,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
561,Exon 45 specific phosphorothioate oligonucleotide,EU/3/12/991,Treatment of Duchenne muscular dystrophy,BioMarin International Limited,26/04/2012,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
562,Exon 51 specific phosphorothioate oligonucleotide,EU/3/08/599,Treatment of Duchenne muscular dystrophy,BioMarin International Limited,27/02/2009,,Q27088998,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
563,Exon 52 specific phosphorothioate oligonucleotide,EU/3/12/1077,Treatment of Duchenne muscular dystrophy,BioMarin International Limited,06/12/2012,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
564,Exon 53 specific phosphorothioate oligonucleotide,EU/3/12/992,Treatment of Duchenne muscular dystrophy,BioMarin International Limited,26/04/2012,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
565,Exon 55 specific phosphorothioate oligonucleotide,EU/3/12/1078,Treatment of Duchenne muscular dystrophy,BioMarin International Limited,06/12/2012,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
566,Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue,EU/3/09/667,Treatment of anal fistula,TiGenix S.A.U.,08/10/2009,,,anal fistula,http://purl.obolibrary.org/obo/DOID_0060328,http://purl.obolibrary.org/obo/HP_0010447,,D012003,Q484765,,
567,Expanded human allogeneic neural retinal progenitor cells extracted from neural retina,EU/3/13/1140,Treatment of retinitis pigmentosa,ReNeuron Ltd,19/06/2013,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
568,"Extract of Sorghum bicolour leaf, Pterocarpus osun stem, Piper guineense seed and Caryophylli flower",EU/3/05/302,Treatment of sickle cell disease,Xechem UK Ltd,26/08/2005,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
569,Ex-vivo cultured adult human mesenchymal stem cells,EU/3/07/432,Treatment of Graft-versus-Host disease,Voisin Consulting S.A.R.L.,20/02/2007,,,graftversushost disease,,,,D006086,,,Q1194520
570,Ex-vivo expanded autologous human corneal epithelium containing stem cells,EU/3/08/579,"Treatment of corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns",Chiesi Farmaceutici S.P.A.,07/11/2008,HoloclarEU/1/14/98719/02/2015,,"corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns",,,,,,,
571,Ex-vivo expanded autologous human corneal epithelium containing stem cells,EU/3/13/1168,Treatment of limbal stem cell deficiency,University of Newcastle upon Tyne,17/07/2013,,,limbal stem cell deficiency,,,,,,,
572,Ex-vivo-cultured human mesenchymal stromal cells,EU/3/14/1253,Prevention of graft rejection following solid organ transplantation,iCell Science AB,26/03/2014,,Q27895485,graft rejection following solid organ transplantation,,,,,,,
573,Ex-vivo-expanded autologous fibroblasts transduced with lentiviral vector containing the COL7A1 gene,EU/3/16/1611,Treatment of epidermolysis bullosa,Dr Waseem Qasim,17/02/2016,,Q27088540,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
574,Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL17A1-encoding retroviral vector,EU/3/15/1467,Treatment of epidermolysis bullosa,Chiesi Farmaceutici S.P.A.,19/03/2015,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
575,Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL7A1-encoding retroviral vector,EU/3/15/1466,Treatment of epidermolysis bullosa,Chiesi Farmaceutici S.P.A.,19/03/2015,,Q27281250,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
576,Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a LAMB3-encoding retroviral vector,EU/3/15/1465,Treatment of epidermolysis bullosa,Chiesi Farmaceutici S.P.A.,19/03/2015,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
577,Fc- and CDR-modified humanised monoclonal antibody against C5,EU/3/16/1661,Treatment of paroxysmal nocturnal haemoglobinuria,Alexion Europe SAS,30/05/2016,,,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
578,Fenfluramine hydrochloride,EU/3/13/1219,Treatment of Dravet syndrome,Zogenix International Ltd,18/12/2013,,Q27126872,dravet syndrome,http://purl.obolibrary.org/obo/DOID_0060171,,http://www.orpha.net/ORDO/Orphanet_33069,D004831,Q1255956,Q1255956,Q17147280
579,Fenretinide,EU/3/16/1630,Treatment of cutaneous T-cell lymphoma,Clinipace GmbH,21/03/2016,,Q5443576,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
580,Fenretinide,EU/3/16/1751,Treatment of peripheral T-cell lymphoma,Clinipace GmbH,14/10/2016,,Q5443576,peripheral tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050749,,,D016411,Q7168693,,
581,Fibrinogen-coated albumin spheres,EU/3/15/1442,Treatment of Ebola virus disease,Fibreu Limited,12/02/2015,,,ebola virus disease,http://purl.obolibrary.org/obo/DOID_4325,,http://www.orpha.net/ORDO/Orphanet_319218,D019142,Q51993,,Q8064876
582,Fibrinogen-coated albumin spheres,EU/3/15/1535,Treatment of acute radiation syndrome,Fibreu Limited,10/08/2015,,,acute radiation syndrome,,,,D054508,,,Q275459
583,filgrastim,EU/3/08/532,Treatment of amyotrophic lateral sclerosis,NeuroVision Pharma GmbH,01/04/2008,,Q3151081,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
584,Filgrastim,EU/3/08/580,Treatment of spinal cord injury,NeuroVision Pharma GmbH,07/11/2008,,Q3151081,spinal cord injury,,,,D013119,,,Q1415275
585,Fimaporfin,EU/3/16/1720,Treatment of cholangiocarcinoma,PCI Biotech AS,29/08/2016,,,cholangiocarcinoma,http://purl.obolibrary.org/obo/DOID_4947,http://purl.obolibrary.org/obo/HP_0030153,http://www.orpha.net/ORDO/Orphanet_70567,D018281,Q124292,,Q18556554
586,Fixed-dose combination of fosfomycin disodium and tobramycin,EU/3/15/1538,Treatment of cystic fibrosis,CURx Pharma (UK) Limited,10/08/2015,,Q27088776,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
587,"Fixed-dose combination of (R-S) baclofen, naltrexone hydrochloride and D-sorbitol",EU/3/14/1260,Treatment of Charcot-Marie-Tooth disease type 1A,Pharnext SA,26/03/2014,,,charcotmarietooth disease type 1a,http://purl.obolibrary.org/obo/DOID_0110148,,http://www.orpha.net/ORDO/Orphanet_101081,,Q27677640,,
588,Florilglutamic acid (18F),EU/3/16/1631,Diagnosis of glioma,Piramal Imaging GmbH,21/03/2016,,Q27262981,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
589,Florilglutamic acid (18F),EU/3/16/1632,Diagnosis of hepatocellular carcinoma,Piramal Imaging GmbH,21/03/2016,,Q27262981,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
590,Fluciclovine (18F),EU/3/15/1472,Diagnosis of glioma,Blue Earth Diagnostics Ltd,24/04/2015,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
591,Fluocinolone acetonide,EU/3/16/1647,Treatment of non-infectious uveitis,Campharm Ltd,28/04/2016,,Q924467,noninfectios uveitis,,,,,,,
592,Fluocinolone acetonide (prolonged-release intravitreal implant),EU/3/05/261,Treatment of non-infectious uveitis affecting the posterior segment of the eye,Bausch & Lomb Ireland,07/03/2005,,,noninfectios uveitis affecting the posterior segment of the eye,,,,,,,
593,Fluticasone propionate,EU/3/16/1815,Treatment of eosinophilic oesophagitis,Adare Pharmaceuticals srl,12/01/2017,,Q8564098,eosinophilic oesophagitis,,,,,,,
594,Forodesine,EU/3/10/780,Treatment of chronic lymphocytic leukaemia,Mundipharma Research Limited,20/09/2010,,Q410040,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
595,Forodesine hydrochloride,EU/3/06/421,Treatment of acute lymphoblastic leukaemia,Napp Pharmaceuticals Research Limited,18/12/2006,,Q27265452,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
596,Forodesine hydrochloride,EU/3/06/428,Treatment of cutaneous T-cell lymphoma,Napp Pharmaceuticals Research Limited,29/01/2007,,Q27265452,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
597,Fosbretabulin tromethamine,EU/3/13/1154,Treatment of ovarian cancer,Diamond BioPharm Limited,17/07/2013,,Q27279017,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
598,Fosbretabulin tromethamine,EU/3/16/1633,Treatment of gastro-entero-pancreatic neuroendocrine tumours,Diamond BioPharm Limited,21/03/2016,,Q27279017,gastroenteropancreatic neuroendocrine tumors,,,,,,,
599,"Fusion proteins composed by a genetically modified cholera toxin subunit A1, peptides from the acetylcholine receptor alpha chain and a dimer of the D fragment from Staphylococcus aureus protein A",EU/3/15/1489,Treatment of myasthenia gravis,Toleranzia AB,21/05/2015,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
600,G17(9) gastrin-diphtheria toxoid conjugate,EU/3/02/129,Treatment of pancreatic cancer,Cato Europe GmbH,24/01/2003,,Q407927,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
601,G17(9) gastrin-diphtheria toxoid conjugate,EU/3/02/130,Treatment of gastric cancer,Cato Europe GmbH,28/01/2003,,Q407927,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
602,Gadodiamide (liposomal),EU/3/08/583,Treatment of glioma,Dr Matthias Luz,03/12/2008,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
603,Gallium (68Ga)-edotreotide,EU/3/15/1450,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,Advanced Accelerator Applications,19/03/2015,,,gastroenteropancreatic neuroendocrine tumors,,,,,,,
604,Gallium (68Ga)-pasireotide tetraxetan,EU/3/11/920,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,OctreoPharm Sciences GmbH,27/10/2011,,,gastroenteropancreatic neuroendocrine tumors,,,,,,,
605,"Gallium [Ga-68]-N-[(4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-Lcysteinyl-L-threonine-cyclic(2-7)disulfide",EU/3/14/1237,Diagnosis of gastro-entero-pancreatic neuroendocrine tumours,Advanced Accelerator Applications,19/02/2014,,,gastroenteropancreatic neuroendocrine tumors,,,,,,,
606,Gemtuzumab Ozogamicin,EU/3/00/005,Treatment of acute myeloid leukaemia,Pfizer Limited,18/10/2000,,Q412685,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
607,Genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimized shRNA-insensitive wildtype PABPN1,EU/3/16/1816,Treatment of oculopharyngeal muscular dystrophy,Clinipace GmbH,12/01/2017,,,oculopharyngeal muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11719,,http://www.orpha.net/ORDO/Orphanet_270,D039141,Q3042171,,Q3042171
608,"Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)",EU/3/06/405,Treatment of renal cell carcinoma,MOLOGEN AG,23/10/2006,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
609,Genetically modified human adenovirus encoding human PH20 hyaluronidase,EU/3/11/880,Treatment of pancreatic cancer,VCN Biosciences S.L.,21/06/2011,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
610,Genetically modified Lactococcus lactis bacteria containing the human trefoil factor 1 gene,EU/3/11/903,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,Intrexon Actobiotics N.V.,27/09/2011,,,oral mucositis in head and neck cancer patients undergoing radiation therapy,,,,,,,
611,Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor,EU/3/14/1265,Treatment of ovarian cancer,Targovax Oy,29/04/2014,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
612,Genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor,EU/3/14/1398,Treatment of malignant mesothelioma,Targovax Oy,16/12/2014,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
613,Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor,EU/3/13/1145,Treatment of soft tissue sarcoma,Targovax Oy,19/06/2013,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
614,Genistein sodium salt dihydrate,EU/3/12/980,Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome),Axcentua Pharmaceuticals AB,02/04/2012,,,mucopolysaccharidosis type iii (sanfilippo syndrome),,,,,,,
615,Gevokizumab,EU/3/13/1111,Treatment of chronic non-infectious uveitis,XOMA UK Limited,12/03/2013,,Q5554924,chronic noninfectios uveitis,,,,,,,
616,Gevokizumab,EU/3/14/1311,Treatment of Schnitzler syndrome,XOMA UK Limited,22/08/2014,,Q5554924,schnitzler syndrome,http://purl.obolibrary.org/obo/DOID_4371,,http://www.orpha.net/ORDO/Orphanet_37748,D019873,Q2259421,,Q2259421
617,Gimatecan,EU/3/03/174,Treatment of glioma,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A,01/12/2003,,Q27268469,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
618,Givinostat,EU/3/09/719,Treatment of polycythaemia vera,Italfarmaco S.p.A.,03/02/2010,,Q426257,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
619,Givinostat,EU/3/12/1009,Treatment of Duchenne muscular dystrophy,Italfarmaco S.p.A.,04/07/2012,,Q426257,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
620,Glibenclamide,EU/3/15/1589,Treatment of neonatal diabetes,AMMTeK,15/01/2016,,Q420626,neonatal diabetes,,,,,,,
621,Glucagon,EU/3/12/960,Treatment of congenital hyperinsulinism,Biodel UK Limited,05/03/2012,,Q28163629,congenital hyperinsulinism,,,,D044903,,,Q5160437
622,Glucagon,EU/3/14/1342,Treatment of congenital hyperinsulinism,S-cubed Ltd,15/10/2014,,Q28163629,congenital hyperinsulinism,,,,D044903,,,Q5160437
623,Glucopyranosyl lipid A stable emulsion and recombinant New York esophageal squamous cell carcinoma-1 protein,EU/3/16/1634,Treatment of soft tissue sarcoma,Immune Design Ltd,21/03/2016,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
624,Glufosfamide,EU/3/11/851,Treatment of pancreatic cancer,Theradex (Europe) Ltd.,15/04/2011,,Q15711735,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
625,[gly2] Recombinant human glucagon-like peptide,EU/3/01/077,Treatment of Short Bowel Syndrome,NPS Pharma Holdings Limited,11/12/2001,RevestiveEU/1/12/78704/09/2012,,short bowel syndrome,http://purl.obolibrary.org/obo/DOID_10605,,http://www.orpha.net/ORDO/Orphanet_104008,D012778,Q662272,,Q662272
626,Glyceryl tri-(4-phenylbutyrate),EU/3/10/733,Treatment of carbamoyl-phosphate synthase-1 deficiency,Horizon Pharma Ireland Limited,10/06/2010,RavictiEU/1/15/106201/12/2015,,carbamoylphosphate synthase1 deficiency,,,,,,,
627,Glyceryl tri-(4-phenylbutyrate),EU/3/10/734,Treatment of ornithine carbamoyltransferase deficiency,Horizon Pharma Ireland Limited,10/06/2010,RavictiEU/1/15/106201/12/2015,,ornithine carbamoyltransferase deficiency,http://purl.obolibrary.org/obo/DOID_9271,,http://www.orpha.net/ORDO/Orphanet_664,D020163,Q3043161,,Q3043161
628,Glyceryl tri-(4-phenylbutyrate),EU/3/10/735,Treatment of citrullinaemia type 1,Horizon Pharma Ireland Limited,10/06/2010,RavictiEU/1/15/106201/12/2015,,citrullinemia type 1,,,http://www.orpha.net/ORDO/Orphanet_247525,D020159,,,Q859142
629,Glyceryl tri-(4-phenylbutyrate),EU/3/10/736,Treatment of argininosuccinic aciduria,Horizon Therapeutics Limited,10/06/2010,RavictiEU/1/15/106201/12/2015,,argininosuccinic aciduria,http://purl.obolibrary.org/obo/DOID_14755,,http://www.orpha.net/ORDO/Orphanet_23,D056807,Q1654860,,Q1654860
630,Glyceryl tri-(4-phenylbutyrate),EU/3/10/737,Treatment of hyperargininaemia,Horizon Pharma Ireland Limited,10/06/2010,RavictiEU/1/15/106201/12/2015,,hyperargininemia,http://purl.obolibrary.org/obo/DOID_9278,,http://www.orpha.net/ORDO/Orphanet_90,D020162,Q890367,,Q890367
631,Glyceryl tri-(4-phenylbutyrate),EU/3/10/738,Treatment of ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria (HHH) syndrome),Horizon Pharma Ireland Limited,10/06/2010,RavictiEU/1/15/106201/12/2015,,ornithine translocase deficiency (hyperornithinemiahyperammonemia homocitrullinuria (hhh) syndrome),,,,,,,
632,Glyceryl tri-(4-phenylbutyrate),EU/3/10/739,Treatment of citrullinaemia type 2,Horizon Pharma Ireland Limited,10/06/2010,,,citrullinemia type 2,,,http://www.orpha.net/ORDO/Orphanet_247585,,,,
633,Glycosylation independent lysosomal targeting tagged recombinant human acid alpha glucosidase,EU/3/11/921,Treatment of glycogen storage disease type II (Pompe's disease),BioMarin Europe Ltd.,27/10/2011,,,glycogen storage disease type ii (pompes disease),,,,,,,
634,Glycyl-L-2-methylprolyl-L-glutamic acid,EU/3/15/1529,Treatment of fragile X syndrome,QRC Consultants Ltd,28/07/2015,,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
635,Glycyl-L-2-methylprolyl-L-glutamic acid,EU/3/15/1534,Treatment of Rett syndrome,QRC Consultants Ltd,10/08/2015,,,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
636,Granulocyte macrophage colony stimulating factor,EU/3/13/1147,Treatment of pulmonary alveolar proteinosis,Savara ApS,17/07/2013,,,pulmonary alveolar proteinosis,http://purl.obolibrary.org/obo/DOID_12120,,,D011649,Q448698,,Q448698
637,Guanabenz,EU/3/09/625,Treatment of traumatic spinal cord injury,Acure Pharma AB,29/04/2009,,Q5613542,traumatic spinal cord injury,,,,,,,
638,Gusperimus trihydrochloride,EU/3/01/034,Treatment of Wegener&#8217;s granulomatosis,Nordic Group B.V.,29/03/2001,,Q27287580,wegeners granulomatosis,http://purl.obolibrary.org/obo/DOID_12132,,,D014890,Q1161568,,Q1161568
639,Haematopoietic stem cells modified with a lentiviral vector containing the CD18 gene,EU/3/16/1753,Treatment of leukocyte adhesion deficiency type I,Centro de Investigación Biomédica en Red (CIBER),14/10/2016,,,leukocyte adhesion deficiency type i,,,http://www.orpha.net/ORDO/Orphanet_99842,,,,
640,Halofuginone Hydrobromide,EU/3/01/074,Treatment of systemic sclerosis,PPD Global Ltd,11/12/2001,,Q27286744,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
641,Halofuginone Hydrobromide,EU/3/12/988,Treatment of Duchenne muscular dystrophy,Biological Consulting Europe Ltd,26/04/2012,,Q27286744,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
642,"H-Arg-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt & H-Tyr-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt",EU/3/07/521,Treatment of TERT positive non-small cell lung cancer in HLA-A2 positive patients,Vaxon Biotech,18/12/2007,,,tert positive nonsmall cell lung cancer in hlaa2 positive patients,,,,,,,
643,H-D-Asp-D-Gln-D-Ser-D-Arg-D-Pro-D-Val-D-Gln-D-Pro-D-Phe-D-Leu-D-Asn-D-Leu-D-Thr-D-Thr-D-Pro-D-Arg-D-Lys-D-Pro-D-Arg-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-NH2,EU/3/05/292,"Treatment of acute sensorineural hearing loss (acute acoustic trauma, sudden deafness and surgery induced acoustic trauma)",Auris Medical Limited,16/06/2005,,,"acute sensorineural hearing loss (acute acostic trauma, sudden deafness and surgery induced acostic trauma)",,,,,,,
644,Heat-killed Mycobacterium obuense (whole cell),EU/3/14/1385,Treatment of pancreatic cancer,Immodulon Therapeutics Ltd,16/12/2014,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
645,Heat-killed Mycobacterium vaccae (whole cell),EU/3/10/786,Treatment of tuberculosis,Immodulon Therapeutics Ltd,20/09/2010,,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
646,Heparin sodium,EU/3/06/371,Treatment of cystic fibrosis,Ockham Biotech Limited,22/05/2006,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
647,Heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulphate hemihydrate),EU/3/10/754,Treatment of traumatic spinal cord injury,Bioarctic AB,27/07/2010,,,traumatic spinal cord injury,,,,,,,
648,"Heparin-binding epidermal growth factor-like growth factor (HB-EGF), amino acids 74-148",EU/3/06/407,Prevention of necrotizing enterocolitis,Dr Michael Moore,31/10/2006,,,necrotizing enterocolitis,http://purl.obolibrary.org/obo/DOID_8677,,,D020345,Q10859678,,Q10859678
649,Hepatitis C Immunoglobulin,EU/3/05/295,Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients,Biotest Pharma GmbH,08/07/2005,,,recurrent hepatitis c virus induced liver disease in liver transplant recipients,,,,,,,
651,Herpes simplex type 1 virus containing cellular B-myb gene as tumour-specific promoter,EU/3/14/1412,Treatment of pancreatic cancer,Karcinolys S.A.S,15/01/2015,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
652,Herpes simplex virus lacking infected cell protein 34.5,EU/3/03/153,Treatment of glioma,Virttu Biologics Limited,09/07/2003,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
653,Heterologous human adult liver derived stem cells,EU/3/07/506,Treatment of Crigler-Najjar syndrome,Promethera Biosciences,29/11/2007,,,criglernajjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,http://www.orpha.net/ORDO/Orphanet_205,D003414,Q1140000,Q1140000,Q1140000
654,Heterologous human adult liver derived stem cells,EU/3/08/530,Treatment of ornithinine transcarbamylase deficiency,Promethera Biosciences,04/02/2008,,,ornithinine transcarbamylase deficiency,,,,,,,
655,Heterologous human adult liver-derived progenitor cells,EU/3/13/1161,Treatment of carbamoyl-phosphate synthase-1 deficiency,Promethera Biosciences,17/07/2013,,,carbamoylphosphate synthase1 deficiency,,,,,,,
656,Heterologous human adult liver-derived progenitor cells,EU/3/13/1162,Treatment of citrullinaemia type 1,Promethera Biosciences,17/07/2013,,,citrullinemia type 1,,,http://www.orpha.net/ORDO/Orphanet_247525,D020159,,,Q859142
657,Heterologous human adult liver-derived progenitor cells,EU/3/13/1163,Treatment of argininosuccinic aciduria,Promethera Biosciences,17/07/2013,,,argininosuccinic aciduria,http://purl.obolibrary.org/obo/DOID_14755,,http://www.orpha.net/ORDO/Orphanet_23,D056807,Q1654860,,Q1654860
658,Heterologous human adult liver-derived progenitor cells,EU/3/13/1164,Treatment of hyperargininaemia,Promethera Biosciences,17/07/2013,,,hyperargininemia,http://purl.obolibrary.org/obo/DOID_9278,,http://www.orpha.net/ORDO/Orphanet_90,D020162,Q890367,,Q890367
659,Heterologous human adult liver-derived progenitor cells,EU/3/13/1165,Treatment of N-acetylglutamate synthetase (NAGS) deficiency,Promethera Biosciences,17/07/2013,,,nacetylglutamate synthetase (nags) deficiency,,,,,,,
660,Heterologous human adult liver-derived progenitor cells,EU/3/13/1166,Treatment of citrullinaemia type 2,Promethera Biosciences,17/07/2013,,,citrullinemia type 2,,,http://www.orpha.net/ORDO/Orphanet_247585,,,,
661,Heterologous human adult liver-derived progenitor cells,EU/3/13/1167,Treatment of ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria (HHH) syndrome),Promethera Biosciences,17/07/2013,,,ornithine translocase deficiency (hyperornithinemiahyperammonemia homocitrullinuria (hhh) syndrome),,,,,,,
662,Heterologous human adult liver-derived stem cells,EU/3/11/904,Treatment of ornithine transcarbamylase deficiency,Fresenius Medical Care Deutschland GmbH,27/09/2011,,,ornithine transcarbamylase deficiency,http://purl.obolibrary.org/obo/DOID_9271,,http://www.orpha.net/ORDO/Orphanet_664,D020163,Q3043161,,Q3043161
663,Heterologous human adult liver-derived stem cells,EU/3/12/971,Treatment of carbamoyl-phosphate synthase-1 deficiency,Fresenius Medical Care Deutschland GmbH,05/03/2012,,,carbamoylphosphate synthase1 deficiency,,,,,,,
664,Heterologous human adult liver-derived stem cells,EU/3/12/983,Treatment of acute liver failure,Fresenius Medical Care Deutschland GmbH,26/04/2012,,,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
665,Hexasodium phytate,EU/3/12/1026,Treatment of calciphylaxis,Laboratoris Sanifit S.L.,17/07/2012,,Q27295268,calciphylaxis,http://purl.obolibrary.org/obo/DOID_4734,,http://www.orpha.net/ORDO/Orphanet_280062,D002115,Q1026326,,Q1026326
666,Histamine dihydrochloride,EU/3/05/272,Treatment of acute myeloid leukaemia,Meda AB,11/04/2005,CepleneEU/1/08/47709/10/2008,Q5772985,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
667,HLA-A2 restricted CD8 T-cell line expressing MART-1 T-cell receptor,EU/3/04/202,Treatment of MART-1 positive malignant melanoma in HLA-A2 positive patients,Cellcure A/S,21/06/2004,,,mart1 positive malignant melanoma in hlaa2 positive patients,,,,,,,
668,HLA-B27 derived peptide (amino acid 125-138),EU/3/04/219,Treatment of autoimmune uveitis,Dr Gerhild Wildner,02/09/2004,,,autoimmune uveitis,,,,,,,
669,H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate,EU/3/16/1662,Treatment of amyotrophic lateral sclerosis,QRC Consultants Ltd,30/05/2016,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
670,Human allogeneic bone marrow derived osteoblastic-like cells,EU/3/13/1176,Treatment of non-traumatic osteonecrosis,Bone Therapeutics SA,05/08/2013,,,nontraumatic osteonecrosis,,,,,,,
671,Human allogeneic bone-marrow-derived osteoblastic cells,EU/3/15/1533,Treatment of osteogenesis imperfecta,Bone Therapeutics SA,10/08/2015,,,osteogenesis imperfecta,http://purl.obolibrary.org/obo/DOID_12347,,http://www.orpha.net/ORDO/Orphanet_666,D010013,Q749409,Q749409,Q749409
672,Human Alpha1-Proteinase Inhibitor (respiratory use),EU/3/01/044,Treatment of emphysema secondary to congenital alpha 1-antitrypsin deficiency,CSL Behring GmbH,09/07/2001,,,emphysema secondary to congenital alpha 1antitrypsin deficiency,,,,,,,
673,Human anti-intercellular adhesion molecule1 monoclonal antibody,EU/3/08/600,Treatment of multiple myeloma,BioInvent International AB,20/01/2009,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
674,Human apotransferrin,EU/3/12/1027,Treatment of congenital hypotransferrinaemia,Sanquin Plasma Products B.V.,17/07/2012,,,congenital hypotransferrinemia,,,http://www.orpha.net/ORDO/Orphanet_1195,,,,
675,Human autologous bone-forming cells derived from bone marrow stem cells,EU/3/07/490,Treatment of non-traumatic osteonecrosis,Bone Therapeutics SA,29/10/2007,,,nontraumatic osteonecrosis,,,,,,,
676,Human autologous mesenchymal adult stem cells extracted from adipose tissue,EU/3/05/303,Treatment of anal fistula,TiGenix S.A.U.,26/08/2005,,,anal fistula,http://purl.obolibrary.org/obo/DOID_0060328,http://purl.obolibrary.org/obo/HP_0010447,,D012003,Q484765,,
677,Human coagulation factor X,EU/3/07/471,Treatment of hereditary factor X deficiency,Bio Products Laboratory,17/09/2007,CoagadexEU/1/16/108718/03/2016,,hereditary factor x deficiency,,,,,,,
678,Human cytomegalovirus immunoglobulin,EU/3/06/408,Prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection,Biotest Pharma GmbH,31/10/2006,,,congenital cytomegalovirus infection following primary cytomegalovirus infection,,,,,,,
679,Human donor haematopoietic stem and progenitor cells that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor,EU/3/16/1817,Treatment in haematopoietic stem cell transplantation,Coté Orphan Consulting UK Limited,12/01/2017,,,hematopoietic stem cell transplantation,,,,D018380,,,
680,Human embryonic stem-cell-derived retinal pigment epithelial cells,EU/3/11/874,Treatment of Stargardt&#8217;s disease,Astellas Pharma Europe B.V.,21/06/2011,,,stargardts disease,,,,,,,
681,Human erythrocytes encapsulating inositol hexaphosphate,EU/3/12/1008,Treatment of sickle cell disease,ERYtech Pharma S.A.,04/07/2012,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
682,Human haptoglobin,EU/3/11/936,Treatment of sickle cell disease,Bio Products Laboratory Ltd,09/12/2011,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
683,Human hemin,EU/3/13/1149,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,Borders Technology Management Ltd,17/07/2013,,,ischemia/reperfusion injury associated with solid organ transplantation,,,,,,,
684,Human hepatoma cell line HepaRG in bioartificial liver,EU/3/16/1818,Treatment of acute liver failure,Hep-Art Medical Devices BV,12/01/2017,,,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
685,Human heterologous liver cells (for infusion),EU/3/06/362,Treatment of acute liver failure,Promethera Biosciences,11/04/2006,,,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
686,Human heterologous liver cells (for infusion),EU/3/07/470,Treatment of ornithine-transcarbamylase deficiency,Promethera Biosciences,14/09/2007,,,ornithinetranscarbamylase deficiency,,,,,,,
687,Human heterologous liver cells (for infusion),EU/3/10/818,Treatment of citrullinaemia type 1,Promethera Biosciences,17/12/2010,,,citrullinemia type 1,,,http://www.orpha.net/ORDO/Orphanet_247525,D020159,,,Q859142
688,Human heterologous liver cells (for infusion),EU/3/10/819,Treatment of hyperargininaemia,Promethera Biosciences,17/12/2010,,,hyperargininemia,http://purl.obolibrary.org/obo/DOID_9278,,http://www.orpha.net/ORDO/Orphanet_90,D020162,Q890367,,Q890367
689,Human heterologous liver cells (for infusion),EU/3/10/820,Treatment of argininosuccinic aciduria,Promethera Biosciences,17/12/2010,,,argininosuccinic aciduria,http://purl.obolibrary.org/obo/DOID_14755,,http://www.orpha.net/ORDO/Orphanet_23,D056807,Q1654860,,Q1654860
690,Human heterologous liver cells (for infusion),EU/3/10/821,Treatment of carbamoyl-phosphate synthase-1 deficiency,Promethera Biosciences,17/12/2010,,,carbamoylphosphate synthase1 deficiency,,,,,,,
691,Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein,EU/3/05/334,Treatment of X-linked hypohidrotic ectodermal dysplasia (Christ-Siemens-Touraine Syndrome),Edimer Ltd,14/12/2005,,,xlinked hypohidrotic ectodermal dysplasia (christsiemenstoraine syndrome),,,,,,,
692,"Human Interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and non-glycosylated) (inhalation use)",EU/3/06/417,Treatment of renal cell carcinoma,Immunservice GmbH,27/10/2006,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
693,Human MHC non-restricted cytotoxic T-cell line,EU/3/09/696,Treatment of ovarian cancer,Galileo Research S.r.l.,30/11/2009,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
694,Human monoclonal antibody against activin A,EU/3/16/1779,Treatment of fibrodysplasia ossificans progressiva,Regeneron Ireland,18/11/2016,,,fibrodysplasia ossificans progressiva,http://purl.obolibrary.org/obo/DOID_13374,,http://www.orpha.net/ORDO/Orphanet_337,D009221,Q1410831,,Q3858675
695,Human monoclonal antibody against CD4,EU/3/04/198,Treatment of cutaneous T-cell lymphoma,TenX Biopharma Ltd,14/04/2004,,,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
696,Human monoclonal antibody against Fas ligand,EU/3/12/956,Treatment of pemphigus,PinCell s.r.l.,09/02/2012,,,pemphigus,http://purl.obolibrary.org/obo/DOID_9182,,,D010392,Q1483214,,Q1483214
697,Human monoclonal antibody against human interleukin 13,EU/3/13/1205,Treatment of eosinophilic oesophagitis,Novartis Europharm Limited,13/11/2013,,,eosinophilic oesophagitis,,,,,,,
698,Human monoclonal antibody against Pseudomonas aeruginosa IATS-O1,EU/3/09/705,Treatment of pneumonia caused by serotype O1 Pseudomonas aeruginosa,Envestia Limited,28/01/2010,,,pneumonia caused by serotype o1 pseudomonas eruginosa,,,,,,,
699,Human monoclonal antibody against Pseudomonas aeruginosa serotype O11,EU/3/06/381,Treatment of pneumonia caused by serotype O11 Pseudomonas aeruginosa,Envestia Limited,29/06/2006,,,pneumonia caused by serotype o11 pseudomonas eruginosa,,,,,,,
700,Human monoclonal antibody targeting Staphylococcus aureus alpha-toxin,EU/3/12/968,Treatment of pneumonia caused by Staphylococcus aureus,Envestia Limited,05/03/2012,,,pneumonia caused by staphylococcus aureus,,,,,,,
701,Human monoclonal IgG1 antibody against tissue factor pathway inhibitor,EU/3/16/1752,Treatment of haemophilia A,Pfizer Limited,14/10/2016,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
702,Human/murine chimeric monoclonal antibody against endoglin,EU/3/16/1648,Treatment of soft tissue sarcoma,Tracon Pharma Limited,28/04/2016,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
703,Human papilloma virus type 16 E6/E7 synthetic long peptides,EU/3/07/520,Treatment of epithelial neoplasia of the vulva positive for human papilloma virus,ISA Therapeutics B.V.,20/12/2007,,,epithelial neoplasia of the vulva positive for human papilloma virus,,,,,,,
704,Human plasma-derived alpha-1 proteinase inhibitor,EU/3/15/1455,Treatment of graft-versus-host disease,Kamada BioPharma Limited,19/03/2015,,,graftversushost disease,,,,D006086,,,Q1194520
705,Human plasmin,EU/3/10/834,Treatment of acute peripheral arterial occlusion,Grifols Deutschland GmbH,23/02/2011,,,acute peripheral arterial occlusion,,,,,,,
706,Human plasminogen,EU/3/07/461,Treatment of ligneous conjunctivitis,Kedrion S.p.A.,03/08/2007,,,ligneos conjunctivitis,,,http://www.orpha.net/ORDO/Orphanet_97231,,,,
707,Human plasminogen,EU/3/15/1511,Treatment of plasminogen deficiency,ProMetic BioTherapeutics Ltd,28/07/2015,,,plasminogen deficiency,,,,,,,
708,Human platelet antigen-1a immunoglobulin,EU/3/11/922,Prevention of fetal and neonatal alloimmune thrombocytopenia due to human platelet antigen-1a incompatibility,Prophylix Pharma AS,27/10/2011,,,fetal and neonatal alloimmune thrombocytopenia due to human platelet antigen1a incompatibility,,,,,,,
709,Human reovirus type 3 Dearing strain,EU/3/15/1469,Treatment of ovarian cancer,Oncolytics Biotech (UK) Limited,19/03/2015,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
710,Human reovirus type 3 Dearing strain,EU/3/15/1477,Treatment of pancreatic cancer,Oncolytics Biotech (UK) Limited,24/04/2015,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
711,Human Staphylococcus aureus immunoglobulin,EU/3/05/319,Treatment of Staphylococcus aureus bacteremia,Biotest Pharma GmbH,28/10/2005,,,staphylococcus aureus bacteremia,,,,,,,
712,Human telomerase reverse transcriptase peptide (611-626),EU/3/06/384,Treatment of pancreatic cancer,Gemvax A/S,25/07/2006,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
713,Human tumour necrosis factor alfa-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys,EU/3/09/677,Treatment of acute lung injury,Apeptico Forschung und Entwicklung GmbH,08/10/2009,,,acute lung injury,,,http://www.orpha.net/ORDO/Orphanet_178320,D055371,,,
714,Humanised anti-alpha ? beta 6 monoclonal antibody,EU/3/14/1301,Treatment of idiopathic pulmonary fibrosis,Biogen Idec Limited,29/07/2014,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
715,Humanised antibody fragment (Ep-CAM)-truncated Pseudomonas exotoxin A fusion protein,EU/3/05/290,Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck,Viventia Biotech (EU) Limited,20/06/2005,,,epcampositive squamos cell carcinoma of the head and neck,,,,,,,
716,Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1,EU/3/15/1494,Treatment of diffuse large B-cell lymphoma,ImmunoGen Europe Limited,21/05/2015,,,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
717,Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4,EU/3/15/1458,Treatment of ovarian cancer,ImmunoGen Europe Limited,19/03/2015,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
718,Humanised anti-IL-6 receptor monoclonal antibody,EU/3/16/1680,Treatment of neuromyelitis optica spectrum disorders,Chugai Pharma Europe Ltd,27/06/2016,,,neuromyelitis optica spectrum disorders,,,,D009471,,,Q611458
719,Humanised Fc engineered monoclonal antibody against CD19,EU/3/14/1286,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,MorphoSys AG,04/07/2014,,,chronic lymphocytic leukemia / small lymphocytic lymphoma,,,,,,,
720,Humanised Fc engineered monoclonal antibody against CD19,EU/3/14/1424,Treatment of diffuse large B-cell lymphoma,MorphoSys AG,15/01/2015,,,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
721,Humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain,EU/3/15/1575,Prevention of graft-versus-host disease,Enpharma Ltd,11/11/2015,,,graftversushost disease,,,,D006086,,,Q1194520
722,Humanised IgG1 kappa antibody against serum amyloid A and AL amyloid,EU/3/13/1100,Treatment of amyloid light-chain amyloidosis,Prothena Therapeutics Limited,08/02/2013,,,amyloid lightchain amyloidosis,,,,,,,
723,Humanised IgG1 monoclonal antibody against human eotaxin-2,EU/3/14/1371,Treatment of systemic sclerosis,FGK Representative Service GmbH,19/11/2014,,Q27291473,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
724,Humanised IgG1 monoclonal antibody against human KIR3DL2,EU/3/14/1322,Treatment of cutaneous T-cell lymphoma,Innate Pharma S.A.,22/08/2014,,,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
725,Humanised IgG1 monoclonal antibody against the receptor-binding site of human placental growth factor,EU/3/16/1819,Treatment of medulloblastoma,Oncurious NV,12/01/2017,,,medulloblastoma,http://purl.obolibrary.org/obo/DOID_0050902,http://purl.obolibrary.org/obo/HP_0002885,http://www.orpha.net/ORDO/Orphanet_616,D008527,Q1333608,,Q18556102
726,Humanised IgG4 monoclonal antibody against extracellular tau,EU/3/15/1522,Treatment of progressive supranuclear palsy,Bristol-Myers Squibb Pharma EEIG,28/07/2015,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
727,"Humanised IgG4 monoclonal antibody against total complement component 1, subcomponent s",EU/3/16/1609,Treatment of autoimmune haemolytic anaemia,Assign Group Development UK Ltd,17/02/2016,,,autoimmune hemolytic anemia,http://purl.obolibrary.org/obo/DOID_718,http://purl.obolibrary.org/obo/HP_0001890,http://www.orpha.net/ORDO/Orphanet_98375,D000744,Q28814,,Q28814
728,Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2,EU/3/09/638,Prevention of the ischaemia/reperfusion injury associated with solid organ transplantation,Opsona Therapeutics Limited,15/05/2009,,,the ischemia/reperfusion injury associated with solid organ transplantation,,,,,,,
729,Humanised monoclonal antibody against CD38,EU/3/14/1268,Treatment of plasma cell myeloma,Sanofi-Aventis groupe,29/04/2014,,,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
730,Humanised monoclonal antibody against myostatin,EU/3/13/1105,Treatment of Duchenne muscular dystrophy,Pfizer Limited,08/02/2013,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
731,Humanised monoclonal antibody against P-selectin,EU/3/12/1034,Treatment of sickle cell disease,Quintiles Ireland Ltd,09/08/2012,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
732,Humanised monoclonal antibody of the IgG4 kappa isotype targeting CD47,EU/3/15/1582,Treatment of acute myeloid leukaemia,ICON Clinical Research Limited,11/11/2015,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
733,Humanised monoclonal antibody targeting interleukin-15,EU/3/16/1681,Treatment of eosinophilic oesophagitis,Dr Alain Vicari,27/06/2016,,,eosinophilic oesophagitis,,,,,,,
734,Humanised monoclonal antibody to the folate receptor alpha,EU/3/08/535,Treatment of ovarian cancer,Eisai Europe Limited,01/04/2008,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
735,Humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor,EU/3/12/1052,Treatment of haemophilia A,Novo Nordisk A/S,10/10/2012,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
736,"Humanised monoclonal modified IgG4 antibody with bispecific structure targeting factors IX, IXa, X and Xa",EU/3/13/1221,Treatment of haemophilia A,Roche Registration Limited,18/12/2013,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
737,Humanised recombinant IgG4 anti-human tau antibody,EU/3/16/1649,Treatment of progressive supranuclear palsy,AbbVie Ltd,28/04/2016,,Q27256246,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
738,Humanised recombinant monoclonal antibody against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F,EU/3/14/1305,Treatment of glioma,AbbVie Ltd,29/07/2014,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
739,Humanised single chain monoclonal antibody against CD37,EU/3/12/1083,Treatment of chronic lymphocytic leukaemia,Emergent Product Development UK Limited,06/12/2012,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
740,Humanized Agonistic Anti-CD28 Monoclonal Antibody,EU/3/05/276,Treatment of B-cell Chronic Lymphocytic Leukaemia (B-CLL),TeGenero AG,11/04/2005,,,bcell chronic lymphocytic leukemia (bcll),,,,,,,
741,Hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]acetate,EU/3/15/1527,Treatment of amyotrophic lateral sclerosis,PBS Regulatory Consulting Group Limited,28/07/2015,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
742,Hydrocortisone (modified release tablet),EU/3/05/296,Treatment of congenital adrenal hyperplasia,Diurnal Limited,27/07/2005,,,congenital adrenal hyperplasia,http://purl.obolibrary.org/obo/DOID_0050811,http://purl.obolibrary.org/obo/HP_0008258,http://www.orpha.net/ORDO/Orphanet_418,D000312,Q366868,Q366868,Q4127186
743,Hydrocortisone (modified release tablet),EU/3/06/372,Treatment of adrenal insufficiency,Shire Services BVBA,22/05/2006,PlenadrenEU/1/11/71514/11/2011,,adrenal insufficiency,,http://purl.obolibrary.org/obo/HP_0000846,,D000309,,,Q2507454
744,Hydrocortisone (modified release tablet),EU/3/07/441,Treatment of adrenal insufficiency,Diurnal Limited,20/03/2007,,,adrenal insufficiency,,http://purl.obolibrary.org/obo/HP_0000846,,D000309,,,Q2507454
745,Hydroxychloroquine,EU/3/16/1820,Treatment of antiphospholipid syndrome,Centre Hospitalier Universitaire d'Angers,12/01/2017,,Q421094,antiphospholipid syndrome,http://purl.obolibrary.org/obo/DOID_2988,,,D016736,Q582207,,Q582207
746,Hydroxy-propyl-beta-cyclodextrin,EU/3/11/895,"Treatment of Niemann-Pick disease, type C",Medical Need Europe AB,30/08/2011,,,"niemannpick disease, type c",,,,D052556,,,Q2067267
747,Hydroxyurea,EU/3/03/154,Treatment of sickle cell syndrome,Addmedica SAS,09/07/2003,SiklosEU/1/07/39705/07/2007,Q212272,sickle cell syndrome,,,,,,,
748,Hypothiocyanite / lactoferrin,EU/3/09/654,Treatment of cystic fibrosis,Alaxia,24/07/2009,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
749,Ibrutinib,EU/3/13/1203,Treatment of diffuse large B-cell lymphoma,Janssen-Cilag International NV,13/11/2013,,Q5984881,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
750,Ibrutinib,EU/3/13/1212,Treatment of follicular lymphoma,Janssen-Cilag International NV,18/12/2013,,Q5984881,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
751,Ibrutinib,EU/3/14/1264,Treatment of lymphoplasmacytic lymphoma,Janssen-Cilag International NV,29/04/2014,IMBRUVICAEU/1/14/94507/07/2015,Q5984881,lymphoplasmacytic lymphoma,http://purl.obolibrary.org/obo/DOID_0050747,,,,Q1778287,,
752,Ibrutinib,EU/3/15/1541,Treatment of marginal zone lymphoma,Janssen-Cilag International NV,10/08/2015,,Q5984881,marginal zone lymphoma,http://purl.obolibrary.org/obo/DOID_0050748,,http://www.orpha.net/ORDO/Orphanet_300912,,Q18553449,,
753,Ibrutinib,EU/3/16/1780,Treatment of graft-versus-host disease,Janssen-Cilag International NV,18/11/2016,,Q5984881,graftversushost disease,,,,D006086,,,Q1194520
754,Ibudilast,EU/3/16/1801,Treatment of amyotrophic lateral sclerosis,MediciNova (Europe) Limited,12/12/2016,,Q261167,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
755,Icatibant acetate,EU/3/03/133,treatment of angioedema,Shire Orphan Therapies GmbH,17/02/2003,FirazyrEU/1/08/46115/07/2008,Q27256146,angioedema,http://purl.obolibrary.org/obo/DOID_1558,http://purl.obolibrary.org/obo/HP_0100665,,D000799,Q1129007,,Q1129007
756,Idebenone,EU/3/01/062,Treatment of Friedreich&#8217;s ataxia,Laboratoires Takeda,20/11/2001,,Q4197874,friedreichs ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
757,Idebenone,EU/3/04/189,Treatment of Friedreich&#8217;s ataxia,Santhera Pharmaceuticals (Deutschland) GmbH,08/03/2004,,Q4197874,friedreichs ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
758,Idebenone,EU/3/07/434,Treatment of Leber's hereditary optic neuropathy,Santhera Pharmaceuticals (Deutschland) GmbH,15/02/2007,RaxoneEU/1/15/102010/09/2015,Q4197874,lebers hereditary optic neuropathy,http://purl.obolibrary.org/obo/DOID_705,,,D029242,Q1262161,,Q1262161
759,Idebenone,EU/3/07/437,Treatment of Duchenne muscular dystrophy,Santhera Pharmaceuticals (Deutschland) GmbH,20/03/2007,,Q4197874,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
760,"IL-12-secreting dendritic cells, loaded with autologous tumour lysate",EU/3/12/1058,Treatment of glioma,Activartis Biotech GmbH,08/11/2012,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
761,Imatinib,EU/3/14/1357,Treatment of acute respiratory distress syndrome,Numedicus Limited,19/11/2014,,Q177094,acute respiratory distress syndrome,,,,D012128,,,Q7315912
762,Imetelstat sodium,EU/3/15/1593,Treatment of myelofibrosis,Janssen-Cilag International NV,14/12/2015,,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
763,Imexon,EU/3/05/341,Treatment of ovarian cancer,ICON Clinical Research (U.K.) Limited,23/12/2005,,Q6003924,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
764,Immortalised human C3A hepatoblastoma cells,EU/3/13/1143,Treatment of acute liver failure,Vital Therapies Limited,19/06/2013,,,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
765,"Immunoglobulin G1, anti-(human tumour-associated calcium signal transducer 2)(human-Mus musculus monoclonal hRS7 heavy chain), disulfide with human-Mus musculus monoclonal hRS7 k-chain, dimer, hexakis(thioether) with (4S)-4-[[[[4-[[(2S)-2-(4-aminobutyl)-2-[[2-[2-[[26-[4-[[[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-3,6,9,12,15,18,21,24-octaoxahexacos-1-yl]amino]-2-oxoethoxy]acetyl]amino]-1-oxoethyl]amino]phenyl]methoxy]carbonyl]oxy]-4,11-diethyl-9-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione",EU/3/14/1343,Treatment of pancreatic cancer,Immunomedics GmbH,15/10/2014,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
766,Inecalcitol,EU/3/13/1223,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,Hybrigenics SA,16/01/2014,,Q27078058,chronic lymphocytic leukemia / small lymphocytic lymphoma,,,,,,,
767,Inecalcitol,EU/3/15/1523,Treatment of acute myeloid leukaemia,Hybrigenics SA,28/07/2015,,Q27078058,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
768,Inolimomab,EU/3/01/028,Treatment of Graft versus Host Disease,Jazz Pharmaceuticals France SAS,05/03/2001,,Q3799026,graft versus host disease,,,http://www.orpha.net/ORDO/Orphanet_39812,D006086,,,Q1194520
769,Inotuzumab ozogamicin,EU/3/13/1127,Treatment of B-cell acute lymphoblastic leukaemia,Pfizer Limited,07/06/2013,,Q3799041,bcell acute lymphoblastic leukemia,,,,,,,
770,Insulin human,EU/3/15/1532,Treatment of short bowel syndrome,Sirius Regulatory Consulting Limited,10/08/2015,,Q39798,short bowel syndrome,http://purl.obolibrary.org/obo/DOID_10605,,http://www.orpha.net/ORDO/Orphanet_104008,D012778,Q662272,,Q662272
771,Interferon alfa-n3,EU/3/15/1568,Treatment of Middle East respiratory syndrome,NV Hemispherx BioPharma Europe,11/11/2015,,Q6046446,middle east respiratory syndrome,,,,D018352,,,
772,Interferon beta,EU/3/07/505,Treatment of acute lung injury,Faron Pharmaceuticals Limited,29/11/2007,,Q27074716,acute lung injury,,,http://www.orpha.net/ORDO/Orphanet_178320,D055371,,,
773,Interferon gamma,EU/3/07/491,Treatment of idiopathic pulmonary fibrosis,mondoBIOTECH Laboratories AG,29/10/2007,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
774,Interferon gamma,EU/3/11/935,Treatment of Friedreich's ataxia,Horizon Pharma Ireland Limited,09/12/2011,,,friedreichs ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
775,Iodine (131I) chlorotoxin,EU/3/07/492,Treatment of glioma,Eisai Europe Limited,22/10/2007,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
776,Iodine (131I) iobenguane,EU/3/07/525,Treatment of neuroblastoma,Molecular Insight Limited,31/01/2008,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
777,Irinotecan hydrochloride (drug eluting beads),EU/3/07/504,Treatment of glioma,Biocompatibles UK Limited,29/11/2007,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
778,Isavuconazonium sulfate,EU/3/14/1276,Treatment of mucormycosis,Basilea Medical Ltd,04/06/2014,CresembaEU/1/15/103619/10/2015,Q27158829,mucormycosis,,,http://www.orpha.net/ORDO/Orphanet_73263,D009091,,,Q6931254
779,Isavuconazonium sulfate,EU/3/14/1284,Treatment of invasive aspergillosis,Basilea Medical Ltd,04/07/2014,CresembaEU/1/15/103619/10/2015,Q27158829,invasive aspergillosis,http://purl.obolibrary.org/obo/DOID_0050073,,,,Q18553203,,
780,Isofagomine tartrate,EU/3/07/493,Treatment of Gaucher Disease,Amicus Therapeutics UK Ltd,23/10/2007,,,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
781,Ivosidenib,EU/3/16/1802,Treatment of acute myeloid leukaemia,QRC Consultants Ltd,12/12/2016,,Q27895417,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
782,Ixazomib,EU/3/12/1060,Treatment of systemic light chain amyloidosis,Takeda Pharma A/S,08/11/2012,,Q20948663,systemic light chain amyloidosis,,,,,,,
783,Ketoconazole,EU/3/12/965,Treatment of Cushing&#8217;s syndrome,Laboratoire HRA Pharma,23/04/2012,Ketoconazole HRAEU/1/14/96521/11/2014,Q407883,cushings syndrome,http://purl.obolibrary.org/obo/DOID_12252,,http://www.orpha.net/ORDO/Orphanet_553,D003480,Q219102,,Q219102
784,Ketoconazole,EU/3/12/1031,Treatment of Cushing&#8217;s syndrome,Agenzia Industrie Difesa-Stabilimento Chimico Farmaceutico Militare,09/08/2012,,Q407883,cushings syndrome,http://purl.obolibrary.org/obo/DOID_12252,,http://www.orpha.net/ORDO/Orphanet_553,D003480,Q219102,,Q219102
785,"l, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane",EU/3/04/227,Treatment to mobilize progenitor cells prior to stem cell transplantation,Genzyme Europe B.V.,20/10/2004,MozobilEU/1/09/53704/08/2009,,mobilise progenitor cells prior to stem cell transplantation,,,,,,,
786,Lactobacillus acidophilus and Bifidobacterium bifidum,EU/3/13/1213,Prevention of necrotising enterocolitis,Laboratorio Farmaceutico S.I.T. s.r.l.,18/12/2013,,,necrotising enterocolitis,,,,,,,
787,Lactobacillus reuteri,EU/3/15/1436,Prevention of necrotising enterocolitis,Infant Bacterial Therapeutics AB,12/02/2015,,,necrotising enterocolitis,,,,,,,
788,Lanreotide acetate,EU/3/15/1514,Treatment of autosomal dominant polycystic kidney disease,Prof. Dr R.T.Gansevoort,10/08/2015,,,autosomal dominant polycystic kidney disease,,,,,,,
789,L-asparaginase encapsulated in erythrocytes,EU/3/06/409,Treatment of acute lymphoblastic leukaemia,ERYtech Pharma S.A.,27/10/2006,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
790,L-asparaginase encapsulated in erythrocytes,EU/3/09/633,Treatment of pancreatic cancer,ERYtech Pharma S.A.,15/05/2009,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
791,L-asparaginase encapsulated in erythrocytes,EU/3/13/1106,Treatment of acute myeloid leukaemia,ERYtech Pharma S.A.,08/02/2013,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
792,"L-cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-, complex with keyhole limpet haemocyanin",EU/3/11/923,Treatment of glioma,Orphix Consulting GmbH,27/10/2011,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
793,Lenalidomide,EU/3/07/494,Treatment of chronic lymphocytic leukaemia,Celgene Europe Limited,19/11/2007,,Q425681,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
794,Lenalidomide,EU/3/11/868,Treatment of diffuse large B-cell lymphoma,Celgene Europe Limited,13/05/2011,,Q425681,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
795,Lenalidomide,EU/3/11/924,Treatment of mantle cell lymphoma,Celgene Europe Limited,27/10/2011,RevlimidEU/1/07/39112/07/2016,Q425681,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
796,Lenalidomide,EU/3/12/1097,Treatment of follicular lymphoma,Celgene Europe Limited,24/01/2013,,Q425681,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
797,Lenalidomide,EU/3/15/1473,Treatment of marginal zone lymphoma,Celgene Europe Limited,24/04/2015,,Q425681,marginal zone lymphoma,http://purl.obolibrary.org/obo/DOID_0050748,,http://www.orpha.net/ORDO/Orphanet_300912,,Q18553449,,
798,Lentiviral vector carrying the Fanconi anaemia-A (FANCA) gene,EU/3/10/822,Treatment of Fanconi anaemia type A,Centro de Investigación Biomédica en Red (CIBER),17/12/2010,,Q21547222,fanconi anemia type a,,,,,,,
799,Lentiviral vector containing the human ABCA4 gene,EU/3/09/720,Treatment of Stargardt's disease,Sanofi-Aventis groupe,02/02/2010,,,stargardts disease,,,,,,,
800,Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene,EU/3/14/1330,Treatment of pyruvate kinase deficiency,Centro de Investigación Biomédica en Red (CIBER),22/08/2014,,,pyruvate kinase deficiency,,,,,,,
801,Lentiviral vector containing the human MYO7A gene,EU/3/10/727,Treatment of retinitis pigmentosa in Usher syndrome 1B,Sanofi-Aventis groupe,23/03/2010,,,retinitis pigmentosa in usher syndrome 1b,,,,,,,
802,Lenvatinib,EU/3/13/1119,Treatment of follicular thyroid cancer,Eisai Europe Limited,26/04/2013,LenvimaEU/1/15/100201/06/2015,Q6523413,follicular thyroid cancer,,,,,,,
803,Lenvatinib,EU/3/13/1121,Treatment of papillary thyroid cancer,Eisai Europe Limited,26/04/2013,LenvimaEU/1/15/100201/06/2015,Q6523413,papillary thyroid cancer,,,,,,,
804,Lenvatinib,EU/3/15/1460,Treatment of hepatocellular carcinoma,Eisai Europe Limited,19/03/2015,,Q6523413,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
805,Letermovir,EU/3/12/999,Treatment of cytomegalovirus disease in patients with impaired cell mediated immunity,Merck Sharp & Dohme Limited,06/06/2012,,Q15409407,cytomegalovirus disease in patients with impaired cell mediated immunity,,,,,,,
806,Leuprorelin acetate,EU/3/16/1821,Treatment of congenital hypogonadotropic hypogonadism,Stichting Centre for Human Drug Research (CHDR),12/01/2017,,Q27104908,congenital hypogonadotropic hypogonadism,,,http://www.orpha.net/ORDO/Orphanet_174590,,,Q17004238,
807,Levamisol hydrochloride,EU/3/05/324,Treatment of nephrotic syndrome,ACE Pharmaceuticals BV,28/10/2005,,,nephrotic syndrome,http://purl.obolibrary.org/obo/DOID_1184,http://purl.obolibrary.org/obo/HP_0000100,,D009404,Q504790,,Q504790
808,Levoglutamide,EU/3/12/1011,Treatment of sickle cell disease,Emmaus Medical Europe Limited,04/07/2012,,Q181619,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
809,Lipid-complexed cisplatin,EU/3/13/1169,Treatment of osteosarcoma,Richardson Associates Regulatory Affairs Ltd,05/08/2013,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
810,Lipopolysaccharide of Ochrobactrum intermedium,EU/3/11/941,Prevention of sepsis in at-risk premature infants of less than or equal to 32 weeks of gestational age,Diomune S.L.,11/01/2012,,,sepsis in atrisk premature infants of less than or equal to 32 weeks of gestational age,,,,,,,
811,Liposomal combination of cytarabine and daunorubicin,EU/3/11/942,Treatment of acute myeloid leukaemia,Jazz Pharmaceuticals Ireland Ltd,11/01/2012,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
812,Lisuride hydrogen maleate,EU/3/11/869,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,Sinoxa Pharma GmbH,13/05/2011,,Q27114683,pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,,,,,,,
813,Lithium citrate tetrahydrate (in reverse-micelle formulation),EU/3/09/706,Treatment of Huntington's disease,Medesis Pharma,28/01/2010,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
814,Live attenuated Listeria monocytogenes bioengineered with a chimeric human epidermal growth factor receptor 2 fused to a truncated form of the Lm protein listeriolysin O,EU/3/15/1595,Treatment of osteosarcoma,Coté Orphan Consulting UK Limited,14/12/2015,,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
815,Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin,EU/3/15/1594,Treatment of malignant mesothelioma,"Aduro Biotech Holdings, Europe B.V.",14/12/2015,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
816,Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin,EU/3/15/1603,Treatment of pancreatic cancer,"Aduro Biotech Holdings, Europe B.V.",11/01/2016,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
817,Live attenuated Listeria monocytogenes transfected with plasmids encoding the HPV-16E7 protein fused to a truncated fragment of the Lm protein listeriolysin O,EU/3/15/1602,Treatment of anal cancer,Dr Ulrich Granzer,11/01/2016,,,anal cancer,http://purl.obolibrary.org/obo/DOID_14110,,,D001005,Q484827,,Q18556540
818,Live-attenuated non-replicative Pseudomonas aeruginosa strain expressing large T antigen of Merkel cell polyomavirus,EU/3/16/1781,Treatment of Merkel cell carcinoma,APCure SAS,18/11/2016,,,merkel cell carcinoma,http://purl.obolibrary.org/obo/DOID_3965,,http://www.orpha.net/ORDO/Orphanet_79140,D015266,Q1711744,,
819,L-Lysine-N-acetyl-L-cysteinate,EU/3/01/026,Treatment of cystic fibrosis,LABORATOIRES SMB SA,14/02/2001,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
820,Lomitapide,EU/3/10/823,Treatment of familial chylomicronaemia,Aegerion Pharmaceuticals Limited,17/12/2010,,Q1268941,familial chylomicronemia,,,,D008072,,,Q2349695
821,Lonafarnib,EU/3/13/1225,Treatment of hepatitis delta virus infection,Eiger Biopharmaceuticals Europe Limited,16/01/2014,,Q3258910,hepatitis delta virus infection,,,,,,,
822,Low molecular weight dextran sulfate,EU/3/09/669,Prevention of graft rejection during pancreatic islet transplantation,TikoMed AB,09/10/2009,,,graft rejection during pancreatic islet transplantation,,,,,,,
823,Low molecular weight dextran sulfate,EU/3/11/883,Treatment for mobilisation of progenitor cells prior to stem cell transplantation,TikoMed AB,05/08/2011,,,mobilisation of progenitor cells prior to stem cell transplantation,,,,,,,
824,L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser,EU/3/13/1191,Treatment of sarcoidosis,Araim Pharma Europe Ltd,07/10/2013,,Q5150955,sarcoidosis,http://purl.obolibrary.org/obo/DOID_11335,,http://www.orpha.net/ORDO/Orphanet_797,D012507,Q193894,Q193894,Q193894
825,L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser,EU/3/16/1721,Prevention of graft loss in pancreatic islet transplantation,Araim Pharma Europe Ltd,29/08/2016,,Q5150955,graft loss in pancreatic islet transplantation,,,,,,,
826,L-selenomethionine,EU/3/16/1782,Treatment of facioscapulohumeral muscular dystrophy,Université de Montpellier,18/11/2016,,Q415925,facioscapulohumeral muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11727,,http://www.orpha.net/ORDO/Orphanet_269,D020391,Q1399182,,Q1399182
827,"L-threo-3,4-dihydroxyphenylserine",EU/3/07/465,Treatment of orthostatic hypotension in patients with pure autonomic failure,H. Lundbeck A/S,02/08/2007,,Q27088845,orthostatic hypotension in patients with pure autonomic failure,,,,,,,
828,"L-threo-3,4-dihydroxyphenylserine",EU/3/07/466,Treatment of orthostatic hypotension in patients with multiple system atrophy,H. Lundbeck A/S,02/08/2007,,Q27088845,orthostatic hypotension in patients with multiple system atrophy,,,,,,,
829,Lurbinectedin,EU/3/12/1053,Treatment of ovarian cancer,Pharma Mar S.A.,10/10/2012,,Q27254568,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
830,Lutetium (177Lu) edotreotide,EU/3/14/1269,Treatment of gastro-entero-pancreatic neuroendocrine tumours,ITG Isotope Technologies Garching GmbH,04/06/2014,,,gastroenteropancreatic neuroendocrine tumors,,,,,,,
831,"Lutetium (177Lu)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide",EU/3/07/523,Treatment of gastro-entero-pancreatic neuroendocrine tumours,Advanced Accelerator Applications,31/01/2008,,Q407329,gastroenteropancreatic neuroendocrine tumors,,,,,,,
832,"Lutetium-177(3+),S2,S7-cyclo[N-{4,7,10-tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl}-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4S)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide]",EU/3/16/1754,Treatment of gastro-entero-pancreatic neuroendocrine tumours,Ipsen Pharma,14/10/2016,,,gastroenteropancreatic neuroendocrine tumors,,,,,,,
833,Macitentan,EU/3/09/707,Treatment of idiopathic pulmonary fibrosis,Actelion Registration Ltd,28/01/2010,,Q6724151,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
834,Macitentan,EU/3/11/909,Treatment of pulmonary arterial hypertension,Actelion Registration Ltd,27/09/2011,OpsumitEU/1/13/89327/12/2013,Q6724151,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
835,Macromolecular conjugate of heparin sodium on a polymer backbone,EU/3/14/1332,Prevention of ischaemia reperfusion injury associated with solid organ transplantation,Corline Biomedical AB,22/08/2014,,,ischemia reperfusion injury associated with solid organ transplantation,,,,,,,
836,"(manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21°-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,4,7,10] tetraazacycloheptadecine-?N5, ?N13, ?N18, ?N21, ?N22]-)",EU/3/07/522,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,Kinesys Consulting Ltd,31/01/2008,,,oral mucositis in head and neck cancer patients undergoing radiation therapy,,,,,,,
837,Mannitolum,EU/3/05/325,Treatment of cystic fibrosis,Pharmaxis Pharmaceuticals Limited,07/11/2005,BronchitolEU/1/12/76018/04/2012,Q407646,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
838,Maribavir,EU/3/07/519,Prevention of cytomegalovirus (CMV) disease in patients with impaired cell mediated immunity deemed at risk,Shire Pharmaceuticals Ireland Limited,18/12/2007,,Q6762512,cytomegalovirus (cmv) disease in patients with impaired cell mediated immunity deemed at risk,,,,,,,
839,Maribavir,EU/3/13/1133,Treatment of cytomegalovirus disease in patients with impaired cell mediated immunity,Shire Pharmaceuticals Ireland Limited,07/06/2013,,Q6762512,cytomegalovirus disease in patients with impaired cell mediated immunity,,,,,,,
840,Marizomib,EU/3/14/1295,Treatment of plasma cell myeloma,Richardson Associates Regulatory Affairs Ltd,29/07/2014,,Q7404722,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
841,Masitinib mesilate,EU/3/09/684,Treatment of pancreatic cancer,AB Science S.A.,28/10/2009,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
842,Masitinib mesilate,EU/3/16/1722,Treatment of amyotrophic lateral sclerosis,AB Science,29/08/2016,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
843,Mavoglurant,EU/3/12/1046,Treatment of fragile X syndrome,Novartis Europharm Limited,10/10/2012,,Q6589598,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
844,Maytansinoid-conjugated human monoclonal antibody against mesothelin,EU/3/12/1073,Treatment of malignant mesothelioma,Bayer Pharma AG,06/12/2012,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
845,Mazindol,EU/3/15/1444,Treatment of narcolepsy,HAC Pharma,12/02/2015,,Q255680,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
846,Mazindol,EU/3/15/1547,Treatment of narcolepsy,NeuroLifeSciences,09/10/2015,,Q255680,narcolepsy,http://purl.obolibrary.org/obo/DOID_8986,http://purl.obolibrary.org/obo/HP_0030050,,D009290,Q189561,,Q189561
847,Mecasermin,EU/3/05/307,Treatment of primary growth hormone insensitivity syndrome,Ipsen Pharma,26/08/2005,,Q6804390,primary growth hormone insensitivity syndrome,,,,,,,
848,Mecasermin,EU/3/06/373,Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects,Ipsen Pharma,22/05/2006,INCRELEXEU/1/07/40207/08/2007,Q6804390,primary insulinlike growth factor1 deficiency due to molecular or genetic defects,,,,,,,
849,Mecasermin rinfabate,EU/3/06/399,Prevention of retinopathy of prematurity in neonates of less than 32 weeks of gestational age,Premacure AB,28/08/2006,,Q6804390,retinopathy of prematurity in neonates of less than 32 weeks of gestational age,,,,,,,
850,Melarsoprol,EU/3/12/1068,Treatment of African trypanosomiasis,Pr. Peter Kennedy,08/11/2012,,Q419753,african trypanosomiasis,http://purl.obolibrary.org/obo/DOID_10112,,http://www.orpha.net/ORDO/Orphanet_3385,D014353,Q203133,,Q203133
851,Melatonin,EU/3/12/978,Treatment of perinatal asphyxia,Chiesi Farmaceutici S.P.A.,02/04/2012,,Q180912,perinatal asphyxia,,,,,,,
852,Melatonin,EU/3/16/1682,Treatment of necrotising enterocolitis,Therapicon Srl,01/08/2016,,Q180912,necrotising enterocolitis,,,,,,,
853,Melatonin,EU/3/16/1683,Treatment of neonatal sepsis,Therapicon Srl,27/06/2016,,Q180912,neonatal sepsis,,http://purl.obolibrary.org/obo/HP_0040187,,D000071074,,,
854,Melatonin,EU/3/16/1755,Treatment of Smith-Magenis syndrome,Therapicon Srl,14/10/2016,,Q180912,smithmagenis syndrome,http://purl.obolibrary.org/obo/DOID_0060768,,http://www.orpha.net/ORDO/Orphanet_819,D058496,Q2295338,,
855,Melphalan flufenamide,EU/3/15/1463,Treatment of plasma cell myeloma,Oncopeptides AB,19/03/2015,,Q27277739,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
856,Mepolizumab,EU/3/04/213,Treatment of hypereosinophilic syndrome,Glaxo Group Ltd,29/07/2004,,Q3306175,hypereosinophilic syndrome,,,http://www.orpha.net/ORDO/Orphanet_168956,D017681,,,Q2551272
857,Mepolizumab,EU/3/13/1116,Treatment of Churg-Strauss Syndrome,Glaxo Group Ltd,12/03/2013,,Q3306175,churgstrauss syndrome,http://purl.obolibrary.org/obo/DOID_3049,,http://www.orpha.net/ORDO/Orphanet_183,D015267,Q32811,,Q32811
858,Mercaptopurine (oral liquid),EU/3/07/496,Treatment of acute lymphoblastic leukaemia,Orbona Pharma Ltd,22/10/2007,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
859,Mercaptopurine (oral suspension),EU/3/09/628,Treatment of acute lymphoblastic leukaemia,Nova Laboratories Limited,30/04/2009,XaluprineEU/1/11/72713/03/2012,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
860,Metastable technetium 99 [99mTc] demogastrin 2,EU/3/06/400,Diagnosis of medullary thyroid carcinoma,Biomedica Life Sciences SA,28/08/2006,,,medullary thyroid carcinoma,http://purl.obolibrary.org/obo/DOID_3973,http://purl.obolibrary.org/obo/HP_0002865,http://www.orpha.net/ORDO/Orphanet_1332,,Q3493538,,
861,Metformin,EU/3/16/1803,Treatment of progressive myoclonic epilepsy type 2 (Lafora disease),Centro de Investigación Biomédica en Red (CIBER),12/12/2016,,Q19484,progressive myoclonic epilepsy type 2 (lafora disease),,,,,,,
862,Methotrexate,EU/3/16/1723,Treatment of alkaptonuria,aimAKU (Associazione Italiana Malati di Alcaptonuria),29/08/2016,,Q422232,alkaptonuria,http://purl.obolibrary.org/obo/DOID_9270,,http://www.orpha.net/ORDO/Orphanet_56,D000474,Q651680,Q651680,Q651680
863,Methotrexate (oral liquid),EU/3/07/495,Treatment of acute lymphoblastic leukaemia,Orbona Pharma Ltd,24/10/2007,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
864,Methoxsalen,EU/3/06/374,Treatment of Graft-versus-Host disease,Therakos (UK) Limited,22/05/2006,,Q408570,graftversushost disease,,,,D006086,,,Q1194520
865,"Methyl 3-((2R)-2-hydroxy-4-(((((S)-1-methoxy-1-oxopropan-2-yl) amino)(phenoxy)phosphoryl)oxy)-3,3-dimethylbutanamido)propanoate",EU/3/16/1612,Treatment of pantothenate-kinase-associated neurodegeneration,Retrophin Europe Limited,17/02/2016,,,pantothenatekinaseassociated neurodegeneration,,,,,,,
866,"Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate",EU/3/07/518,Treatment of pulmonary arterial hypertension including treatment of chronic thromboembolic pulmonary hypertension,Bayer Pharma AG,20/12/2007,AdempasEU/1/13/90731/03/2014,Q27270515,pulmonary arterial hypertension including treatment of chronic thromboembolic pulmonary hypertension,,,,,,,
867,"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-a-asparaginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-lysyl]amino]ethoxy]ethoxy]ethoxy]ethyl]-2,3-di-O-methyl-6-O-sulfo-a-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-ß-D-glucopyranuronosyl-(1->4)-O-2,3,6-tri-O-sulfo-a-D-glucopyranosyl-(1->4)-O-2,3-di-O-methyl-a-L-idopyranuronosyl-(1->4)-3-O-methyl-a-D-glucopyranoside 2,6-bis(hydrogen sulfate) octasodium salt",EU/3/11/884,Prevention of ischaemia/reperfusion injury associated with solid organ transplantation,Endotis Pharma,05/08/2011,,,ischemia/reperfusion injury associated with solid organ transplantation,,,,,,,
868,Methylthioninium,EU/3/10/804,Treatment of progressive supranuclear palsy,TauRx Therapeutics Europe Ltd,26/11/2010,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
869,Methylthioninium,EU/3/10/805,Treatment of behavioural variant frontotemporal dementia,TauRx Therapeutics Europe Ltd,26/11/2010,,,behavioral variant frontotemporal dementia,,,,,,,
870,Methylthioninium,EU/3/10/806,Treatment of progressive non-fluent aphasia,TauRx Therapeutics Europe Ltd,26/11/2010,,,progressive nonfluent aphasia,,,http://www.orpha.net/ORDO/Orphanet_100070,D057178,,,
871,Methylthioninium,EU/3/10/807,Treatment of frontotemporal dementia with parkinsonism-17,TauRx Therapeutics Europe Ltd,26/11/2010,,,frontotemporal dementia with parkinsonism17,,,,D057180,,,
872,Metreleptin,EU/3/12/1022,Treatment of Familial Partial Lipodystrophy,Aegerion Pharmaceuticals Limited,17/07/2012,,,familial partial lipodystrophy,http://purl.obolibrary.org/obo/DOID_0050440,,http://www.orpha.net/ORDO/Orphanet_98306,D052496,Q5432945,Q5432945,Q5432945
873,Metreleptin,EU/3/12/1023,Treatment of Barraquer-Simons syndrome,Aegerion Pharmaceuticals Limited,17/07/2012,,,barraquersimons syndrome,,,http://www.orpha.net/ORDO/Orphanet_79087,,,Q4863247,
874,Metreleptin,EU/3/12/1024,Treatment of Lawrence syndrome,Aegerion Pharmaceuticals Limited,17/07/2012,,,lawrence syndrome,,,http://www.orpha.net/ORDO/Orphanet_79086,,,,
875,Metreleptin,EU/3/12/1025,Treatment of Berardinelli-Seip syndrome,Aegerion Pharmaceuticals Limited,17/07/2012,,,berardinelliseip syndrome,,,,D052497,,,Q3242224
876,Metronidazole,EU/3/11/875,Treatment of pouchitis,Avivia Projects BV,21/06/2011,,Q169569,pochitis,,,,D019449,,,
877,Mexiletine hydrochloride,EU/3/13/1126,Treatment of non-dystrophic myotonia,Prof. Michael Hanna,07/06/2013,,Q27107357,nondystrophic myotonia,,,,,,,
878,Mexiletine hydrochloride,EU/3/13/1189,Treatment of myotonic disorders,Agenzia Industrie Difesa-Stabilimento Chimico Farmaceutico Militare,07/10/2013,,Q27107357,myotonic disorders,,,,D020967,,,Q18556352
879,Mexiletine hydrochloride,EU/3/14/1353,Treatment of myotonic disorders,Lupin (Europe) Limited,19/11/2014,,Q27107357,myotonic disorders,,,,D020967,,,Q18556352
880,Midostaurin,EU/3/04/214,Treatment of acute myeloid leukaemia,Novartis Europharm Limited,29/07/2004,,Q6842945,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
881,Midostaurin,EU/3/10/765,Treatment of mastocytosis,Novartis Europharm Limited,04/08/2010,,Q6842945,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
882,Mifamurtide,EU/3/16/1699,Treatment of echinococcosis,Delta Proteomics SAS,14/07/2016,,Q411175,echinococcosis,http://purl.obolibrary.org/obo/DOID_1496,,,D004443,Q777087,,Q777087
883,Mifamurtide,EU/3/16/1700,Treatment of hepatocellular carcinoma,Delta Proteomics SAS,14/07/2016,,Q411175,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
884,Mifepristone,EU/3/09/614,Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin,EXELGYN,27/02/2009,,Q411240,hypercortisolism (cushings syndrome) of endogenos origin,,,,,,,
885,Mifepristone,EU/3/11/925,Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin,Dr Ulrich Granzer,27/10/2011,,Q411240,hypercortisolism (cushings syndrome) of endogenos origin,,,,,,,
886,Miglustat,EU/3/06/351,"Treatment of Niemann-Pick disease, type C",Actelion Registration Ltd,16/02/2006,ZavescaEU/1/02/23828/01/2009,Q425911,"niemannpick disease, type c",,,,D052556,,,Q2067267
887,Milatuzumab,EU/3/08/601,Treatment of multiple myeloma,Immunomedics GmbH,19/01/2009,,Q3857819,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
888,Milatuzumab,EU/3/08/602,Treatment of chronic lymphocytic leukaemia,Immunomedics GmbH,19/01/2009,,Q3857819,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
889,Milciclib maleate,EU/3/12/1059,Treatment of malignant thymoma,Tiziana Life Sciences PLC,08/11/2012,,,malignant thymoma,http://purl.obolibrary.org/obo/DOID_3284,,http://www.orpha.net/ORDO/Orphanet_99868,,Q7799620,Q7799620,
890,Miltefosine,EU/3/02/104,Treatment of visceral leishmaniasis,Zentaris GmbH,12/06/2002,,Q411787,visceral leishmaniasis,http://purl.obolibrary.org/obo/DOID_9146,,,D007898,Q2046113,,Q2046113
891,Miltefosine,EU/3/05/282,Treatment of Acanthamoeba keratitis,Orpha-Devel Handels und Vertriebs GmbH,27/05/2005,,Q411787,acanthamoeba keratitis,,,http://www.orpha.net/ORDO/Orphanet_67043,D015823,,,
892,Miltefosine,EU/3/08/567,Treatment of cutaneous T-cell lymphoma,ExperGen Drug Development GmbH,22/09/2008,,Q411787,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
893,Mixture of seven synthetic fragments consisting of p21 RAS peptides,EU/3/11/885,Treatment of pancreatic cancer,Targovax ASA,05/08/2011,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
894,Mixture of two adeno-associated viral vectors of serotype 8 containing the 5'-half sequence of human ABCA4 gene and the 3'-half sequence of human ABCA4 gene,EU/3/14/1283,Treatment of Stargardt's disease,Fondazione Telethon,04/07/2014,,,stargardts disease,,,,,,,
895,Mixture of two adeno-associated viral vectors of serotype 8 containing the 5'-half sequence of human MYO7A gene and the 3'-half sequence of human MYO7A gene,EU/3/14/1282,Treatment of Usher syndrome,Fondazione Telethon,04/07/2014,,Q199678,usher syndrome,http://purl.obolibrary.org/obo/DOID_0050439,,http://www.orpha.net/ORDO/Orphanet_886,D052245,Q917399,Q917399,Q917399
896,"Mixture of two allogeneic human pancreatic cancer cell lines stably transduced with a retroviral vector encoding the murine alpha-(1,3)-galactosyltransferase gene",EU/3/12/1048,Treatment of pancreatic cancer,European Medical Advisory Services Limited,10/10/2012,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
897,Modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL,EU/3/15/1516,Treatment of pancreatic cancer,Lokon Pharma AB,28/07/2015,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
898,Modified mRNA encoding the UGT1A1 protein,EU/3/16/1684,Treatment of Crigler-Najjar syndrome,Alexion Europe SAS,27/06/2016,,,criglernajjar syndrome,http://purl.obolibrary.org/obo/DOID_3803,,http://www.orpha.net/ORDO/Orphanet_205,D003414,Q1140000,Q1140000,Q1140000
899,Modified recombinant human C-type natriuretic peptide,EU/3/12/1094,Treatment of achondroplasia,BioMarin Europe Ltd.,24/01/2013,,,achondroplasia,http://purl.obolibrary.org/obo/DOID_4480,,http://www.orpha.net/ORDO/Orphanet_15,D000130,Q340594,,Q340594
900,Mogamulizumab,EU/3/11/943,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",Kyowa Kirin Limited,11/01/2012,,Q6890447,"peripheral tcell lymphoma (nodal, other extranodal and leukemic/disseminated)",,,,,,,
901,Mogamulizumab,EU/3/16/1756,Treatment of cutaneous T-cell lymphoma,Kyowa Kirin Limited,14/10/2016,,Q6890447,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
902,Molgramostim,EU/3/16/1685,Treatment of acute respiratory distress syndrome,Savara ApS,27/06/2016,,Q6896158,acute respiratory distress syndrome,,,,D012128,,,Q7315912
903,Monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E,EU/3/08/595,Treatment of anaplastic large cell lymphoma,Takeda Pharma A/S,15/01/2009,ADCETRISEU/1/12/79430/10/2012,,anaplastic large cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050744,,http://www.orpha.net/ORDO/Orphanet_98841,D017728,Q18553446,,
904,Monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E,EU/3/08/596,Treatment of Hodgkin lymphoma,Takeda Pharma A/S,15/01/2009,ADCETRISEU/1/12/79430/10/2012,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
905,Moxetumomab pasudotox,EU/3/13/1150,Treatment of B-lymphoblastic leukaemia/lymphoma,MedImmune Ltd,17/07/2013,,Q14605217,blymphoblastic leukemia/lymphoma,,,,,,,
906,"Multilamellar microvesicle comprising phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phospatidylinositol and cholesterol",EU/3/11/896,Treatment of cystic fibrosis,Lamellar Biomedical Ltd,30/08/2011,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
907,Muramyl tripeptide phosphatidyl ethanolamine,EU/3/04/206,Treatment of osteosarcoma,Takeda France SAS,21/06/2004,MepactEU/1/08/50223/03/2009,,osteosarcoma,http://purl.obolibrary.org/obo/DOID_3347,http://purl.obolibrary.org/obo/HP_0002669,http://www.orpha.net/ORDO/Orphanet_668,D012516,Q549534,,Q549534
908,Murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38,EU/3/08/592,Treatment of hairy cell leukaemia,MedImmune Ltd,04/12/2008,,,hairy cell leukemia,http://purl.obolibrary.org/obo/DOID_285,,http://www.orpha.net/ORDO/Orphanet_58017,D007943,Q201299,,Q201299
909,Murine IgM monoclonal antibody binding to alpha beta T-cell receptor,EU/3/13/1113,Prevention of graft rejection following solid organ transplantation,CTI Clinical Trial and Consulting Services Europe GmbH,12/03/2013,,,graft rejection following solid organ transplantation,,,,,,,
910,Murine monoclonal antibody against CD26,EU/3/10/808,Treatment of graft-versus-host disease,ADIENNE S.r.l.,26/11/2010,,,graftversushost disease,,,,D006086,,,Q1194520
911,Myriocin,EU/3/15/1449,Treatment of retinitis pigmentosa,Nanovector s.r.l.,12/02/2015,,Q6948247,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
912,N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide,EU/3/07/478,Treatment of Hodgkin lymphoma,Mapi Ireland Limited,14/09/2007,,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
913,N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide,EU/3/07/526,Treatment of acute myeloid leukaemia,Mapi Ireland Limited,31/01/2008,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
914,"N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide",EU/3/08/556,Treatment of cystic fibrosis,Vertex Pharmaceuticals (Europe) Limited,08/07/2008,KalydecoEU/1/12/78225/07/2012,Q6095693,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
915,"N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide",EU/3/15/1560,Treatment of Duchenne muscular dystrophy,FGK Representative Service GmbH,09/10/2015,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
916,"N-[2,6-bis(1-methylethyl)phenyl]-N’-[[1-[4-(dimethylamino) phenyl]cyclopentyl]methyl]urea, hydrochloride salt",EU/3/13/1128,Treatment of adrenocortical carcinoma,Millendo Therapeutics Ltd,07/06/2013,,,adrenocortical carcinoma,http://purl.obolibrary.org/obo/DOID_3948,http://purl.obolibrary.org/obo/HP_0006744,http://www.orpha.net/ORDO/Orphanet_1501,D018268,Q918285,,Q918285
917,"N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate",EU/3/10/747,Treatment of renal cell carcinoma,EUSA Pharma (UK) Limited,09/06/2010,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
918,N2'-Deacetyl-N2'-[4-methyl-4-(oxobutyldithio)-1-oxopentyl]-maytansine-chimerised anti-CD138 IgG4 Monoclonal Antibody,EU/3/08/593,Treatment of multiple myeloma,Biotest AG,03/12/2008,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
919,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl) amino] isonicotinamide hydrochloride",EU/3/10/824,Treatment of acute myeloid leukaemia,Merck KGaA,17/12/2010,,Q7363205,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
920,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride",EU/3/09/685,Treatment of pancreatic cancer,Merck KGaA,09/11/2009,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
921,"N-[(2S)-5-{[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosylate salt",EU/3/16/1757,Treatment of myelofibrosis,Imago BioSciences Ltd.,14/10/2016,,,myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,http://purl.obolibrary.org/obo/HP_0011974,,D055728,Q1752571,,Q1752571
922,N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt,EU/3/15/1446,Treatment of progressive supranuclear palsy,AlzProtect sas,12/02/2015,,,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
923,"N-3[[4(aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[2,4-dimethyl-8-quinolinyl) oxy]methyl] phenyl]sulphonyl]-(2S)-2-pyrrolidinecarboxamide, di(methanesulfonate)",EU/3/04/188,Treatment of moderate and severe traumatic brain injury,Xytis Pharmaceuticals Limited,23/02/2004,,,moderate and severe traumatic brain injury,,,,,,,
924,"N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine to be used with folic acid",EU/3/12/1043,Diagnosis of positive folate receptor status in ovarian cancer,Voisin Consulting S.A.R.L.,10/09/2012,,,positive folate receptor status in ovarian cancer,,,,,,,
925,"N-(4-methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine",EU/3/16/1618,Treatment of glioma,FLAG Therapeutics Ltd,17/02/2016,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
926,"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4 methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide",EU/3/15/1580,Treatment of neuroblastoma,Pharma Gateway AB,11/11/2015,,,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
927,"N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide",EU/3/16/1783,Treatment of acute pancreatitis,EMAS Pharma Limited,18/11/2016,,,acute pancreatitis,http://purl.obolibrary.org/obo/DOID_2913,http://purl.obolibrary.org/obo/HP_0001735,,,Q854573,,
928,"N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide",EU/3/08/568,Treatment of partial deep dermal and full thickness burn wounds,Creative Antibiotics Sweden AB,22/09/2008,,,partial deep dermal and full thickness burn wonds,,,,,,,
929,"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",EU/3/11/897,Treatment of tuberculosis,RLM Consulting,30/08/2011,,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
930,"N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt",EU/3/09/622,Treatment of acute myeloid leukaemia,Daiichi Sankyo Europe GmbH,23/03/2009,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
931,N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide,EU/3/10/793,Treatment of Friedreich's ataxia,Repligen Europe Limited,01/10/2010,,,friedreichs ataxia,http://purl.obolibrary.org/obo/DOID_12705,,,D005621,Q913856,,Q913856
932,N-acetyl-D-mannosamine monohydrate,EU/3/16/1635,Treatment of GNE myopathy,Escala Therapeutics Ltd,21/03/2016,,,gne myopathy,,,http://www.orpha.net/ORDO/Orphanet_602,,,Q3331460,
933,N-adamantanyl-N'-geranyl-ethylenediamine,EU/3/07/479,Treatment of tuberculosis,RLM Consulting,14/09/2007,,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
934,Nafamostat mesilate,EU/3/10/782,Treatment of cystic fibrosis,Mucokinetica Ltd,20/09/2010,,Q27273902,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
935,Naloxone hydrochloride dihydrate,EU/3/12/1057,Treatment of cutaneous T-cell lymphoma,Winston Laboratories Ltd,08/11/2012,,Q27262715,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
936,Nanobody directed towards the human A1 domain of von Willebrand factor,EU/3/09/629,Treatment of thrombotic thrombocytopenic purpura,Ablynx N.V.,30/04/2009,,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
937,Nanoliposomal irinotecan,EU/3/11/933,Treatment of pancreatic cancer,Baxalta Innovations GmbH,09/12/2011,OnivydeEU/1/16/113018/10/2016,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
938,Naproxcinod,EU/3/13/1194,Treatment of Duchenne muscular dystrophy,NicOx,07/10/2013,,Q3335996,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
939,Naptumomab estafenatox,EU/3/07/480,Treatment of renal cell carcinoma,Active Biotech AB,14/09/2007,,Q6965148,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
940,N-Butyldeoxygalactonojirimycin,EU/3/12/1033,Treatment of Fabry disease,Actelion Registration Ltd,09/08/2012,,,fabry disease,http://purl.obolibrary.org/obo/DOID_14499,,http://www.orpha.net/ORDO/Orphanet_324,D000795,Q615645,,Q615645
941,N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-carbamoyl}-methyl)-2-[2-(2-fluoro-phenyl)-ethylamino]-N-isobutyl-acetamide,EU/3/14/1248,Treatment of optic neuritis,Bionure Farma SL,19/02/2014,,,optic neuritis,http://purl.obolibrary.org/obo/DOID_1210,http://purl.obolibrary.org/obo/HP_0100653,,D009902,Q972514,,Q972514
942,"N-carboxymethyl-glycyl-L-threonyl-L-histidyl-L-3,3-diphenylalanyl-L-piperidincarboxy-3-yl-L-arginyl-L-S-methylthio-cystyl-L-arginyl-L-tryptophyl-aminohexanyl-N-carboxamidomethyl-glycine N-hexadecylamide",EU/3/16/1650,Treatment of beta thalassaemia intermedia and major,QRC Consultants Ltd,28/04/2016,,,beta thalassemia intermedia and major,,,,,,,
943,"N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt",EU/3/11/886,Treatment of post-polycythaemia vera myelofibrosis,Gilead Sciences International Ltd,05/08/2011,,,postpolycythemia vera myelofibrosis,,,,,,,
944,"N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt",EU/3/11/887,Treatment of post-essential thrombocythaemia myelofibrosis,Gilead Sciences International Ltd,05/08/2011,,,postessential thrombocythemia myelofibrosis,,,,,,,
945,"N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt",EU/3/11/888,Treatment of primary myelofibrosis,Gilead Sciences International Limited,05/08/2011,,,primary myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,,http://www.orpha.net/ORDO/Orphanet_824,D055728,Q1752571,,Q1752571
946,nelarabine,EU/3/05/293,Treatment of acute lymphoblastic leukaemia,Novartis Europharm Limited,16/06/2005,AtrianceEU/1/07/40324/08/2007,Q1216264,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
947,Nemorubicin hydrochloride,EU/3/05/300,Treatment of hepatocellular carcinoma,Nerviano Medical Sciences Srl,28/07/2005,,Q27255470,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
948,NGR-human tumour necrosis factor,EU/3/08/549,Treatment of malignant mesothelioma,MolMed S.p.A.,03/06/2008,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
949,NGR-human tumour necrosis factor,EU/3/09/686,Treatment of hepatocellular carcinoma,MolMed S.p.A.,09/11/2009,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
950,NH2-Cys-Ser-Ser-Val-Thr-Ala-Trp-Thr-Thr-Gly-Cys-Gly-CONH2,EU/3/11/910,Treatment of traumatic spinal cord injury,PHARMAXON,27/09/2011,,,traumatic spinal cord injury,,,,,,,
951,N-hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide,EU/3/12/993,Treatment of neurofibromatosis type 2,Sirius Regulatory Consulting Limited,26/04/2012,,,neurofibromatosis type 2,http://purl.obolibrary.org/obo/DOID_8712,,http://www.orpha.net/ORDO/Orphanet_637,D016518,Q847605,Q847605,Q1935832
952,N-hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide,EU/3/12/996,Treatment of meningioma,Sirius Regulatory Consulting Limited,06/06/2012,,,meningioma,http://purl.obolibrary.org/obo/DOID_3565,http://purl.obolibrary.org/obo/HP_0002858,http://www.orpha.net/ORDO/Orphanet_2495,D008579,Q369157,,Q18557816
953,N-hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide,EU/3/12/997,Treatment of schwannoma,Sirius Regulatory Consulting Limited,06/06/2012,,,schwannoma,http://purl.obolibrary.org/obo/DOID_3192,http://purl.obolibrary.org/obo/HP_0100008,,D009442,Q369148,,Q654485
954,Nilotinib,EU/3/06/375,Treatment of chronic myeloid leukaemia,Novartis Europharm Limited,22/05/2006,TasignaEU/1/07/42221/11/2007,Q412327,chronic myeloid leukemia,http://purl.obolibrary.org/obo/DOID_8552,http://purl.obolibrary.org/obo/HP_0005506,http://www.orpha.net/ORDO/Orphanet_521,D015464,Q729735,,Q729735
955,Nimodipine,EU/3/15/1554,Treatment of aneurysmal subarachnoid haemorrhage,Dr Stefan Blesse,09/10/2015,,Q421429,aneurysmal subarachnoid hemorrhage,,,,D013345,,,Q693442
956,Nimorazole,EU/3/10/842,Treatment of squamous cell carcinoma of the head and neck in patients undergoing radiotherapy,Azanta A/S,23/02/2011,,Q7037737,squamos cell carcinoma of the head and neck in patients undergoing radiotherapy,,,,,,,
957,Nimorazole maleate,EU/3/12/952,Treatment of squamous cell carcinoma of the head and neck in patients undergoing radiotherapy,Conventia Medical LLP,09/02/2012,,,squamos cell carcinoma of the head and neck in patients undergoing radiotherapy,,,,,,,
958,Nimotuzumab,EU/3/08/550,Treatment of pancreatic cancer,Oncoscience AG,03/06/2008,,Q3877039,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
959,Nintedanib,EU/3/13/1123,Treatment of idiopathic pulmonary fibrosis,Boehringer Ingelheim International GmbH,26/04/2013,OfevEU/1/14/97919/01/2015,Q15149723,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
960,Nintedanib,EU/3/16/1724,Treatment of systemic sclerosis,Boehringer Ingelheim International GmbH,29/08/2016,,Q15149723,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
961,Nitisinone,EU/3/02/096,Treatment of alkaptonuria,Swedish Orphan Biovitrum AB (publ),13/03/2002,,Q3877355,alkaptonuria,http://purl.obolibrary.org/obo/DOID_9270,,http://www.orpha.net/ORDO/Orphanet_56,D000474,Q651680,Q651680,Q651680
962,Nitric oxide,EU/3/13/1209,Treatment of cystic fibrosis,Novoteris,18/12/2013,,Q207843,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
963,Nitric oxide,EU/3/14/1344,Treatment of cystic fibrosis,PD Dr med. Joachim Riethmüller,15/10/2014,,Q207843,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
964,Nitric oxide,EU/3/15/1484,Treatment of cystic fibrosis,Biological Consulting Europe Ltd,24/04/2015,,Q207843,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
965,Nitroglycerin,EU/3/15/1435,Treatment of systemic sclerosis,Covis Pharma S.à.r.l.,12/02/2015,,Q162867,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
966,"[Nle4, D-Phe7]-alpha-melanocyte stimulating hormone",EU/3/08/541,Treatment of erythropoietic protoporphyria,Clinuvel UK Limited,08/05/2008,ScenesseEU/1/14/96929/12/2014,,erythropoietic protoporphyria,http://purl.obolibrary.org/obo/DOID_13270,,,D046351,Q1759600,,Q1759600
967,"[Nle4, D-Phe7]-alpha-melanocyte stimulating hormone",EU/3/08/545,Treatment of congenital erythropoietic porphyria,Clinuvel UK Limited,08/05/2008,,,congenital erythropoietic porphyria,,,http://www.orpha.net/ORDO/Orphanet_120431,D017092,,,Q1759389
968,"N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate",EU/3/06/401,Treatment of familial amyloid polyneuropathy,Pfizer Limited,28/08/2006,VyndaqelEU/1/11/71718/11/2011,,familial amyloid polyneuropathy,http://purl.obolibrary.org/obo/DOID_0050638,,,D028227,Q2844603,,
969,N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride,EU/3/13/1132,Treatment of malignant mesothelioma,TMC Pharma Services Ltd,07/06/2013,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
970,N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride,EU/3/14/1429,Treatment of ovarian cancer,TMC Pharma Services Ltd,15/01/2015,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
971,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole,EU/3/04/242,Treatment of mastocytosis,AB Science S.A.,16/11/2004,,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
972,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole,EU/3/04/251,Treatment of malignant gastro intestinal stromal tumours,AB Science S.A.,21/12/2004,,,malignant gastro intestinal stromal tumors,,,,,,,
973,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole,EU/3/05/286,Treatment of multiple myeloma,Dr Geoffrey Allan,20/06/2005,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
974,"N,N'-bis(2-mercaptoethyl)isophthalamide",EU/3/11/944,Treatment of mercury toxicity,NBMI Science Limited,11/01/2012,,,mercury toxicity,,,,,,,
975,Norursodeoxycholic acid,EU/3/14/1288,Treatment of primary sclerosing cholangitis,Dr Falk Pharma GmbH,04/07/2014,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
976,N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase,EU/3/09/615,"Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome)",Dr Ulrich Granzer,27/02/2009,,,"mucopolysaccharidosis, type iva (morquio a syndrome)",,,,,,,
977,N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate,EU/3/10/794,Treatment of primary myelofibrosis,Sanofi-Aventis groupe,01/10/2010,,,primary myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,,http://www.orpha.net/ORDO/Orphanet_824,D055728,Q1752571,,Q1752571
978,N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate,EU/3/10/810,Treatment of post-essential thrombocythaemia myelofibrosis,Sanofi-Aventis groupe,26/11/2010,,,postessential thrombocythemia myelofibrosis,,,,,,,
979,N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate,EU/3/10/811,Treatment of post-polycythaemia vera myelofibrosis,Sanofi-Aventis groupe,26/11/2010,,,postpolycythemia vera myelofibrosis,,,,,,,
980,Obeticholic acid,EU/3/13/1228,Treatment of primary sclerosing cholangitis,Intercept Pharma Ltd,16/01/2014,,Q15708271,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
981,Obinutuzumab,EU/3/12/1054,Treatment of chronic lymphocytic leukaemia,Roche Registration Limited,10/10/2012,GazyvaroEU/1/14/93724/07/2014,Q389496,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
982,Obinutuzumab,EU/3/14/1325,Treatment of diffuse large B-cell lymphoma,Roche Registration Limited,22/08/2014,,Q389496,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
983,Obinutuzumab,EU/3/15/1504,Treatment of follicular lymphoma,Roche Registration Limited,19/06/2015,,Q389496,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
984,Octenidine dihydrochloride,EU/3/10/755,Prevention of late-onset sepsis in premature infants of less than or equal to 32 weeks of gestational age,Schülke & Mayr GmbH,27/07/2010,,,lateonset sepsis in premature infants of less than or equal to 32 weeks of gestational age,,,,,,,
985,Octreotide acetate (oral use),EU/3/13/1170,Treatment of acromegaly,Larode Ltd,05/08/2013,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
986,Octreotide chloride (lipid depot solution),EU/3/09/645,Treatment of acromegaly,Novartis Europharm Limited,12/06/2009,,Q27274745,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
987,Ofatumumab,EU/3/08/581,Treatment of chronic lymphocytic leukaemia,Novartis Europharm Limited,07/11/2008,ArzerraEU/1/10/62521/04/2010,Q410656,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
988,Olaparib,EU/3/07/501,Treatment of ovarian cancer,AstraZeneca AB,06/12/2007,LynparzaEU/1/14/95918/12/2014,Q7083106,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
989,Olaptesed pegol,EU/3/14/1364,Treatment of glioma,Noxxon Pharma AG,19/11/2014,,Q27256082,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
990,Olaratumab,EU/3/15/1447,Treatment of soft tissue sarcoma,Eli Lilly Nederland B.V.,12/02/2015,LartruvoEU/1/16/114311/11/2016,Q7083108,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
991,Oleylphosphocholine,EU/3/12/964,Treatment of leishmaniasis,Oblita Therapeutics,23/04/2012,,,leishmaniasis,http://purl.obolibrary.org/obo/DOID_9065,,http://www.orpha.net/ORDO/Orphanet_507,D007896,Q331283,Q2046113,Q331283
992,"Oligonucleotide phosphorothioate (TAAACGTTATAACGTTATGACGTCAT), sodium salt",EU/3/05/327,Treatment of glioma,Oligovax,28/10/2005,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
993,Omigapil maleate,EU/3/08/540,Treatment of congenital muscular dystrophy with collagen VI deficiency (Ullrich Syndrome and Bethlem Myopathy).,Santhera Pharmaceuticals (Deutschland) GmbH,08/05/2008,,Q27257894,congenital muscular dystrophy with collagen vi deficiency (ullrich syndrome and bethlem myopathy).,,,,,,,
994,Omigapil maleate,EU/3/08/544,Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency,Santhera Pharmaceuticals (Deutschland) GmbH,08/05/2008,,Q27257894,congenital muscular dystrophy with merosin (laminin alpha 2) deficiency,,,,,,,
995,Oregovomab,EU/3/02/109,Treatment of ovarian cancer,ViRexx International Corp. Limited,30/07/2002,,Q7101491,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
996,Ornithine phenylacetate,EU/3/11/945,Treatment of acute liver failure,Amiculum Consulting Limited,11/01/2012,,Q27272385,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
997,Osilodrostat,EU/3/14/1345,Treatment of Cushing's syndrome,Novartis Europharm Limited,15/10/2014,,Q27088216,cushings syndrome,http://purl.obolibrary.org/obo/DOID_12252,,http://www.orpha.net/ORDO/Orphanet_553,D003480,Q219102,,Q219102
998,Ovine anti-colchicine polyclonal antibody fragments,EU/3/10/825,Treatment of colchicine poisoning,Laboratoires SERB,17/12/2010,,Q5423588,colchicine poisoning,,,http://www.orpha.net/ORDO/Orphanet_31824,,,Q21402492,
999,Ovine-specific immunoglobulin (Fab) fragments raised against Vipera berus venom,EU/3/15/1548,Treatment of snakebite envenomation,MicroPharm Limited,09/10/2015,,,snakebite envenomation,,,http://www.orpha.net/ORDO/Orphanet_449285,,,,
1000,Oxalobacter formigenes strain HC-1,EU/3/06/354,Treatment of primary hyperoxaluria,OxThera AB,17/02/2006,,,primary hyperoxaluria,http://purl.obolibrary.org/obo/DOID_2977,,http://www.orpha.net/ORDO/Orphanet_416,D006960,Q7243137,,Q7243137
1001,Oxalobacter formigenes strain HC-1,EU/3/14/1346,Treatment of short bowel syndrome,OxThera AB,15/10/2014,,,short bowel syndrome,http://purl.obolibrary.org/obo/DOID_10605,,http://www.orpha.net/ORDO/Orphanet_104008,D012778,Q662272,,Q662272
1002,Oxytocin,EU/3/14/1302,Treatment of Prader-Willi syndrome,Maïthé Tauber,29/07/2014,,Q169960,praderwilli syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
1003,Paclitaxel (aqueous gel),EU/3/10/846,Treatment of oesophagus carcinoma,BTG plc,23/02/2011,,,oesophagus carcinoma,,,,,,,
1004,Paclitaxel (liposomal),EU/3/06/419,Treatment of pancreatic cancer,SynCore Biotechnology Europe GmbH,31/10/2006,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1005,Paclitaxel (micellar),EU/3/06/422,Treatment of ovarian cancer,Oasmia Pharmaceutical AB,18/12/2006,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1006,Paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe,EU/3/14/1274,Treatment of glioma,Orphit,04/06/2014,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1007,Palovarotene,EU/3/14/1368,Treatment of fibrodysplasia ossificans progressiva,Medpace Germany GmbH,19/11/2014,,Q15708269,fibrodysplasia ossificans progressiva,http://purl.obolibrary.org/obo/DOID_13374,,http://www.orpha.net/ORDO/Orphanet_337,D009221,Q1410831,,Q3858675
1008,"Pancreatic enzymes (cross linked enzyme crystal lipase, protease, amylase)",EU/3/04/222,Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency,TRX Services Limited,02/09/2004,,,malabsorption due to exocrine pancreatic enzyme insufficiency,,,,,,,
1009,Panobinostat,EU/3/12/1063,Treatment of multiple myeloma,Novartis Europharm Limited,08/11/2012,FarydakEU/1/15/102301/09/2015,Q7131441,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1010,Paquinimod,EU/3/10/836,Treatment of systemic sclerosis,Active Biotech AB,23/02/2011,,Q27279838,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1011,Para-aminosalicylic acid,EU/3/10/826,Treatment of tuberculosis,Lucane Pharma SA,17/12/2010,GranupasEU/1/13/89609/04/2014,Q229924,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
1012,Parathyroid hormone (1-34) transglutaminase fusion protein fibrin matrix complex,EU/3/06/367,Treatment of solitary bone cysts,Kuros Biosurgery International AG,11/04/2006,,,solitary bone cysts,,,,,,,
1013,"Particles comprised of methacrylic acid based co-polymer, cross-linked with a bi-functional cross-linker, purified to bind L-phenylalanine and L-phenylalanine containing peptides",EU/3/16/1784,Treatment of hyperphenylalaninaemia,MipSalus ApS,18/11/2016,,,hyperphenylalaninemia,,http://purl.obolibrary.org/obo/HP_0004923,http://www.orpha.net/ORDO/Orphanet_238583,D010661,,Q7706537,Q5958471
1014,pasireotide,EU/3/09/670,Treatment of acromegaly,Novartis Europharm Limited,08/10/2009,SigniforEU/1/12/75321/11/2014,Q3896970,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
1015,pasireotide,EU/3/09/671,Treatment of Cushing's disease,Novartis Europharm Limited,08/10/2009,SigniforEU/1/12/75327/04/2012,Q3896970,cushings disease,,,,,,,
1016,Pegylated arginine deiminase,EU/3/05/289,Treatment of hepatocellular carcinoma,Dr Francesco Izzo,20/06/2005,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1017,Pegylated B-domain-deleted sequence-modified recombinant human factor VIII,EU/3/10/847,Treatment of haemophilia A,Bayer Pharma AG,23/02/2011,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
1018,Pegylated carboxyhaemoglobin,EU/3/09/698,Treatment of sickle cell disease,Voisin Consulting S.A.R.L.,26/11/2009,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1019,Pegylated L-asparaginase,EU/3/08/569,Treatment of acute lymphoblastic leukaemia,"Sigma-Tau Rare Diseases, S.A.",22/09/2008,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
1020,Pegylated proline-interferon alpha-2b,EU/3/11/932,Treatment of polycythaemia vera,AOP Orphan Pharmaceuticals AG,09/12/2011,,,polycythemia vera,http://purl.obolibrary.org/obo/DOID_8997,,http://www.orpha.net/ORDO/Orphanet_729,D011087,Q948318,,Q948318
1021,Pegylated recombinant arginine deiminase,EU/3/14/1409,Treatment of malignant mesothelioma,Designerx Europe Limited,15/01/2015,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
1022,Pegylated recombinant Erwinia chrysanthemi L-asparaginase,EU/3/11/889,Treatment of acute lymphoblastic leukaemia,Jazz Pharmaceuticals France SAS,05/08/2011,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
1023,Pegylated recombinant factor VIII,EU/3/12/995,Treatment of haemophilia A,Novo Nordisk A/S,26/04/2012,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
1024,Pegylated recombinant human factor IX,EU/3/09/640,Treatment of haemophilia B,Novo Nordisk A/S,15/05/2009,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
1025,Pegylated recombinant human hyaluronidase PH20,EU/3/14/1394,Treatment of pancreatic cancer,Pharm Research Associates (UK) Limited,16/12/2014,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1026,Pegylated recombinant human interleukin-10,EU/3/16/1804,Treatment of pancreatic cancer,Larode Ltd,12/12/2016,,Q339866,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1027,Pegylated recombinant phenylalanine ammonia lyase,EU/3/09/708,Treatment of hyperphenylalaninaemia,BioMarin International Limited,28/01/2010,,,hyperphenylalaninemia,,http://purl.obolibrary.org/obo/HP_0004923,http://www.orpha.net/ORDO/Orphanet_238583,D010661,,Q7706537,Q5958471
1028,Pentetrazol,EU/3/15/1569,Treatment of idiopathic hypersomnia,"Balance Therapeutics, Limited",11/11/2015,,Q412391,idiopathic hypersomnia,,,http://www.orpha.net/ORDO/Orphanet_33208,D020177,,Q2730080,Q2730080
1029,Pentosan polysulfate sodium,EU/3/14/1359,Treatment of mucopolysaccharidosis type I,Plexcera Therapeutics EU Limited,19/11/2014,,,mucopolysaccharidosis type i,,,http://www.orpha.net/ORDO/Orphanet_579,D008059,,,Q1906054
1030,Pentosan polysulfate sodium,EU/3/14/1411,Treatment of interstitial cystitis,bene-Arzneimittel GmbH,15/01/2015,,,interstitial cystitis,http://purl.obolibrary.org/obo/DOID_13949,,http://www.orpha.net/ORDO/Orphanet_37202,D018856,Q1671412,,Q27675337
1031,Pentosan polysulfate sodium,EU/3/16/1663,Treatment of interstitial cystitis,NextraResearch S.r.l.,30/05/2016,,,interstitial cystitis,http://purl.obolibrary.org/obo/DOID_13949,,http://www.orpha.net/ORDO/Orphanet_37202,D018856,Q1671412,,Q27675337
1032,Pentosan polysulfate sodium,EU/3/16/1822,Treatment of interstitial cystitis,Kyoto Tech Limited,12/01/2017,,,interstitial cystitis,http://purl.obolibrary.org/obo/DOID_13949,,http://www.orpha.net/ORDO/Orphanet_37202,D018856,Q1671412,,Q27675337
1033,Peptide 144 TGF- ß1 inhibitor (TSLDASIIWAMMQN),EU/3/05/326,Treatment of systemic sclerosis,Digna Biotech S.L.,28/10/2005,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1034,Peptide 144 TGF- ß1 inhibitor (TSLDASIIWAMMQN),EU/3/05/329,Treatment of the localised scleroderma,Digna Biotech S.L.,28/10/2005,,,the localised scleroderma,,,,,,,
1035,Peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis,EU/3/09/689,Treatment of myasthenia gravis,CuraVac Europe SA,09/11/2009,,,myasthenia gravis,http://purl.obolibrary.org/obo/DOID_437,,http://www.orpha.net/ORDO/Orphanet_589,D009157,Q8285,Q8285,Q8285
1036,Peretinoin,EU/3/11/890,Treatment of hepatocellular carcinoma,Kowa Pharmaceutical Europe Co. Ltd,05/08/2011,,Q18326479,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1037,P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide,EU/3/16/1758,Treatment of acute myeloid leukaemia,Clinical Network Services (UK) Ltd,14/10/2016,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1038,"Phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis(1,1-dimethylethyl)monohydrochloride",EU/3/15/1481,Treatment of Huntington&#8217;s disease,Ipsen Pharma,24/04/2015,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1039,Phenylephrine Hydrochloride,EU/3/01/069,Treatment of ileal pouch anal anastomosis related faecal incontinence,S.L.A. Pharma (UK) Limited,20/11/2001,,Q27107758,ileal poch anal anastomosis related fecal incontinence,,,,,,,
1040,Phosphorothioate oligonucleotide targeted to apolipoprotein C-III,EU/3/14/1249,Treatment of familial chylomicronemia syndrome,Ionis USA Limited,19/02/2014,,,familial chylomicronemia syndrome,,,http://www.orpha.net/ORDO/Orphanet_444490,,,,
1041,Phosphorothioate oligonucleotide targeted to transthyretin,EU/3/14/1250,Treatment of ATTR amyloidosis,Ionis USA Limited,26/03/2014,,,attr amyloidosis,,,,,,,
1042,Pioglitazone,EU/3/14/1245,Treatment of adrenoleukodystrophy,Minoryx Therapeutics S.L.,19/02/2014,,Q417765,adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_117677,D000326,Q366964,,Q366964
1043,Pioglitazone hydrochloride,EU/3/16/1823,Treatment of sudden sensorineural hearing loss,Regiomedica GmbH,12/01/2017,,Q27281642,sudden sensorineural hearing loss,,,,,,,
1044,Pirfenidone,EU/3/04/241,Treatment of idiopathic pulmonary fibrosis,Roche Registration Limited,16/11/2004,EsbrietEU/1/11/66702/03/2011,Q2060696,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
1045,"Plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a non-viral, cationic lipid based gene transfer agent",EU/3/14/1277,Treatment of cystic fibrosis,Imperial Innovations Limited,04/06/2014,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1046,Plerixafor,EU/3/14/1403,Treatment of WHIM syndrome,Groupe d'étude des neutropénies,16/12/2014,,Q905835,whim syndrome,http://purl.obolibrary.org/obo/DOID_0060591,,http://www.orpha.net/ORDO/Orphanet_51636,,Q1258463,,
1047,Polihexanide,EU/3/07/498,Treatment of Acanthamoeba keratitis,S.I.F.I. Società Industria Farmaceutica Italiana S.p.A.,14/11/2007,,,acanthamoeba keratitis,,,http://www.orpha.net/ORDO/Orphanet_67043,D015823,,,
1048,Poloxamer 188,EU/3/13/1112,Treatment of sickle cell disease,Theradex (Europe) Ltd.,12/03/2013,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1049,"Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}ethyl]sulfanyl}-3-{[(2S)-1-ethoxy-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}propanamido)-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)propanoyl Ethyl ester) )-methoxy]acetyl}oxy)butyl)sulfanyl]-3-(hexadecylcarbamoyl)propanoic acid]-poly(ethylene glycol)-ester]",EU/3/13/1220,Treatment of dengue,Coté Orphan Consulting UK Limited,18/12/2013,,,dengue,,,,D003715,,,Q30953
1050,Polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase,EU/3/16/1664,Treatment of homocystinuria,Alan Boyd Consultants Ltd,30/05/2016,,,homocystinuria,http://purl.obolibrary.org/obo/DOID_9263,http://purl.obolibrary.org/obo/HP_0002156,,D006712,Q994859,,Q994859
1051,"Poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-,amide with arginase 1 [cobalt cofactor] (synthetic human) (1:10), trimer",EU/3/16/1701,Treatment of hyperargininaemia,ERA Consulting GmbH,14/07/2016,,,hyperargininemia,http://purl.obolibrary.org/obo/DOID_9278,,http://www.orpha.net/ORDO/Orphanet_90,D020162,Q890367,,Q890367
1052,Pomalidomide,EU/3/09/672,Treatment of multiple myeloma,Celgene Europe Limited,08/10/2009,ImnovidEU/1/13/85008/08/2013,Q7227206,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1053,Ponatinib hydrochloride,EU/3/14/1421,Treatment of gastrointestinal stromal tumours,Incyte Biosciences UK Ltd,15/01/2015,,Q27271925,gastrointestinal stromal tumors,,http://purl.obolibrary.org/obo/HP_0100723,,D046152,,,Q1495661
1054,Pralatrexate,EU/3/07/444,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",Allos Therapeutics Limited,13/04/2007,,Q637059,"peripheral tcell lymphoma (nodal, other extranodal and leukemic/disseminated)",,,,,,,
1055,Pralatrexate,EU/3/08/603,Treatment of non-papillary transitional cell carcinoma of the urinary bladder,Allos Therapeutics Limited,19/01/2009,,Q637059,nonpapillary transitional cell carcinoma of the urinary bladder,,,,,,,
1056,Pralatrexate,EU/3/10/741,Treatment of cutaneous T-cell lymphoma,Allos Therapeutics Limited,10/06/2010,,Q637059,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1057,Pralatrexate,EU/3/10/795,Treatment of Hodgkin's lymphoma,Allos Therapeutics Limited,01/10/2010,,Q637059,hodgkins lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
1058,Prasterone,EU/3/03/156,Treatment of adrenal insufficiency,Medicom Healthcare BV,28/07/2003,,Q408376,adrenal insufficiency,,http://purl.obolibrary.org/obo/HP_0000846,,D000309,,,Q2507454
1059,Pravastatin / zoledronic acid,EU/3/10/748,Treatment of Hutchinson-Gilford progeria,Prenyl BIO SAS,09/06/2010,,,hutchinsongilford progeria,,,,,,,
1060,Pr-D-Cys-Met-Pip-Arg-Leu-Arg-Sar-Cys-Lys-Arg-Pro-Tyr-Tle-Leu-OH,EU/3/16/1824,Treatment of perinatal asphyxia,VECT-HORUS,12/01/2017,,,perinatal asphyxia,,,,,,,
1061,Propranolol,EU/3/16/1805,Treatment of soft tissue sarcoma,The Anticancer Fund,12/12/2016,,Q423364,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1062,Pro-Pro-Thr-Val-Pro-Thr-Arg,EU/3/14/1375,Treatment of xeroderma pigmentosum,ProGeLife S.A.S.,19/11/2014,,Q18216,xeroderma pigmentosum,http://purl.obolibrary.org/obo/DOID_0050427,,http://www.orpha.net/ORDO/Orphanet_910,D014983,Q612693,,Q612693
1063,Purified bromelain,EU/3/02/107,Treatment of partial deep dermal and full thickness burns,MediWound Germany GmbH,30/07/2002,NexoBridEU/1/12/80320/12/2012,Q27293882,partial deep dermal and full thickness burns,,,,,,,
1064,"Pyr-His-Trp-Ser-Tyr-D-Lys(doxorubicinylglutarate)-Leu-Arg-Pro-Gly-NH2, acetate salt",EU/3/10/766,Treatment of ovarian cancer,Æterna Zentaris GmbH,04/08/2010,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1065,Pyridoxal 5'-phosphate,EU/3/14/1347,Treatment of pyridoxamine 5'-phosphate oxidase deficiency,"Great Ormond Street Hospital for Children, NHS Foundation Trust",15/10/2014,,Q418957,pyridoxamine 5phosphate oxidase deficiency,,,http://www.orpha.net/ORDO/Orphanet_79096,,,,
1066,Pyridoxalated haemoglobin polyoxyethylene,EU/3/07/463,Treatment of cardiogenic shock,Curacyte AG,02/08/2007,,,cardiogenic shock,,http://purl.obolibrary.org/obo/HP_0030149,,D012770,,,
1067,Pyridoxine and L-pyroglutamic acid,EU/3/16/1673,Treatment of fragile X syndrome,FGK Representative Service Ltd.,27/06/2016,,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
1068,"(R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea",EU/3/15/1588,Treatment of gastro-entero-pancreatic neuroendocrine tumours,Trio Medicines Ltd,14/12/2015,,Q7670203,gastroenteropancreatic neuroendocrine tumors,,,,,,,
1069,"R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea",EU/3/07/452,Treatment of gastric carcinoid,Trio Medicines Ltd,14/06/2007,,,gastric carcinoid,,,,,,,
1070,"(R)-2-Methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole",EU/3/07/524,Treatment of tuberculosis,Otsuka Novel Products GmbH,01/02/2008,DeltybaEU/1/13/87530/04/2014,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
1071,"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride",EU/3/16/1657,Treatment of biliary tract cancer,QRC Consultants Ltd,30/05/2016,,Q7118312,biliary tract cancer,http://purl.obolibrary.org/obo/DOID_4607,,,D001661,Q18556397,,Q18556397
1072,Radio-iodinated (131I) anti-CD45 murine monoclonal antibody,EU/3/16/1760,Treatment in haematopoietic stem cell transplantation,PharmaLex UK Services Limited,14/10/2016,,,hematopoietic stem cell transplantation,,,,D018380,,,
1073,Raloxifene hydrochloride,EU/3/10/730,Treatment of hereditary haemorrhagic telangiectasia,Consejo Superior de Investigaciones Cientificas (CSIC),10/06/2010,,Q27122215,hereditary hemorrhagic telangiectasia,http://purl.obolibrary.org/obo/DOID_1270,,http://www.orpha.net/ORDO/Orphanet_774,D013683,Q776881,Q776881,Q776881
1074,Ramiprilat,EU/3/13/1117,Treatment of Stargardt&#8217;s disease,Iris Pharma,12/03/2013,,Q27088514,stargardts disease,,,,,,,
1075,Ramoplanin,EU/3/01/049,Prevention of invasive infections due to Vancomycin Resistant Enterococci (VRE) in colonised patients deemed at risk of infection,"Vicuron Pharmaceuticals Italy srl,",09/07/2001,,Q7289964,invasive infections due to vancomycin resistant enterococci (vre) in colonised patients deemed at risk of infection,,,,,,,
1076,Raxibacumab,EU/3/14/1352,Treatment of inhalation anthrax disease,GlaxoSmithKline Trading Services Limited,15/10/2014,,Q7297093,inhalation anthrax disease,,,http://www.orpha.net/ORDO/Orphanet_247257,,,,
1077,R-azasetron besylate,EU/3/16/1785,Treatment of sudden sensorineural hearing loss,Sensorion,18/11/2016,,,sudden sensorineural hearing loss,,,,,,,
1078,R-baclofen,EU/3/11/858,Treatment of fragile X syndrome,Lakeside Regulatory Consulting Services Ltd,15/04/2011,,,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
1079,Recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene,EU/3/12/1018,Treatment of glycogen storage disease type II (Pompe's disease),Audentes Therapeutics UK Limited,04/07/2012,,,glycogen storage disease type ii (pompes disease),,,,,,,
1080,Recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene,EU/3/07/440,Treatment of congenital alpha-1 antitrypsin deficiency,TMC Pharma Services Ltd,20/03/2007,,,congenital alpha1 antitrypsin deficiency,,,,,,,
1081,Recombinant adeno-associated viral vector containing human CNGA3 gene,EU/3/15/1556,Treatment of achromatopsia caused by mutations in the CNGA3 gene,TMC Pharma Services Ltd,09/10/2015,,,achromatopsia caused by mutations in the cnga3 gene,,,,,,,
1082,Recombinant adeno-associated viral vector containing the human CNGB3 gene,EU/3/13/1099,Treatment of achromatopsia caused by mutations in the CNGB3 gene,TMC Pharma Services Ltd,08/02/2013,,,achromatopsia caused by mutations in the cngb3 gene,,,,,,,
1083,Recombinant adeno-associated viral vector containing the human retinoschisin gene,EU/3/13/1107,Treatment of X-linked juvenile retinoschisis,TMC Pharma Services Ltd,12/03/2013,,,xlinked juvenile retinoschisis,http://purl.obolibrary.org/obo/DOID_0060763,,http://www.orpha.net/ORDO/Orphanet_792,D041441,Q28065568,Q3458131,Q1049881
1084,Recombinant adeno-associated viral vector containing the human RPGR gene,EU/3/16/1665,Treatment of retinitis pigmentosa caused by mutations in the RPGR gene,TMC Pharma Services Ltd,30/05/2016,,,retinitis pigmentosa caused by mutations in the rpgr gene,,,,,,,
1085,Recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter,EU/3/16/1759,Treatment of Duchenne muscular dystrophy,Pharma Gateway AB,14/10/2016,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1086,Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein,EU/3/16/1786,Treatment of aromatic L-amino acid decarboxylase deficiency,Voisin Consulting S.A.R.L.,18/11/2016,,,aromatic lamino acid decarboxylase deficiency,,,http://www.orpha.net/ORDO/Orphanet_35708,,,,
1087,Recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase,EU/3/16/1651,Treatment of Angelman syndrome,Voisin Consulting S.A.R.L.,28/04/2016,,,angelman syndrome,http://purl.obolibrary.org/obo/DOID_1932,,http://www.orpha.net/ORDO/Orphanet_120365,D017204,Q535364,,Q535364
1088,Recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene,EU/3/16/1825,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),Ser-mes Planificación SL,12/01/2017,,,mucopolysaccharidosis type iiib (sanfilippo b syndrome),,,,,,,
1089,Recombinant antibody construct against human CD30 and CD16A,EU/3/09/673,Treatment of Hodgkin lymphoma,Affimed GmbH,09/10/2009,,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
1090,Recombinant antibody derivative against human CD19 and CD3,EU/3/03/175,Treatment of mantle cell lymphoma,Amgen Europe B.V.,01/12/2003,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
1091,Recombinant antibody derivative against human CD19 and CD3,EU/3/03/176,Treatment of chronic lymphocytic leukaemia,Amgen Europe B.V.,01/12/2003,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1092,Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein,EU/3/12/1038,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",AOP Orphan Pharmaceuticals AG,09/08/2012,,,"peripheral tcell lymphoma (nodal, other extranodal and leukemic/disseminated)",,,,,,,
1093,Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein,EU/3/12/1039,Treatment of cutaneous T-cell lymphoma,AOP Orphan Pharmaceuticals AG,09/08/2012,,,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1094,Recombinant chimeric monoclonal antibody against CD20,EU/3/09/699,Treatment of chronic lymphocytic leukaemia,LFB-Biotechnologies,26/11/2009,,,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1095,Recombinant derivative of C3 transferase,EU/3/08/563,Treatment of traumatic spinal cord injury,Vertex Pharmaceuticals (U.K.) Limited,05/09/2008,,,traumatic spinal cord injury,,,,,,,
1096,Recombinant dog gastric lipase,EU/3/03/157,Treatment of cystic fibrosis,Meristem Therapeutics S.A.,09/07/2003,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1097,Recombinant factor VIIa modified with three terminal repeats derived from the ß chain of human chorionic gonadotropin,EU/3/14/1312,Treatment of congenital factor VII deficiency,Richardson Associates Regulatory Affairs Ltd,22/08/2014,,,congenital factor vii deficiency,,,http://www.orpha.net/ORDO/Orphanet_327,,,,
1098,Recombinant factor VIIa modified with three terminal repeats derived from the ß chain of human chorionic gonadotropin,EU/3/14/1316,Treatment of haemophilia A,Richardson Associates Regulatory Affairs Ltd,22/08/2014,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
1099,Recombinant factor VIIa modified with three terminal repeats derived from the ß chain of human chorionic gonadotropin,EU/3/14/1319,Treatment of haemophilia B,Richardson Associates Regulatory Affairs Ltd,22/08/2014,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
1100,Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain,EU/3/14/1300,Treatment of beta-thalassaemia intermedia and major,Celgene Europe Limited,29/07/2014,,,betathalassemia intermedia and major,,,,,,,
1101,Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain,EU/3/14/1331,Treatment of myelodysplastic syndromes,Celgene Europe Limited,22/08/2014,,,myelodysplastic syndromes,,,,D009190,,,Q954625
1102,Recombinant fusion protein consisting of human coagulation factor IX attached to the Fc domain of human IgG1,EU/3/07/453,Treatment of haemophilia B (congenital factor IX deficiency),Swedish Orphan Biovitrum AB (publ),08/06/2007,ALPROLIXEU/1/16/109813/05/2016,,hemophilia b (congenital factor ix deficiency),,,,,,,
1103,Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule,EU/3/06/411,Prevention of Graft-versus-Host disease,Apogenix GmbH,31/10/2006,,,graftversushost disease,,,,D006086,,,Q1194520
1104,Recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule,EU/3/09/709,Treatment of glioma,Apogenix GmbH,28/01/2010,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1105,Recombinant fusion protein linking coagulation factor VIIa with albumin,EU/3/13/1188,Treatment of congenital factor VII deficiency,CSL Behring GmbH,07/10/2013,,,congenital factor vii deficiency,,,http://www.orpha.net/ORDO/Orphanet_327,,,,
1106,Recombinant fusion protein linking human coagulation factor IX with human albumin,EU/3/09/723,Treatment of haemophilia B,CSL Behring GmbH,04/02/2010,IDELVIONEU/1/16/109513/05/2016,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
1107,Recombinant fusion protein linking human coagulation factor VIIa with human albumin,EU/3/11/855,Treatment of haemophilia A,CSL Behring GmbH,15/04/2011,,Q27294965,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
1108,Recombinant fusion protein linking human coagulation factor VIIa with human albumin,EU/3/11/863,Treatment of haemophilia B,CSL Behring GmbH,13/05/2011,,Q27294965,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
1109,"Recombinant fusion protein of circulary-permuted IL-4 and pseudomonas exotoxin A, [IL-4(38-37)-PE38KDEL]",EU/3/08/553,Treatment of glioma,Envigo Pharma Consulting Ltd,03/06/2008,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1110,Recombinant glycoprotein gp350 of Epstein-Barr virus,EU/3/02/118,Prevention of post transplantation lympho-proliferative disorders,Henogen S.A.,22/10/2002,,,post transplantation lymphoproliferative disorders,,,,,,,
1111,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,EU/3/04/248,Treatment of multiple myeloma,CellGenix GmbH,21/12/2004,,,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1112,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,EU/3/04/249,Treatment of follicular lymphoma,CellGenix GmbH,23/12/2004,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1113,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,EU/3/04/250,Treatment of mantle cell lymphoma,CellGenix GmbH,21/12/2004,,,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
1114,Recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors,EU/3/09/656,Treatment of diffuse large B-cell lymphoma,CellGenix GmbH,24/07/2009,,,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1115,Recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues,EU/3/16/1726,Treatment of glycogen storage disease type II (Pompe&#8217;s disease),NanoMedSyn,29/08/2016,,,glycogen storage disease type ii (pompes disease),,,,,,,
1116,Recombinant human acid ceramidase,EU/3/14/1243,Treatment of Farber disease,Plexcera Therapeutics EU Limited,21/02/2014,,,farber disease,http://purl.obolibrary.org/obo/DOID_0050464,,http://www.orpha.net/ORDO/Orphanet_333,D055577,Q1396345,,Q1396345
1117,Recombinant human acid ceramidase,EU/3/15/1536,Treatment of cystic fibrosis,Plexcera Therapeutics EU Limited,10/08/2015,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1118,Recombinant human acid sphingomyelinase,EU/3/01/056,Treatment of Niemann-Pick disease,Genzyme Europe B.V.,19/09/2001,,,niemannpick disease,http://purl.obolibrary.org/obo/DOID_14504,,,D009542,Q1419931,,Q3281285
1119,Recombinant human ADAMTS-13,EU/3/08/588,Treatment of thrombotic thrombocytopenic purpura,Baxalta Innovations GmbH,03/12/2008,,,thrombotic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_10772,,http://www.orpha.net/ORDO/Orphanet_54057,D011697,Q1426491,,Q1426491
1120,Recombinant human alkaline phosphatase,EU/3/14/1427,Treatment of hypophosphatasia,AM-Pharma BV,15/01/2015,,Q27258840,hypophosphatasia,http://purl.obolibrary.org/obo/DOID_14213,,http://www.orpha.net/ORDO/Orphanet_436,D007014,Q1313510,,Q1313510
1121,Recombinant human alpha 1 chain homotrimer of type VII collagen,EU/3/14/1272,Treatment of epidermolysis bullosa,Shire Pharmaceuticals Ireland Limited,04/06/2014,,,epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_2730,,,D004820,Q923020,,Q923020
1122,Recombinant human alpha-1-microglobulin,EU/3/14/1289,Treatment of pre-eclampsia,A1M Pharma AB,04/07/2014,,,preeclampsia,http://purl.obolibrary.org/obo/DOID_10591,http://purl.obolibrary.org/obo/HP_0100602,http://www.orpha.net/ORDO/Orphanet_275555,D011225,Q2421435,Q61335,Q2421435
1123,Recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan,EU/3/14/1251,Treatment of glycogen storage disease type II (Pompe's disease),Genzyme Europe B.V.,26/03/2014,,,glycogen storage disease type ii (pompes disease),,,,,,,
1124,Recombinant human alpha-N-acetylglucosaminidase,EU/3/13/1144,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome),Alexion Europe SAS,19/06/2013,,,mucopolysaccharidosis type iiib (sanfilippo b syndrome),,,,,,,
1125,Recombinant human anti-interferon gamma monoclonal antibody,EU/3/10/749,Treatment of haemophagocytic lymphohistiocytosis,NovImmune B.V.,09/06/2010,,,hemophagocytic lymphohistiocytosis,http://purl.obolibrary.org/obo/DOID_0050120,,http://www.orpha.net/ORDO/Orphanet_158032,D051359,Q1642170,,Q1642170
1126,Recombinant human apolipoprotein A-I in a complex with phospholipids,EU/3/14/1314,Treatment of ATP-binding cassette transporter A1 deficiency,Cerenis Therapeutics Holding SA,22/08/2014,,,atpbinding cassette transporter a1 deficiency,,,http://www.orpha.net/ORDO/Orphanet_31150,,,,
1127,Recombinant human apolipoprotein A-I in a complex with phospholipids,EU/3/14/1315,Treatment of apolipoprotein A-I deficiency,Cerenis Therapeutics Holding SA,22/08/2014,,,apolipoprotein ai deficiency,,,http://www.orpha.net/ORDO/Orphanet_425,,,,
1128,Recombinant human arylsulfatase A,EU/3/10/813,Treatment of metachromatic leukodystrophy,Shire Pharmaceuticals Ireland Limited,26/11/2010,,,metachromatic leukodystrophy,http://purl.obolibrary.org/obo/DOID_10581,,http://www.orpha.net/ORDO/Orphanet_512,D007966,Q1120682,Q1120682,Q1120682
1129,Recombinant human aspartylglucosaminidase,EU/3/14/1410,Treatment of aspartylglucosaminuria,ACE BioSciences A/S,15/01/2015,,,aspartylglucosaminuria,http://purl.obolibrary.org/obo/DOID_0050461,http://purl.obolibrary.org/obo/HP_0012068,http://www.orpha.net/ORDO/Orphanet_93,D054880,Q4412533,Q4412533,Q4412533
1130,Recombinant human beta-glucuronidase,EU/3/12/973,Treatment of mucopolysaccharidosis type VII (Sly syndrome),Ultragenyx Germany GmbH,21/03/2012,,,mucopolysaccharidosis type vii (sly syndrome),,,,,,,
1131,Recombinant human bone morphogenetic protein 4,EU/3/14/1348,Treatment of glioma,STEMGEN S.p.A,15/10/2014,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1132,Recombinant human C1-inhibitor,EU/3/07/435,Prevention of delayed graft function after solid organ transplantation,Pharming Group N.V.,20/02/2007,,,delayed graft function after solid organ transplantation,,,,,,,
1133,Recombinant human cerebral dopamine neurotrophic factor,EU/3/16/1652,Treatment of amyotrophic lateral sclerosis,Herantis Pharma Plc,28/04/2016,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1134,Recombinant human club cell 10 KDa protein,EU/3/15/1456,Prevention of bronchopulmonary dysplasia,RLM Consulting,19/03/2015,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
1135,Recombinant human CXCL8 mutant,EU/3/08/570,Prevention of delayed graft function after solid organ transplantation,ProtAffin Biotechnologie AG,22/09/2008,,,delayed graft function after solid organ transplantation,,,,,,,
1136,Recombinant human CXCL8 mutant,EU/3/13/1131,Treatment of cystic fibrosis,ProtAffin Biotechnologie AG,07/06/2013,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1137,Recombinant human diamine oxidase,EU/3/14/1320,Treatment of mastocytosis,Medical University of Vienna,22/08/2014,,,mastocytosis,http://purl.obolibrary.org/obo/DOID_350,http://purl.obolibrary.org/obo/HP_0100495,http://www.orpha.net/ORDO/Orphanet_98292,D008415,Q112670,,Q112670
1138,Recombinant human dyskerin,EU/3/12/1070,Treatment of dyskeratosis congenita,Advanced Medical Projects,08/11/2012,,,dyskeratosis congenita,http://purl.obolibrary.org/obo/DOID_2729,,http://www.orpha.net/ORDO/Orphanet_1775,D019871,Q3709312,Q3709312,Q3709312
1139,Recombinant human elafin,EU/3/09/710,Treatment of oesophagus carcinoma,Proteo Biotech AG,28/01/2010,,,oesophagus carcinoma,,,,,,,
1140,Recombinant human galactocerebrosidase,EU/3/11/911,Treatment of globoid cell leukodystrophy (Krabbe disease),ACE BioSciences A/S,27/09/2011,,,globoid cell leukodystrophy (krabbe disease),,,,,,,
1141,Recombinant human glutamate oxaloacetate transaminase 1,EU/3/15/1443,Treatment of glioma,Dr Regenold GmbH Development·Regulatory·Market Access,12/02/2015,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1142,Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains,EU/3/13/1179,Treatment of growth hormone deficiency,Larode Ltd,05/08/2013,,,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
1143,Recombinant human heat shock protein 70,EU/3/13/1110,"Treatment of Niemann-Pick disease, type C",Orphazyme ApS,12/03/2013,,,"niemannpick disease, type c",,,,D052556,,,Q2067267
1144,Recombinant human heparan N-sulfatase,EU/3/08/582,"Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",Shire Pharmaceutical Development Limited,07/11/2008,,Q27122045,"mucopolysaccharidosis, type iiia (sanfilippo a syndrome)",,,,,,,
1145,Recombinant human hepatitis C monoclonal antibody against C4 region of E1,EU/3/07/503,Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients,GENimmune N.V,06/12/2007,,,recurrent hepatitis c virus induced liver disease in liver transplant recipients,,,,,,,
1146,Recombinant human hepatocarcinoma-intestine-pancreas / pancreatic associated protein,EU/3/08/611,Treatment of acute liver failure,Alfact Innovation SAS,11/02/2009,,,acute liver failure,,http://purl.obolibrary.org/obo/HP_0006554,http://www.orpha.net/ORDO/Orphanet_90062,D017114,,,
1147,Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3,EU/3/07/516,Treatment of acute myeloid leukaemia,Xenetic Biosciences Plc,20/12/2007,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1148,Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3,EU/3/10/840,Treatment of acute lymphoblastic leukaemia,Xenetic Biosciences Plc,23/02/2011,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
1149,Recombinant human IgG1 kappa light chain monoclonal antibody targeting plasma kallikrein,EU/3/15/1551,Treatment of hereditary angioedema,Dyax Ltd,09/10/2015,,,hereditary angioedema,http://purl.obolibrary.org/obo/DOID_14735,,http://www.orpha.net/ORDO/Orphanet_91378,D054179,Q2096745,,Q2096745
1150,Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase,EU/3/13/1198,Treatment of mucopolysaccharidosis type II (Hunter's syndrome),Voisin Consulting S.A.R.L.,13/11/2013,,,mucopolysaccharidosis type ii (hunters syndrome),,,,,,,
1151,Recombinant human insulin receptor monoclonal antibody-fused-a-L-iduronidase,EU/3/14/1349,Treatment of mucopolysaccharidosis type I,Voisin Consulting S.A.R.L.,15/10/2014,,,mucopolysaccharidosis type i,,,http://www.orpha.net/ORDO/Orphanet_579,D008059,,,Q1906054
1152,Recombinant human interleukin-12,EU/3/16/1727,Treatment of acute radiation syndrome,Coté Orphan Consulting UK Limited,29/08/2016,,Q238474,acute radiation syndrome,,,,D054508,,,Q275459
1153,Recombinant human interleukin-3 truncated diphtheria toxin fusion protein,EU/3/15/1563,Treatment of acute myeloid leukaemia,Spector Consulting SAS,09/10/2015,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1154,Recombinant human interleukin-3 truncated diphtheria toxin fusion protein,EU/3/15/1567,Treatment of blastic plasmacytoid dendritic cell neoplasm,Spector Consulting SAS,11/11/2015,,,blastic plasmacytoid dendritic cell neoplasm,,,http://www.orpha.net/ORDO/Orphanet_86870,,,,
1155,Recombinant human interleukin-7,EU/3/12/1013,Treatment of progressive multifocal leukoencephalopathy,Inserm-ANRS (Agence Nationale de Recherches sur le Sida et les Hépatites Virales),04/07/2012,,,progressive multifocal leukoencephalopathy,http://purl.obolibrary.org/obo/DOID_643,,http://www.orpha.net/ORDO/Orphanet_217260,D007968,Q704930,,Q704930
1156,Recombinant human lecithin cholesterol acyltransferase,EU/3/12/1051,Treatment of lecithin cholesterol acyltransferase deficiency,AstraZeneca UK Limited,10/10/2012,,,lecithin cholesterol acyltransferase deficiency,,,,D007863,,,Q3441028
1157,Recombinant human lysosomal acid lipase,EU/3/10/827,Treatment of lysosomal acid lipase deficiency,Alexion Europe SAS,17/12/2010,KanumaEU/1/15/103301/09/2015,,lysosomal acid lipase deficiency,,,http://www.orpha.net/ORDO/Orphanet_275761,,,,
1158,Recombinant human mesencephalic astrocyte-derived neurotrophic factor,EU/3/15/1486,Treatment of retinitis pigmentosa,Regintel Limited,24/04/2015,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1159,Recombinant human methionine proinsulin,EU/3/12/985,Treatment of retinitis pigmentosa,ProRetina Therapeutics S.L.,26/04/2012,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1160,Recombinant human minibody against complement component C5,EU/3/08/571,Treatment of atypical Haemolytic Uraemic Syndrome (aHUS) associated with an inherited abnormality of the complement system,ADIENNE S.r.l.,22/09/2008,,,atypical hemolytic uremic syndrome (ahus) associated with an inherited abnormality of the complement system,,,,,,,
1161,Recombinant human minibody against complement component C5,EU/3/11/926,Treatment of primary membranoproliferative glomerulonephritis,ADIENNE S.r.l.,27/10/2011,,,primary membranoproliferative glomerulonephritis,,,http://www.orpha.net/ORDO/Orphanet_54370,,,,
1162,Recombinant Human minibody against complement component C5 fused with RGD-motif,EU/3/08/604,Prevention of the ischemia/reperfusion injury associated with solid organ transplantation,ADIENNE S.r.l.,20/01/2009,,,the ischemia/reperfusion injury associated with solid organ transplantation,,,,,,,
1163,Recombinant human monoclonal antibody against activin receptor type IIB,EU/3/12/1035,Treatment of inclusion body myositis,Novartis Europharm Limited,09/08/2012,,,inclusion body myositis,http://purl.obolibrary.org/obo/DOID_3429,,http://www.orpha.net/ORDO/Orphanet_611,D018979,Q1848471,,Q1848471
1164,Recombinant human monoclonal antibody against hepatitis B virus,EU/3/13/1156,Prevention of hepatitis B re-infection following liver transplantation,inVentiv Health Germany GmbH,17/07/2013,,,hepatitis b reinfection following liver transplantation,,,,,,,
1165,Recombinant human monoclonal antibody binding to vascular adhesion protein-1,EU/3/15/1461,Treatment of primary sclerosing cholangitis,Biotie Therapies Corp,19/03/2015,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
1166,Recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor,EU/3/14/1350,"Treatment of tenosynovial giant cell tumour, localised and diffused type",Novartis Europharm Limited,15/10/2014,,,"tenosynovial giant cell tumor, localised and diffused type",,,,,,,
1167,Recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/kappa class,EU/3/08/605,Treatment of spinal cord injury,Novartis Europharm Limited,19/01/2009,,,spinal cord injury,,,,D013119,,,Q1415275
1168,Recombinant human monoclonal antibody to insulin receptor,EU/3/16/1702,Treatment of congenital hyperinsulinism,XOMA UK Limited,14/07/2016,,,congenital hyperinsulinism,,,,D044903,,,Q5160437
1169,Recombinant human monoclonal IgG1 antibody against programmed death ligand-1,EU/3/15/1590,Treatment of Merkel cell carcinoma,Merck Serono Europe Limited,14/12/2015,,,merkel cell carcinoma,http://purl.obolibrary.org/obo/DOID_3965,,http://www.orpha.net/ORDO/Orphanet_79140,D015266,Q1711744,,
1170,Recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23,EU/3/14/1351,Treatment of X-linked hypophosphataemia,Kyowa Kirin Limited,15/10/2014,,,xlinked hypophosphatemia,http://purl.obolibrary.org/obo/DOID_0050445,,http://www.orpha.net/ORDO/Orphanet_89936,D053098,Q1779987,Q1779987,Q1779987
1171,Recombinant human monoclonal IgM antibody targeting glucose-regulated protein 78,EU/3/13/1190,Treatment of plasma cell myeloma,Patrys GmbH,07/10/2013,,,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1172,Recombinant human N-acetylgalactosamine-6-sulfatase,EU/3/09/657,"Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome)",BioMarin Europe Ltd.,24/07/2009,VimizimEU/1/14/91430/04/2014,,"mucopolysaccharidosis, type iva (morquio a syndrome)",,,,,,,
1173,Recombinant human nerve growth factor,EU/3/13/1135,Treatment of retinitis pigmentosa,Dompé farmaceutici s.p.a.,07/06/2013,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1174,Recombinant human nerve growth factor,EU/3/15/1586,Treatment of neurotrophic keratitis,Dompé farmaceutici s.p.a.,14/12/2015,,,neurotrophic keratitis,,,http://www.orpha.net/ORDO/Orphanet_137596,,,,
1175,Recombinant human parathyroid hormone,EU/3/13/1210,Treatment of hypoparathyroidism,Shire Pharmaceuticals Ireland Limited,18/12/2013,,,hypoparathyroidism,http://purl.obolibrary.org/obo/DOID_11199,http://purl.obolibrary.org/obo/HP_0000829,,D007011,Q1586088,,Q1586088
1176,Recombinant human pentraxin-2,EU/3/12/1020,Treatment of idiopathic pulmonary fibrosis,FGK Representative Service GmbH,17/07/2012,,,idiopathic pulmonary fibrosis,http://purl.obolibrary.org/obo/DOID_0050156,,http://www.orpha.net/ORDO/Orphanet_2032,D054990,Q2290446,,Q2290446
1177,Recombinant human pentraxin-2,EU/3/14/1358,Treatment of post-essential thrombocythaemia myelofibrosis,FGK Representative Service GmbH,19/11/2014,,,postessential thrombocythemia myelofibrosis,,,,,,,
1178,Recombinant human pentraxin-2,EU/3/14/1365,Treatment of post-polycythaemia vera myelofibrosis,FGK Representative Service GmbH,19/11/2014,,,postpolycythemia vera myelofibrosis,,,,,,,
1179,Recombinant human pentraxin-2,EU/3/14/1366,Treatment of primary myelofibrosis,FGK Representative Service GmbH,19/11/2014,,,primary myelofibrosis,http://purl.obolibrary.org/obo/DOID_4971,,http://www.orpha.net/ORDO/Orphanet_824,D055728,Q1752571,,Q1752571
1180,Recombinant Human Porphobilinogen Deaminase,EU/3/02/103,Treatment of acute intermittent porphyria,Zymenex A/S,12/06/2002,,,acute intermittent porphyria,http://purl.obolibrary.org/obo/DOID_3890,,http://www.orpha.net/ORDO/Orphanet_79276,D017118,Q424247,,Q424247
1181,Recombinant human proinsulin,EU/3/08/612,Treatment of retinitis pigmentosa,ProRetina Therapeutics S.L.,11/02/2009,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1182,Recombinant human soluble Fc-gamma receptor Iib,EU/3/07/462,Treatment of idiopathic thrombocytopenic purpura,SuppreMol GmbH,02/08/2007,,,idiopathic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_8924,http://purl.obolibrary.org/obo/HP_0001973,,D016553,Q638729,,Q638729
1183,Recombinant human surfactant protein D,EU/3/14/1262,Prevention of bronchopulmonary dysplasia,Dr Ulrich Granzer,11/04/2014,,,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
1184,Recombinant human tissue non-specific alkaline phosphatase - Fc - deca-aspartate fusion protein,EU/3/08/594,Treatment of hypophosphatasia,Alexion Europe SAS,03/12/2008,StrensiqEU/1/15/101501/09/2015,Q2974480,hypophosphatasia,http://purl.obolibrary.org/obo/DOID_14213,,http://www.orpha.net/ORDO/Orphanet_436,D007014,Q1313510,,Q1313510
1185,Recombinant human transglutaminase 1 encapsulated into liposomes,EU/3/13/1130,Treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis,Westfälische Wilhelms-Universität Münster,07/06/2013,,,transglutaminase1deficient autosomal recessive congenital ichthyosis,,,,,,,
1186,Recombinant human tripeptidyl-peptidase 1,EU/3/13/1118,Treatment of neuronal ceroid lipofuscinosis type 2,BioMarin International Limited,12/03/2013,,,neuronal ceroid lipofuscinosis type 2,,,,,,,
1187,Recombinant human type I pancreatic elastase,EU/3/13/1218,Prevention of arteriovenous access dysfunction in haemodialysis patients,Proteon Therapeutics Limited,18/12/2013,,,arteriovenos access dysfunction in hemodialysis patients,,,,,,,
1188,Recombinant human vascular endothelial growth factor,EU/3/09/711,Treatment of amyotrophic lateral sclerosis,Newron Sweden AB,29/01/2010,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1189,Recombinant human von Willebrand factor,EU/3/10/814,Treatment of von Willebrand disease,Baxalta Innovations GmbH,26/11/2010,,,von willebrand disease,http://purl.obolibrary.org/obo/DOID_12531,,http://www.orpha.net/ORDO/Orphanet_903,D014842,Q709360,,Q709360
1190,Recombinant human a-Mannosidase,EU/3/04/260,Treatment of &#945;-Mannosidosis,Chiesi Farmaceutici S.P.A.,26/01/2005,,,αmannosidosis,,,,,,,
1191,Recombinant humanised anti-human interleukin-1 beta monoclonal antibody,EU/3/10/796,Treatment of Beh&ccedil;et's disease,XOMA UK Limited,01/10/2010,,,beh&ccedil;ets disease,,,,,,,
1192,Recombinant humanised monoclonal antibody against human complement component C5a,EU/3/16/1728,Treatment of graft-versus-host disease,Alexion Europe SAS,29/08/2016,,,graftversushost disease,,,,D006086,,,Q1194520
1193,Recombinant humanised monoclonal IgG2 lambda antibody against human sclerostin,EU/3/16/1686,Treatment of osteogenesis imperfecta,Mereo Biopharma Group Limited,27/06/2016,,,osteogenesis imperfecta,http://purl.obolibrary.org/obo/DOID_12347,,http://www.orpha.net/ORDO/Orphanet_666,D010013,Q749409,Q749409,Q749409
1194,Recombinant IgG degrading enzyme of Streptococcus pyogenes,EU/3/16/1826,Prevention of graft rejection following solid organ transplantation,Hansa Medical AB,12/01/2017,,,graft rejection following solid organ transplantation,,,,,,,
1195,Recombinant kallikrein inhibitor,EU/3/09/712,Treatment of Netherton syndrome,Dermadis S.A.S.,29/01/2010,,,netherton syndrome,http://purl.obolibrary.org/obo/DOID_0050474,,http://www.orpha.net/ORDO/Orphanet_634,D056770,Q9390284,Q9390284,Q9390284
1196,Recombinant megakaryopoeisis-stimulating protein,EU/3/05/283,Treatment of idiopathic thrombocytopenic purpura,Amgen Europe B.V.,27/05/2005,NplateEU/1/08/49706/02/2009,,idiopathic thrombocytopenic purpura,http://purl.obolibrary.org/obo/DOID_8924,http://purl.obolibrary.org/obo/HP_0001973,,D016553,Q638729,,Q638729
1197,Recombinant modified human growth hormone,EU/3/12/1087,Treatment of growth hormone deficiency,Richardson Associates Regulatory Affairs Ltd,24/01/2013,,Q411294,growth hormone deficiency,,http://purl.obolibrary.org/obo/HP_0000824,,,,,
1198,Recombinant modified vaccinia Ankara expressing human 5T4,EU/3/06/429,Treatment of renal cell carcinoma,Oxford Biomedica (UK) Ltd,26/01/2007,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1199,Recombinant monoclonal antibody to human serum amyloid P component,EU/3/14/1293,Treatment of AL amyloidosis,GlaxoSmithKline Trading Services Limited,30/07/2014,,,al amyloidosis,,,http://www.orpha.net/ORDO/Orphanet_85443,,,,
1200,Recombinant monoclonal IgG1 antibody against T-cell immune response cDNA 7,EU/3/15/1479,Prevention of graft rejection following solid organ transplantation,Nekonal S.a.r.l.,24/04/2015,,,graft rejection following solid organ transplantation,,,,,,,
1201,Recombinant protein consisting of modified human growth hormone releasing hormone and the translocation and endopeptidase domains of botulinum toxin serotype D,EU/3/11/947,Treatment of acromegaly,Syntaxin Limited,11/01/2012,,,acromegaly,http://purl.obolibrary.org/obo/DOID_2449,http://purl.obolibrary.org/obo/HP_0000845,http://www.orpha.net/ORDO/Orphanet_963,D000172,Q189580,,Q189580
1202,Recombinant protein derived from the saliva of the Ornithodoros moubata tick,EU/3/16/1687,Treatment of Guillain-Barr&eacute; syndrome,Akari Therapeutics Plc,27/06/2016,,Q2297773,guillainbarr&eacute; syndrome,,,,,,,
1203,Recombinant protein derived from the saliva of the Ornithodoros moubata tick,EU/3/16/1725,Treatment of paroxysmal nocturnal haemoglobinuria,Akari Therapeutics Plc,29/08/2016,,Q2297773,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
1204,Recombinant P-selectin glycoprotein immunoglobulin,EU/3/06/376,Prevention of post transplantation graft dysfunction,RJM Consultancy Ltd,22/05/2006,,,post transplantation graft dysfunction,,,,,,,
1205,Recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene,EU/3/16/1806,Treatment of neuronal ceroid lipofuscinosis,Ser-mes Planificación SL,12/12/2016,,Q423971,neuronal ceroid lipofuscinosis,http://purl.obolibrary.org/obo/DOID_14503,,http://www.orpha.net/ORDO/Orphanet_216,D009472,Q4358039,Q4358039,Q4358039
1206,Recombinant thymidine phosphorylase encapsulated in autologous erythrocytes,EU/3/11/856,Treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) due to thymidine phosphorylase deficiency,St George's University of London,15/04/2011,,,mitochondrial neurogastrointestinal encephalomyopathy (mngie) due to thymidine phosphorylase deficiency,,,,,,,
1207,Reduced oxydised N-acetyl heparin,EU/3/15/1487,Treatment of plasma cell myeloma,Leadiant Biosciences Ltd,21/05/2015,,,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1208,Reparixin,EU/3/11/912,Prevention of graft rejection in pancreatic islet transplantation,Dompé farmaceutici s.p.a.,27/09/2011,,Q27088533,graft rejection in pancreatic islet transplantation,,,,,,,
1209,Repertaxin L-lysine salt,EU/3/01/058,Prevention of delayed graft function in organ transplant,Dompé farmaceutici s.p.a.,19/09/2001,,,delayed graft function in organ transplant,,,,,,,
1210,Resiquimod,EU/3/16/1653,Treatment of cutaneous T-cell lymphoma,Galderma R&D,28/04/2016,,Q426054,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1211,Resminostat,EU/3/11/913,Treatment of hepatocellular carcinoma,4SC AG,27/09/2011,,Q18394103,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1212,Resminostat,EU/3/11/930,Treatment of Hodgkin's lymphoma,4SC AG,09/12/2011,,Q18394103,hodgkins lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
1213,Retinol,EU/3/14/1307,Prevention of bronchopulmonary dysplasia,Dr Philipp Heinrich Novak,22/08/2014,,Q424976,bronchopulmonary dysplasia,,,http://www.orpha.net/ORDO/Orphanet_70589,D001997,,,
1214,Retroviral gamma-c cDNA containing vector,EU/3/01/038,Treatment of Severe Combined Immunodeficiency (SCID)-Xl Disease,GENOPOIETIC S.A.S.,30/05/2001,,,severe combined immunodeficiency (scid)xl disease,,,,,,,
1215,Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide,EU/3/08/542,Treatment of acute myeloid leukaemia,Dr Ulrich Granzer,08/05/2008,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1216,Rifapentine,EU/3/10/750,Treatment of tuberculosis,Sanofi-Aventis groupe,09/06/2010,,Q3935297,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
1217,Rilonacept,EU/3/07/456,"Treatment of cryopirin-associated periodic syndromes (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)",Regeneron UK Limited,10/07/2007,Rilonacept RegeneronEU/1/09/58227/10/2009,Q7334300,"cryopirinassociated periodic syndromes (familial cold urticaria syndrome (fcus), mucklewells syndrome (mws), and neonatal onset multisystem inflammatory disease (nomid), also known as chronic infantile neurological cutaneos articular syndrome (cinca)",,,,,,,
1218,Rilotumumab,EU/3/14/1291,Treatment of gastric cancer,Amgen Europe B.V.,29/07/2014,,Q7334301,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
1219,Riluzole,EU/3/14/1401,Treatment of traumatic spinal cord injury,Dr Laurent Vinay,16/12/2014,,Q415744,traumatic spinal cord injury,,,,,,,
1220,Rimeporide,EU/3/15/1478,Treatment of Duchenne muscular dystrophy,EUDRAC Limited,24/04/2015,,Q21098945,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1221,Rimiducid,EU/3/16/1666,Treatment of graft-versus-host disease,QRC Consultants Ltd,30/05/2016,,Q27279658,graftversushost disease,,,,D006086,,,Q1194520
1222,Rintatolimod,EU/3/15/1480,Treatment of Ebola virus disease,NV Hemispherx BioPharma Europe,24/04/2015,,Q7335107,ebola virus disease,http://purl.obolibrary.org/obo/DOID_4325,,http://www.orpha.net/ORDO/Orphanet_319218,D019142,Q51993,,Q8064876
1223,Riociguat,EU/3/14/1299,Treatment of systemic sclerosis,Bayer Pharma AG,29/07/2014,,Q2154494,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1224,"RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a?5') (C-m5U-m5U-A-C-A-G-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5' [P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N-dimethylaminophosphonamidate], 3'[2'a-[N2-acetyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-ß-alanyl-L-arginyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-ß-alanyl-L-arginyl-6-aminohexanoyl-ß-alanyl], octahydrochloride",EU/3/09/725,Treatment of Duchenne muscular dystrophy,AVI BioPharma International Ltd,02/02/2010,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1225,"RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a?5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy] ethoxy]carbonyl]-1-piperazinyl]-N,Ndimethylaminophosphonamidate",EU/3/08/586,Treatment of Duchenne muscular dystrophy,AVI BioPharma International Ltd,03/12/2008,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1226,Rovalpituzumab tesirine,EU/3/16/1667,Treatment of small cell lung cancer,Aceso Biologics Consulting Ltd,30/05/2016,,,small cell lung cancer,,http://purl.obolibrary.org/obo/HP_0030357,http://www.orpha.net/ORDO/Orphanet_70573,D055752,,,Q19000544
1227,R-salbutamol sulphate,EU/3/07/481,Treatment of cutaneous forms of lupus erythematosus,Astion Pharma A/S,14/09/2007,,,cutaneos forms of lupus erythematosus,,,,,,,
1228,"R,S-O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride",EU/3/13/1122,Treatment of Duchenne muscular dystrophy,Vudbenk Life Science Kft.,26/04/2013,,,duchenne muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11723,,http://www.orpha.net/ORDO/Orphanet_98896,D020388,Q1648484,,Q1648484
1229,Rubitecan,EU/3/03/145,Treatment of pancreatic cancer,Eurogen Pharmaceuticals Limited,10/06/2003,,Q510113,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1230,Rucaparib,EU/3/12/1049,Treatment of ovarian cancer,Clovis Oncology UK Limited,10/10/2012,,Q7376558,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1231,Rufinamide,EU/3/04/240,Treatment of Lennox-Gastaut syndrome,Eisai Limited,20/10/2004,InovelonEU/1/06/37818/01/2007,Q408565,lennoxgastaut syndrome,http://purl.obolibrary.org/obo/DOID_0050561,,http://www.orpha.net/ORDO/Orphanet_2382,,Q1544884,,
1232,S[+] apomorphine,EU/3/12/954,Treatment of amyotrophic lateral sclerosis,University of Sheffield,09/02/2012,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1233,"(S)-10-[(dimethylamino)methyl]-4-ethyl-9-hydroxy-4-O-[alpha-(2'', 4'', 5'', 7''-tetranitro-9''-fluorenylideneaminooxy)propionyl]-1H-pyrano[3', 4', 6', 7']indolizino[1,2-beta]-quinoline-3, 14-(4H), 12H)-dione, hydrochloride",EU/3/10/788,Treatment of hepatocellular carcinoma,TLC Biopharmaceuticals B.V.,01/10/2010,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1234,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",EU/3/14/1335,Treatment of pemphigus,"Almirall, S.A.",15/10/2014,,,pemphigus,http://purl.obolibrary.org/obo/DOID_9182,,,D010392,Q1483214,,Q1483214
1235,"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDESNISFKEK",EU/3/09/634,Treatment of pancreatic cancer,MBiotec GmbH,15/05/2009,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1236,"(S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine",EU/3/07/513,Treatment of tuberculosis,FGK Representative Service GmbH,29/11/2007,,,tuberculosis,http://purl.obolibrary.org/obo/DOID_399,,http://www.orpha.net/ORDO/Orphanet_3389,D014376,Q12204,,Q12204
1237,(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one,EU/3/13/1125,Treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma,Voisin Consulting S.A.R.L.,26/04/2013,,,chronic lymphocytic leukemia/small lymphocytic lymphoma,http://purl.obolibrary.org/obo/DOID_6354,,,,Q18557229,,
1238,(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one,EU/3/13/1157,Treatment of follicular lymphoma,Voisin Consulting S.A.R.L.,17/07/2013,,,follicular lymphoma,http://purl.obolibrary.org/obo/DOID_0050873,,http://www.orpha.net/ORDO/Orphanet_545,D008224,Q123251,,
1239,"(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt",EU/3/09/647,Treatment of chronic iron overload requiring chelation therapy,Shire Pharmaceutical Development Limited,24/07/2009,,,chronic iron overload requiring chelation therapy,,,,,,,
1240,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",EU/3/14/1327,Treatment of paroxysmal nocturnal haemoglobinuria,Amyndas Pharmaceuticals S.A.,22/08/2014,,Q27290286,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
1241,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",EU/3/16/1608,Treatment of C3 glomerulopathy,Amyndas Pharmaceuticals S.A.,17/02/2016,,Q27290286,c3 glomerulopathy,,,http://www.orpha.net/ORDO/Orphanet_329918,,,,
1242,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",EU/3/14/1336,Treatment of Leigh syndrome,Khondrion BV,15/10/2014,,,leigh syndrome,http://purl.obolibrary.org/obo/DOID_3652,,http://www.orpha.net/ORDO/Orphanet_506,D007888,Q1815019,Q1815019,Q1815019
1243,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",EU/3/15/1543,"Treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes",Khondrion BV,10/08/2015,,,"mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes",,,,D017241,,,Q2666433
1244,"(S)-{8-fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl} acetic acid",EU/3/11/849,Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity deemed at risk,Merck Sharp & Dohme Limited,15/04/2011,,,cytomegalovirus disease in patients with impaired cellmediated immunity deemed at risk,,,,,,,
1245,"S-acetyl-(S)-4'-phosphopantetheine, calcium salt",EU/3/16/1654,Treatment of pantothenate-kinase-associated neurodegeneration,Acies Bio d.o.o.,28/04/2016,,,pantothenatekinaseassociated neurodegeneration,,,,,,,
1246,Sacrosidase,EU/3/13/1183,Treatment of congenital sucrase-isomaltase deficiency,QOL Therapeutics UK Ltd,05/08/2013,,,congenital sucraseisomaltase deficiency,,,http://www.orpha.net/ORDO/Orphanet_35122,,,,
1247,Salirasib,EU/3/11/871,Treatment of pancreatic cancer,Kadmon International Ltd,21/06/2011,,Q27088685,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1248,Sapacitabine,EU/3/08/557,Treatment of myelodysplastic syndromes,Cyclacel Limited,08/07/2008,,Q7420893,myelodysplastic syndromes,,,,D009190,,,Q954625
1249,Sapacitabine,EU/3/08/558,Treatment of acute myeloid leukaemia,Cyclacel Limited,10/07/2008,,Q7420893,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1250,Sarizotan hydrochloride,EU/3/15/1531,Treatment of Rett syndrome,Newron Pharmaceuticals SpA,28/07/2015,,Q27262685,rett syndrome,http://purl.obolibrary.org/obo/DOID_1206,,http://www.orpha.net/ORDO/Orphanet_778,D015518,Q917357,,Q917357
1251,Self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene,EU/3/16/1761,Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),Ser-mes Planificación SL,14/10/2016,,,mucopolysaccharidosis type iiia (sanfilippo a syndrome),,,,,,,
1252,Selinexor,EU/3/14/1354,Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma,Karyopharm Europe GmbH,19/11/2014,,Q27256082,chronic lymphocytic leukemia / small lymphocytic lymphoma,,,,,,,
1253,Selinexor,EU/3/14/1355,Treatment of plasma cell myeloma,Karyopharm Europe GmbH,19/11/2014,,Q27256082,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1254,"(S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate",EU/3/09/661,Treatment of carcinoid syndrome,Ipsen Pharma,08/10/2009,,,carcinoid syndrome,,,,,,,
1255,Setmelanotide,EU/3/16/1688,Treatment of Prader-Willi syndrome,TMC Pharma Services Ltd,27/06/2016,,Q21098917,praderwilli syndrome,http://purl.obolibrary.org/obo/DOID_11983,,http://www.orpha.net/ORDO/Orphanet_739,D011218,Q594013,,Q594013
1256,Setmelanotide,EU/3/16/1703,Treatment of pro-opiomelanocortin deficiency,TMC Pharma Services Ltd,14/07/2016,,Q21098917,proopiomelanocortin deficiency,,,,,,,
1257,Sevuparin sodium,EU/3/15/1433,Treatment of sickle cell disease,Dilaforette AB,12/02/2015,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1258,Sialic acid,EU/3/12/972,Treatment of GNE myopathy,Ultragenyx Germany GmbH,05/03/2012,,Q27120624,gne myopathy,,,http://www.orpha.net/ORDO/Orphanet_602,,,Q3331460,
1259,Sildenafil citrate,EU/3/10/815,Treatment of postcardiotomy right ventricular failure,Pfizer Limited,26/11/2010,,Q27126379,postcardiotomy right ventricular failure,,,,,,,
1260,"Silibinin-C-2',3-dihydrogensuccinate, disodium salt",EU/3/10/828,Prevention of recurrent hepatitis C in liver transplant recipients,Rottapharm S.p.A,17/12/2010,,,recurrent hepatitis c in liver transplant recipients,,,,,,,
1261,"Sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleoyl phosphatidylglycerol and palmitic acid",EU/3/01/079,Treatment of acute lung injury,Pharm Research Associates (UK) Limited,04/02/2002,,,acute lung injury,,,http://www.orpha.net/ORDO/Orphanet_178320,D055371,,,
1262,"Sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleoyl phosphatidylglycerol and palmitic acid",EU/3/04/216,Prevention of respiratory distress syndrome in premature neonates of less than 32 weeks of gestational age,Pharm Research Associates (UK) Limited,29/07/2004,,,respiratory distress syndrome in premature neonates of less than 32 weeks of gestational age,,,,,,,
1263,"Sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleoyl phosphatidylglycerol and palmitic acid",EU/3/04/217,Treatment of respiratory distress syndrome in premature neonates of less than 37 weeks of gestational age,Pharm Research Associates (UK) Limited,29/07/2004,,,respiratory distress syndrome in premature neonates of less than 37 weeks of gestational age,,,,,,,
1264,"Sinapultide, dipalmitoylphosphatidylcholine, palmitoyl-oleoyl phosphatidylglycerol, sodium salt and palmitic acid",EU/3/11/927,Treatment of cystic fibrosis,Pharm Research Associates (UK) Limited,27/10/2011,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1265,Sindbis virus envelope pseudotyped lentiviral vector encoding New York esophageal squamous cell carcinoma-1 protein,EU/3/16/1636,Treatment of soft tissue sarcoma,Immune Design Ltd,21/03/2016,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1266,Single-chain urokinase plasminogen activator,EU/3/14/1383,Treatment of pleural empyema,Coté Orphan Consulting UK Limited,16/12/2014,,,pleural empyema,http://purl.obolibrary.org/obo/DOID_3798,http://purl.obolibrary.org/obo/HP_0011919,http://www.orpha.net/ORDO/Orphanet_449266,D016724,Q200781,,Q200781
1267,Siponimod,EU/3/14/1369,Treatment of dermatomyositis,Novartis Europharm Limited,19/11/2014,,Q27288262,dermatomyositis,http://purl.obolibrary.org/obo/DOID_10223,,http://www.orpha.net/ORDO/Orphanet_221,D003882,Q681160,,Q6318950
1268,Siponimod,EU/3/14/1370,Treatment of polymyositis,Novartis Europharm Limited,19/11/2014,,Q27288262,polymyositis,,,http://www.orpha.net/ORDO/Orphanet_732,D017285,,,
1269,Sirolimus,EU/3/11/898,Treatment of chronic non-infectious uveitis,Santen Oy,30/08/2011,,Q32089,chronic noninfectios uveitis,,,,,,,
1270,Sirolimus,EU/3/13/1204,Prevention of arteriovenous access dysfunction in patients undergoing surgical creation of an arteriovenous access for haemodialysis,S-cubed Ltd,13/11/2013,,Q32089,arteriovenos access dysfunction in patients undergoing surgical creation of an arteriovenos access for hemodialysis,,,,,,,
1271,Sirolimus,EU/3/15/1557,Treatment of tuberous sclerosis,Desitin Arzneimittel GmbH,09/10/2015,,Q32089,tuberos sclerosis,http://purl.obolibrary.org/obo/DOID_13515,,http://www.orpha.net/ORDO/Orphanet_805,D014402,Q1362721,,Q1362721
1272,Sirolimus,EU/3/15/1585,Treatment of beta thalassaemia intermedia and major,Rare Partners srl Impresa Sociale,14/12/2015,,Q32089,beta thalassemia intermedia and major,,,,,,,
1273,Sirolimus,EU/3/16/1704,Treatment of sporadic lymphangioleiomyomatosis,Best Regulatory Consulting Ltd,14/07/2016,,Q32089,sporadic lymphangioleiomyomatosis,,,,,,,
1274,Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector,EU/3/09/630,Treatment of dystrophic epidermolysis bullosa,Prof. Alain Hovnanian,30/04/2009,,,dystrophic epidermolysis bullosa,http://purl.obolibrary.org/obo/DOID_4959,,http://www.orpha.net/ORDO/Orphanet_303,D016108,Q3589131,,Q3589131
1275,Smilagenin,EU/3/11/914,Treatment of amyotrophic lateral sclerosis,QRC Consultants Ltd,27/09/2011,,Q27103971,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1276,"(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate",EU/3/15/1606,Treatment of soft tissue sarcoma,TMC Pharma Services Ltd,11/01/2016,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1277,S-nitrosoglutathione,EU/3/11/870,Treatment of pre-eclampsia,Salupont Consulting Ltd,13/05/2011,,Q7387071,preeclampsia,http://purl.obolibrary.org/obo/DOID_10591,http://purl.obolibrary.org/obo/HP_0100602,http://www.orpha.net/ORDO/Orphanet_275555,D011225,Q2421435,Q61335,Q2421435
1278,Sodium 2-hydroxylinoleate,EU/3/15/1485,Treatment of neuroblastoma,Ability Pharmaceuticals SL,24/04/2015,,Q2154494,neuroblastoma,http://purl.obolibrary.org/obo/DOID_769,http://purl.obolibrary.org/obo/HP_0003006,http://www.orpha.net/ORDO/Orphanet_635,D009447,Q938205,Q938205,Q938205
1279,"Sodium (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl ((2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl phosphate",EU/3/15/1597,Treatment of acute myeloid leukaemia,Otsuka Pharmaceutical Europe Ltd.,14/12/2015,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1280,"Sodium 3-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H-imidazo[1,2-a]purin-9-one",EU/3/15/1462,Treatment of retinitis pigmentosa,Universitätsklinikum Tübingen (UKT),19/03/2015,,,retinitis pigmentosa,http://purl.obolibrary.org/obo/DOID_10584,http://purl.obolibrary.org/obo/HP_0000510,http://www.orpha.net/ORDO/Orphanet_791,D012174,Q847057,Q847057,Q847057
1281,Sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH,EU/3/14/1294,Treatment for necrotising soft tissue infections,FGK Representative Service GmbH,29/07/2014,,,necrotising soft tissue infections,,,,,,,
1282,Sodium ascorbate and menadione sodium bisulfite,EU/3/14/1308,Treatment of autosomal dominant polycystic liver disease,MCA Regulatory Limited,22/08/2014,,,autosomal dominant polycystic liver disease,,,http://www.orpha.net/ORDO/Orphanet_2924,,,Q246002,
1283,Sodium benzoate,EU/3/15/1600,Treatment of hyperargininaemia,Syri Limited,11/01/2016,,Q423971,hyperargininemia,http://purl.obolibrary.org/obo/DOID_9278,,http://www.orpha.net/ORDO/Orphanet_90,D020162,Q890367,,Q890367
1284,Sodium benzoate,EU/3/15/1601,Treatment of argininosuccinic aciduria,Syri Limited,11/01/2016,,Q423971,argininosuccinic aciduria,http://purl.obolibrary.org/obo/DOID_14755,,http://www.orpha.net/ORDO/Orphanet_23,D056807,Q1654860,,Q1654860
1285,Sodium benzoate,EU/3/16/1705,Treatment of ornithine transcarbamylase deficiency,Lucane Pharma SA,14/07/2016,,Q423971,ornithine transcarbamylase deficiency,http://purl.obolibrary.org/obo/DOID_9271,,http://www.orpha.net/ORDO/Orphanet_664,D020163,Q3043161,,Q3043161
1286,Sodium benzoate,EU/3/16/1706,Treatment of carbamoyl-phosphate synthase-1 deficiency,Lucane Pharma SA,14/07/2016,,Q423971,carbamoylphosphate synthase1 deficiency,,,,,,,
1287,Sodium benzoate,EU/3/16/1707,Treatment of citrullinaemia type 1,Lucane Pharma SA,14/07/2016,,Q423971,citrullinemia type 1,,,http://www.orpha.net/ORDO/Orphanet_247525,D020159,,,Q859142
1288,Sodium benzoate,EU/3/16/1708,Treatment of hyperargininaemia,Lucane Pharma SA,14/07/2016,,Q423971,hyperargininemia,http://purl.obolibrary.org/obo/DOID_9278,,http://www.orpha.net/ORDO/Orphanet_90,D020162,Q890367,,Q890367
1289,Sodium benzoate,EU/3/16/1729,Treatment of lysinuric protein intolerance,Lucane Pharma SA,29/08/2016,,Q423971,lysinuric protein intolerance,http://purl.obolibrary.org/obo/DOID_0060439,,http://www.orpha.net/ORDO/Orphanet_470,,Q3153671,Q3153671,
1290,Sodium benzoate,EU/3/16/1730,Treatment of ornithine translocase deficiency,Lucane Pharma SA,29/08/2016,,Q423971,ornithine translocase deficiency,http://purl.obolibrary.org/obo/DOID_0050720,,http://www.orpha.net/ORDO/Orphanet_415,,Q7103627,Q7103627,
1291,Sodium benzoate,EU/3/16/1787,Treatment of argininosuccinic aciduria,Lucane Pharma SA,18/11/2016,,Q423971,argininosuccinic aciduria,http://purl.obolibrary.org/obo/DOID_14755,,http://www.orpha.net/ORDO/Orphanet_23,D056807,Q1654860,,Q1654860
1292,Sodium benzoate,EU/3/16/1788,Treatment of N-acetylglutamate synthetase deficiency,Lucane Pharma SA,18/11/2016,,Q423971,nacetylglutamate synthetase deficiency,,,,,,,
1293,Sodium butyrate (rectal use),EU/3/05/284,Prevention of radiation proctitis,Promefarm srl,27/05/2005,,,radiation proctitis,,,http://www.orpha.net/ORDO/Orphanet_70475,,,,
1294,Sodium chlorite,EU/3/13/1139,Treatment of amyotrophic lateral sclerosis,Shore Limited,19/06/2013,,Q411294,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1295,Sodium hypochlorite,EU/3/16/1709,Treatment of partial deep dermal and full thickness burns,Hypo-Stream Ltd,14/07/2016,,Q407204,partial deep dermal and full thickness burns,,,,,,,
1296,Sodium nitrite,EU/3/12/967,Treatment of pulmonary arterial hypertension,FGK Representative Service GmbH,05/03/2012,,Q339975,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
1297,Sodium nitrite,EU/3/13/1224,Treatment of aneurysmal subarachnoid haemorrhage,"Hope Pharmaceuticals, Ltd",16/01/2014,,Q339975,aneurysmal subarachnoid hemorrhage,,,,D013345,,,Q693442
1298,Sodium nitrite and ethylenediaminetetraacetic acid,EU/3/16/1668,Treatment of cystic fibrosis,Arch Bio Ireland Ltd,30/05/2016,,,cystic fibrosis,http://purl.obolibrary.org/obo/DOID_1485,,http://www.orpha.net/ORDO/Orphanet_586,D003550,Q178194,,Q178194
1299,Sodium phenylbutyrate,EU/3/11/948,Treatment of 5q spinal muscular atrophy,GMP-Orphan SA,11/01/2012,,Q7553358,5q spinal muscular atrophy,,,,,,,
1300,Sodium phenylbutyrate,EU/3/15/1581,Treatment of pyruvate dehydrogenase complex deficiency,Fondazione Telethon,11/11/2015,,Q7553358,pyruvate dehydrogenase complex deficiency,,http://purl.obolibrary.org/obo/HP_0002928,http://www.orpha.net/ORDO/Orphanet_765,D015325,,,Q7263801
1301,Sodium thiosulfate,EU/3/10/848,Treatment of calciphylaxis,Dr Franz Köhler Chemie GmbH,23/02/2011,,Q410739,calciphylaxis,http://purl.obolibrary.org/obo/DOID_4734,,http://www.orpha.net/ORDO/Orphanet_280062,D002115,Q1026326,,Q1026326
1302,Sodium thiosulfate,EU/3/12/979,Treatment of calciphylaxis,Aptiv Solutions (UK) Limited,02/04/2012,,Q410739,calciphylaxis,http://purl.obolibrary.org/obo/DOID_4734,,http://www.orpha.net/ORDO/Orphanet_280062,D002115,Q1026326,,Q1026326
1303,Sodium thiosulfate,EU/3/14/1414,Treatment for calciphylaxis,"Hope Pharmaceuticals, Ltd",15/01/2015,,Q410739,calciphylaxis,http://purl.obolibrary.org/obo/DOID_4734,,http://www.orpha.net/ORDO/Orphanet_280062,D002115,Q1026326,,Q1026326
1304,Sodium valproate,EU/3/14/1428,Treatment of Wolfram syndrome,Alan Boyd Consultants Ltd,15/01/2015,,,wolfram syndrome,http://purl.obolibrary.org/obo/DOID_10632,,http://www.orpha.net/ORDO/Orphanet_3463,D014929,Q1153641,,Q1153641
1305,"Soluble yeast beta-1,3/1,6-glucan",EU/3/05/294,Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy,Biotec Pharmacon ASA,16/06/2005,,Q617563,oral mucositis in head and neck cancer patients undergoing radiation therapy,,,,,,,
1307,Sorafenib tosylate,EU/3/06/364,Treatment of hepatocellular carcinoma,Bayer Pharma AG,11/04/2006,NexavarEU/1/06/34231/10/2007,Q27122250,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1308,Sorafenib tosylate,EU/3/13/1199,Treatment of follicular thyroid cancer,Bayer Pharma AG,13/11/2013,NexavarEU/1/06/34227/05/2014,Q27122250,follicular thyroid cancer,,,,,,,
1309,Sorafenib tosylate,EU/3/13/1200,Treatment of papillary thyroid cancer,Bayer Pharma AG,13/11/2013,NexavarEU/1/06/34227/05/2014,Q27122250,papillary thyroid cancer,,,,,,,
1310,Soraprazan,EU/3/13/1208,Treatment of Stargardt&#8217;s disease,Katairo GmbH,13/11/2013,,Q27263004,stargardts disease,,,,,,,
1311,Sulfonated monophosphorylated mannose oligosaccharide,EU/3/11/872,Treatment of hepatocellular carcinoma,S-cubed Ltd,21/06/2011,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1312,Synthetic 12 amino acids peptide designed after subcommissural organ spondin,EU/3/13/1206,Treatment of spinal cord injury,Neuronax SAS,13/11/2013,,,spinal cord injury,,,,D013119,,,Q1415275
1313,Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker,EU/3/16/1762,Treatment of paroxysmal nocturnal haemoglobinuria,Ra Europe Limited,14/10/2016,,,paroxysmal nocturnal hemoglobinuria,http://purl.obolibrary.org/obo/DOID_0060284,http://purl.obolibrary.org/obo/HP_0004818,http://www.orpha.net/ORDO/Orphanet_231527,D006457,Q1479494,,Q1479494
1314,"Synthetic 47-amino-acid N-myristoylated lipopeptide, derived from the preS region of hepatitis B virus",EU/3/15/1500,Treatment of hepatitis delta virus infection,MYR GmbH,19/06/2015,,,hepatitis delta virus infection,,,,,,,
1315,"Synthetic double-stranded oligomer specific to the SERPINA1 gene and containing a cholesterol-conjugated, acyclic nucleobase analogue",EU/3/15/1605,Treatment of congenital alpha-1 antitrypsin deficiency,Pharma Gateway AB,11/01/2016,,,congenital alpha1 antitrypsin deficiency,,,,,,,
1316,Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene,EU/3/15/1528,Treatment of primary hyperoxaluria type 1,Dicerna EU Limited,28/07/2015,,,primary hyperoxaluria type 1,,,http://www.orpha.net/ORDO/Orphanet_119538,,,,
1317,Synthetic double-stranded short interfering RNA oligonucleotide directed against proopiomelanocortin,EU/3/10/798,Treatment of adrenocorticotropin-dependent Cushing's syndrome,Diurnal Limited,01/10/2010,,,adrenocorticotropindependent cushings syndrome,,,,,,,
1318,Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues,EU/3/14/1297,Treatment of haemophilia A,Alnylam UK Limited,29/07/2014,,,hemophilia a,,,http://www.orpha.net/ORDO/Orphanet_121677,D006467,,,Q2092064
1319,Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues,EU/3/14/1298,Treatment of haemophilia B,Alnylam UK Limited,29/07/2014,,,hemophilia b,http://purl.obolibrary.org/obo/DOID_12259,,http://www.orpha.net/ORDO/Orphanet_121683,D002836,Q2562598,,Q2562598
1320,Synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine (prior to administration of doxorubicin),EU/3/12/1065,Treatment of glioma,Avena Therapeutics Ltd,08/11/2012,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1321,Synthetic double-stranded siRNA oligonucleotide directed against delta-aminolevulinic acid synthase 1 mRNA covalently linked to a ligand containing three N-acetylgalactosamine residues,EU/3/16/1731,Treatment of acute hepatic porphyria,Alnylam UK Limited,29/08/2016,,,acute hepatic porphyria,,,http://www.orpha.net/ORDO/Orphanet_95157,,,,
1322,Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues,EU/3/16/1637,Treatment of primary hyperoxaluria,Alnylam UK Limited,21/03/2016,,,primary hyperoxaluria,http://purl.obolibrary.org/obo/DOID_2977,,http://www.orpha.net/ORDO/Orphanet_416,D006960,Q7243137,,Q7243137
1323,Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA,EU/3/10/751,Prevention of delayed graft function after renal transplantation,ProductLife Limited,09/06/2010,,,delayed graft function after renal transplantation,,,,,,,
1324,Synthetic double-stranded siRNA oligonucleotide directed against the keratin 6a N171K mutation,EU/3/13/1141,Treatment of pachyonychia congenita,Alan Irvine,19/06/2013,,,pachyonychia congenita,http://purl.obolibrary.org/obo/DOID_0050449,,http://www.orpha.net/ORDO/Orphanet_2309,D053549,Q3360152,,Q3360152
1325,Synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA,EU/3/11/857,Treatment of familial amyloid polyneuropathy,Alnylam UK Limited,15/04/2011,,,familial amyloid polyneuropathy,http://purl.obolibrary.org/obo/DOID_0050638,,,D028227,Q2844603,,
1326,Synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues,EU/3/14/1267,Treatment of ATTR amyloidosis,Alnylam UK Limited,29/04/2014,,,attr amyloidosis,,,,,,,
1327,Synthetic hepcidin,EU/3/15/1555,Treatment of beta thalassaemia intermedia and major,EMAS Pharma Limited,09/10/2015,,,beta thalassemia intermedia and major,,,,,,,
1328,Synthetic human hepcidin,EU/3/16/1789,Treatment of sickle cell disease,EMAS Pharma Limited,18/11/2016,,,sickle cell disease,,,http://www.orpha.net/ORDO/Orphanet_232,D000755,,,Q185034
1329,Synthetic hypericin,EU/3/15/1515,Treatment of cutaneous T-cell lymphoma,Kinesys Consulting Ltd,28/07/2015,,,cutaneos tcell lymphoma,http://purl.obolibrary.org/obo/DOID_0060061,http://purl.obolibrary.org/obo/HP_0012192,,D016410,Q5196687,,Q5196687
1330,"Synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-, cyclic (1.fwdarw.17)-disulfide",EU/3/15/1549,Treatment of primary graft dysfunction following lung transplantation,Apeptico Forschung und Entwicklung GmbH,09/10/2015,,,primary graft dysfunction following lung transplantation,,,,,,,
1331,"Synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-, cyclic (1.fwdarw.17)-disulfide",EU/3/15/1591,Treatment of pseudohypoaldosteronism type 1B,Apeptico Forschung und Entwicklung GmbH,14/12/2015,,,pseudohypoaldosteronism type 1b,,,,,,,
1332,Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid,EU/3/16/1732,Treatment of amyotrophic lateral sclerosis,Biogen Idec Limited,29/08/2016,,,amyotrophic lateral sclerosis,http://purl.obolibrary.org/obo/DOID_332,http://purl.obolibrary.org/obo/HP_0007354,http://www.orpha.net/ORDO/Orphanet_803,D000690,Q206901,Q21124521,Q206901
1333,Synthetic signal peptide of human mucin-1 (amino acids 1-21),EU/3/14/1423,Treatment of plasma cell myeloma,Richardson Associates Regulatory Affairs Ltd,15/01/2015,,,plasma cell myeloma,http://purl.obolibrary.org/obo/DOID_9538,,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1334,Tadekinig alfa,EU/3/16/1763,Treatment of haemophagocytic lymphohistiocytosis,Coté Orphan Consulting UK Limited,14/10/2016,,,hemophagocytic lymphohistiocytosis,http://purl.obolibrary.org/obo/DOID_0050120,,http://www.orpha.net/ORDO/Orphanet_158032,D051359,Q1642170,,Q1642170
1335,tafamidis,EU/3/12/1066,Treatment of senile systemic amyloidosis,Pfizer Limited,08/11/2012,,Q519447,senile systemic amyloidosis,,,http://www.orpha.net/ORDO/Orphanet_330001,,,,
1336,Talactoferrinum alfa,EU/3/07/448,Treatment of renal cell carcinoma,Agennix Limited,05/06/2007,,,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1337,Taliglucerase alfa,EU/3/10/726,Treatment of Gaucher Disease,Pfizer Limited,23/03/2010,,Q7679506,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
1338,Tasimelteon,EU/3/10/841,Treatment of non-24-hour sleep-wake disorders in blind people with no light perception,Vanda Pharmaceuticals Limited,23/02/2011,HetliozEU/1/15/100807/07/2015,Q7687250,non24hor sleepwake disorders in blind people with no light perception,,,,,,,
1339,Temocillin sodium,EU/3/03/183,Treatment of Burkholderia cepacia lung infection in cystic fibrosis,Eumedica N.V.,14/01/2004,,Q27123437,burkholderia cepacia lung infection in cystic fibrosis,,,,,,,
1340,Temozolomide,EU/3/16/1733,Treatment of glioma,Double Bond Pharmaceutical AB,29/08/2016,,Q425088,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1341,Temsirolimus,EU/3/06/365,Treatment of renal cell carcinoma,Pfizer Limited,06/04/2006,ToriselEU/1/07/42421/11/2007,Q7699074,renal cell carcinoma,http://purl.obolibrary.org/obo/DOID_4450,http://purl.obolibrary.org/obo/HP_0005584,http://www.orpha.net/ORDO/Orphanet_217071,D002292,Q1164529,,Q18975905
1342,Temsirolimus,EU/3/06/420,Treatment of mantle cell lymphoma,Pfizer Limited,06/11/2006,ToriselEU/1/07/42425/08/2009,Q7699074,mantle cell lymphoma,http://purl.obolibrary.org/obo/DOID_0050746,,http://www.orpha.net/ORDO/Orphanet_52416,D020522,Q268713,,
1343,Temsirolimus,EU/3/16/1669,Treatment of adrenoleukodystrophy,Centro de Investigación Biomédica en Red (CIBER),30/05/2016,,Q7699074,adrenoleukodystrophy,http://purl.obolibrary.org/obo/DOID_10588,,http://www.orpha.net/ORDO/Orphanet_117677,D000326,Q366964,,Q366964
1344,Tenofovir disoproxil fumarate,EU/3/14/1419,Treatment of Aicardi-Gouti&egrave;res syndrome,Dr Yanick Crow,15/01/2015,,Q27132754,aicardigoti&egrave;res syndrome,,,,,,,
1345,Terguride,EU/3/07/499,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,Ergonex Licensing and Regulatory Services AG,29/11/2007,,Q7702355,pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,,,,,,,
1346,Terguride,EU/3/12/1096,Treatment of systemic sclerosis,medac Gesellschaft für klinische Spezialpräparate mbH,24/01/2013,,Q7702355,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1347,Teriparatide,EU/3/16/1689,Treatment of hypoparathyroidism,Alacrita LLP,27/06/2016,,Q411781,hypoparathyroidism,http://purl.obolibrary.org/obo/DOID_11199,http://purl.obolibrary.org/obo/HP_0000829,,D007011,Q1586088,,Q1586088
1348,Tesetaxel,EU/3/10/829,Treatment of gastric cancer,Genta Development Limited,17/12/2010,,Q7705452,gastric cancer,,http://purl.obolibrary.org/obo/HP_0012126,,D013274,,,Q189588
1349,Tetrahydrobiopterin,EU/3/04/199,Treatment of hyperphenylalaninemia,BioMarin International Limited,08/06/2004,KuvanEU/1/08/48104/12/2008,Q419808,hyperphenylalaninemia,,http://purl.obolibrary.org/obo/HP_0004923,http://www.orpha.net/ORDO/Orphanet_238583,D010661,,Q7706537,Q5958471
1350,Tetrofosmin,EU/3/16/1764,Diagnosis of glioma,ProActina,14/10/2016,,Q27257279,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1351,TGF-beta2 specific phosphorothioate antisense oligodeoxynucleotide,EU/3/02/091,Treatment of high-grade glioma,Dr Ulrich Granzer,22/03/2002,,Q240642,highgrade glioma,,,,,,,
1352,Thalidomide,EU/3/01/067,Treatment of multiple myeloma,Celgene Europe Limited,20/11/2001,Thalidomide CelgeneEU/1/08/44318/04/2008,Q203174,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1354,Three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein,EU/3/15/1558,Treatment for Ebola virus disease,Dr Stefan Blesse,09/10/2015,,,ebola virus disease,http://purl.obolibrary.org/obo/DOID_4325,,http://www.orpha.net/ORDO/Orphanet_319218,D019142,Q51993,,Q8064876
1355,Thymalfasin,EU/3/02/110,Treatment of hepatocellular carcinoma,SciClone Pharmaceuticals Italy S.r.l,30/07/2002,,Q20817234,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1356,Tideglusib,EU/3/15/1452,Treatment of fragile X syndrome,AMO Pharma Ltd,19/03/2015,,Q10382411,fragile x syndrome,http://purl.obolibrary.org/obo/DOID_14261,,http://www.orpha.net/ORDO/Orphanet_908,D005600,Q221472,Q221472,Q221472
1357,Tipifarnib,EU/3/05/269,Treatment of acute myeloid leukaemia,TMC Pharma Services Ltd,10/03/2005,,Q7808830,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1358,Tivantinib,EU/3/13/1202,Treatment of hepatocellular carcinoma,Daiichi Sankyo Europe GmbH,13/11/2013,,Q17123902,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1359,Tobramycin (inhalation powder),EU/3/03/140,Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis,Novartis Europharm Limited,17/03/2003,TOBI PodhalerEU/1/10/65225/07/2011,,pseudomonas eruginosa lung infection in cystic fibrosis,,,,,,,
1360,Tolfenamic acid,EU/3/16/1613,Treatment of progressive supranuclear palsy,RV Developpement,17/02/2016,,Q59412,progressive supranuclear palsy,http://purl.obolibrary.org/obo/DOID_678,,http://www.orpha.net/ORDO/Orphanet_683,D013494,Q945930,Q945930,Q945930
1361,Tolfenamic acid,EU/3/16/1614,Treatment of behavioural variant frontotemporal dementia,RV Developpement,17/02/2016,,Q59412,behavioral variant frontotemporal dementia,,,,,,,
1362,Topotecan hydrochloride (liposomal),EU/3/08/562,Treatment of glioma,Dr Matthias Luz,05/09/2008,,,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1363,Tosedostat,EU/3/09/659,Treatment of acute myeloid leukaemia,Voisin Consulting S.A.R.L.,24/07/2009,,Q27166812,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1364,Trabectedin,EU/3/03/171,Treatment of ovarian cancer,Pharma Mar S.A.,17/10/2003,YondelisEU/1/07/41730/10/2009,Q2637746,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1365,Trabedersen,EU/3/09/660,Treatment of pancreatic cancer,Dr Ulrich Granzer,24/07/2009,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1366,Tranilast,EU/3/10/756,Prevention of scarring post glaucoma filtration surgery,Altacor Ltd,27/07/2010,,Q2325594,scarring post glaucoma filtration surgery,,,,,,,
1367,Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt,EU/3/12/1036,Treatment of familial chylomicronaemia syndrome (type I hyperlipoproteinaemia),Novartis Europharm Limited,14/09/2012,,Q27254747,familial chylomicronemia syndrome (type i hyperlipoproteinemia),,,,,,,
1368,"Trans-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride",EU/3/13/1174,Treatment of acute myeloid leukaemia,Roche Registration Limited,05/08/2013,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1369,Trans-resveratrol,EU/3/16/1827,Treatment of spinocerebellar ataxia,Luis Pereira de Almeida,12/01/2017,,Q407329,spinocerebellar ataxia,,,,D020754,,,Q899726
1370,Trebananib,EU/3/13/1207,Treatment of ovarian cancer,Amgen Europe B.V.,13/11/2013,,Q27272385,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1371,Trehalose,EU/3/15/1496,Treatment of oculopharyngeal muscular dystrophy,Dr Ulrich Granzer,21/05/2015,,Q27109935,oculopharyngeal muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11719,,http://www.orpha.net/ORDO/Orphanet_270,D039141,Q3042171,,Q3042171
1372,Trehalose,EU/3/15/1502,Treatment of spinocerebellar ataxia,Dr Ulrich Granzer,19/06/2015,,Q27109935,spinocerebellar ataxia,,,,D020754,,,Q899726
1374,Treprostinil diethanolamine,EU/3/09/635,Treatment of systemic sclerosis,United Therapeutics Europe Ltd,15/05/2009,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1375,Treprostinil diethanolamine (oral use),EU/3/05/310,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,United Therapeutics Europe Ltd,26/08/2005,,Q15408413,pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,,,,,,,
1376,Treprostinil sodium,EU/3/13/1103,Treatment of chronic thromboembolic pulmonary hypertension,SciPharm S.a.r.L,08/02/2013,,Q18578845,chronic thromboembolic pulmonary hypertension,,,http://www.orpha.net/ORDO/Orphanet_70591,,,,
1377,Treprostinil sodium (inhalation use),EU/3/04/197,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,United Therapeutics Europe Ltd,14/04/2004,,,pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,,,,,,,
1378,Tretazicar,EU/3/08/529,Treatment of visceral leishmaniasis,Morvus Technology Limited,04/02/2008,,Q27095075,visceral leishmaniasis,http://purl.obolibrary.org/obo/DOID_9146,,,D007898,Q2046113,,Q2046113
1379,Triamcinolone acetonide,EU/3/15/1490,Treatment of non-infectious uveitis,S-cubed Ltd,21/05/2015,,Q2211240,noninfectios uveitis,,,,,,,
1380,Trientine dihydrochloride,EU/3/03/172,Treatment of Wilson's disease,Univar BV,24/10/2003,,,wilsons disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
1381,Trientine tetrahydrochloride,EU/3/15/1471,Treatment of Wilson&#8217;s disease,GMP-Orphan SA,19/03/2015,,Q27266138,wilsons disease,http://purl.obolibrary.org/obo/DOID_893,,,D006527,Q117121,,Q117121
1382,Triheptanoin,EU/3/15/1495,Treatment of glucose transporter type-1 deficiency syndrome,Pharma Gateway AB,21/05/2015,,Q414576,glucose transporter type1 deficiency syndrome,,,,,,,
1383,Triheptanoin,EU/3/15/1508,Treatment of very long-chain acyl-CoA dehydrogenase deficiency,Ultragenyx UK Limited,19/06/2015,,Q414576,very longchain acylcoa dehydrogenase deficiency,,,,,,,
1384,Triheptanoin,EU/3/15/1524,Treatment of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Ultragenyx UK Limited,28/07/2015,,Q414576,longchain 3hydroxyacylcoa dehydrogenase deficiency,,,,,,,
1385,Triheptanoin,EU/3/15/1525,Treatment of mitochondrial trifunctional protein deficiency,Ultragenyx UK Limited,28/07/2015,,Q414576,mitochondrial trifunctional protein deficiency,,,http://www.orpha.net/ORDO/Orphanet_746,,,,
1386,Triheptanoin,EU/3/15/1526,Treatment of carnitine palmitoyltransferase II deficiency,Ultragenyx UK Limited,28/07/2015,,Q414576,carnitine palmitoyltransferase ii deficiency,http://purl.obolibrary.org/obo/DOID_0060235,,http://www.orpha.net/ORDO/Orphanet_157,,Q2033861,Q2033861,
1387,Triheptanoin,EU/3/16/1710,Treatment of McArdle&#8217;s disease,Vall d'Hebron Institute of Research,14/07/2016,,Q414576,mcardles disease,http://purl.obolibrary.org/obo/DOID_2746,,,D006012,Q787751,,Q787751
1388,Two allogenic irradiated pancreatic tumour cell lines,EU/3/15/1604,Treatment of pancreatic cancer,"Aduro Biotech Holdings, Europe B.V.",11/01/2016,,Q27253946,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1389,Type I native bovine skin collagen,EU/3/08/607,Treatment of systemic sclerosis,arGentis Autoimmune Europe Limited,09/02/2009,,,systemic sclerosis,http://purl.obolibrary.org/obo/DOID_418,,http://www.orpha.net/ORDO/Orphanet_90291,D012595,Q5340515,,Q5340515
1390,Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Gly-Gly-Asp-Leu-Leu-Pro-Arg-Gly-Ser,EU/3/16/1790,Treatment of Huntington&#8217;s disease,Dr Ulrich Granzer,18/11/2016,,,huntingtons disease,http://purl.obolibrary.org/obo/DOID_12858,,,D006816,Q190564,,Q190564
1391,"Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met-His-Gln-Arg-Asn-Met-Thr-Lys-Leu and Pro-Gly-Cys-Asn-Lys-Arg-Tyr-Phe-Lys-Leu-Ser-His-Leu-Gln-Met-His-Ser-Arg-Lys-His-Thr-Gly",EU/3/16/1655,Treatment of acute myeloid leukaemia,"SELLAS Life Sciences Group UK, Limited",28/04/2016,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1392,"Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met-His-Gln-Arg-Asn-Met-Thr-Lys-Leu and Pro-Gly-Cys-Asn-Lys-Arg-Tyr-Phe-Lys-Leu-Ser-His-Leu-Gln-Met-His-Ser-Arg-Lys-His-Thr-Gly",EU/3/16/1656,Treatment of malignant mesothelioma,"SELLAS Life Sciences Group UK, Limited",28/04/2016,,,malignant mesothelioma,http://purl.obolibrary.org/obo/DOID_1790,http://purl.obolibrary.org/obo/HP_0100001,,,Q1077603,,
1393,Ubenimex,EU/3/16/1638,Treatment of pulmonary arterial hypertension,Eiger Biopharmaceuticals Europe Limited,21/03/2016,,Q27075116,pulmonary arterial hypertension,,http://purl.obolibrary.org/obo/HP_0002092,http://www.orpha.net/ORDO/Orphanet_182090,,,,
1394,Ubiquinol,EU/3/16/1765,Treatment of primary coenzyme Q10 deficiency syndrome,Centro de Investigación Biomédica en Red (CIBER),14/10/2016,,Q411963,primary coenzyme q10 deficiency syndrome,,,,,,,
1395,Udenafil,EU/3/16/1807,Treatment of functional single ventricle congenital heart disease,Mapi Ireland Limited,12/12/2016,,Q4815980,functional single ventricle congenital heart disease,,,,,,,
1396,Ulinastatin,EU/3/14/1318,Treatment of acute pancreatitis,BSV BioScience GmbH,22/08/2014,,,acute pancreatitis,http://purl.obolibrary.org/obo/DOID_2913,http://purl.obolibrary.org/obo/HP_0001735,,,Q854573,,
1397,Ulocuplumab,EU/3/15/1445,Treatment of acute myeloid leukaemia,Bristol-Myers Squibb Pharma EEIG,12/02/2015,,Q21098907,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1398,Vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions,EU/3/16/1791,Treatment of ovarian cancer,Dr Ulrich Granzer,18/11/2016,,,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1399,Vaccinia GM-CSF/TK-deactivated virus,EU/3/09/700,Treatment of hepatocellular carcinoma,Transgene S.A.,26/11/2009,,,hepatocellular carcinoma,http://purl.obolibrary.org/obo/DOID_684,http://purl.obolibrary.org/obo/HP_0001402,http://www.orpha.net/ORDO/Orphanet_88673,D006528,Q1148337,,Q1148337
1400,Valproic Acid,EU/3/16/1734,Treatment of McArdle&#8217;s disease,Vall d'Hebron Institute of Research,29/08/2016,,Q240642,mcardles disease,http://purl.obolibrary.org/obo/DOID_2746,,,D006012,Q787751,,Q787751
1401,Valproic acid,EU/3/16/1792,Treatment of diffuse large B-cell lymphoma,Valcuria AB,18/11/2016,,Q240642,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1402,Variant of recombinant human fibroblast growth factor 19,EU/3/14/1329,Treatment of primary biliary cirrhosis,Diamond BioPharm Limited,22/08/2014,,,primary biliary cirrhosis,http://purl.obolibrary.org/obo/DOID_12236,http://purl.obolibrary.org/obo/HP_0002613,http://www.orpha.net/ORDO/Orphanet_186,D008105,Q1072420,Q1072420,Q1072420
1403,Variant of recombinant human fibroblast growth factor 19,EU/3/15/1584,Treatment of primary sclerosing cholangitis,Diamond BioPharm Limited,14/12/2015,,,primary sclerosing cholangitis,http://purl.obolibrary.org/obo/DOID_0060643,,http://www.orpha.net/ORDO/Orphanet_171,D015209,Q1058608,,Q18554727
1404,Vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar,EU/3/04/201,Prevention of stenosis in synthetic grafts used in haemodialysis,Finvector Vision Therapies Limited,08/06/2004,,Q27264888,stenosis in synthetic grafts used in hemodialysis,,,,,,,
1405,Vasoactive Intestinal Peptide,EU/3/03/173,Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,mondoBIOTECH Laboratories AG,22/12/2003,,,pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension,,,,,,,
1406,"Vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gene under the control of the human thyroxine binding globulin promoter",EU/3/14/1326,Treatment of mitochondrial neurogastrointestinal encephalomyopathy,Vall d'Hebron Institute of Research,22/08/2014,,,mitochondrial neurogastrointestinal encephalomyopathy,,,http://www.orpha.net/ORDO/Orphanet_298,,,,
1407,Velaglucerase alfa,EU/3/10/752,Treatment of Gaucher disease,Shire Pharmaceuticals Ireland Limited,09/06/2010,VPRIVEU/1/10/64630/08/2010,Q3492447,gaucher disease,http://purl.obolibrary.org/obo/DOID_1926,,http://www.orpha.net/ORDO/Orphanet_355,D005776,Q861645,Q861645,Q861645
1408,Veliparib,EU/3/10/830,Treatment of ovarian cancer,AbbVie Ltd,17/12/2010,,Q7919041,ovarian cancer,http://purl.obolibrary.org/obo/DOID_2394,,http://www.orpha.net/ORDO/Orphanet_213500,D010051,Q172341,,Q172341
1409,Veltuzumab,EU/3/09/713,Treatment of chronic lymphocytic leukaemia,Immunomedics GmbH,29/01/2010,,Q4009438,chronic lymphocytic leukemia,http://purl.obolibrary.org/obo/DOID_1040,http://purl.obolibrary.org/obo/HP_0005550,,D015451,Q1088156,,Q1088156
1410,Vemurafenib,EU/3/16/1670,Treatment of Langerhans&#8217; cell histiocytosis,Groupe d’étude des histiocytoses,30/05/2016,,Q423111,langerhans cell histiocytosis,,,http://www.orpha.net/ORDO/Orphanet_389,D006646,,,Q6533637
1411,Venetoclax,EU/3/16/1617,Treatment of acute myeloid leukaemia,AbbVie Ltd,17/02/2016,,Q23671272,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1412,Venetoclax,EU/3/16/1766,Treatment of diffuse large B-cell lymphoma,AbbVie Ltd,14/10/2016,,Q23671272,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1413,Venetoclax,EU/3/16/1767,Treatment of multiple myeloma,AbbVie Ltd,14/10/2016,,Q23671272,multiple myeloma,http://purl.obolibrary.org/obo/DOID_9538,http://purl.obolibrary.org/obo/HP_0006775,http://www.orpha.net/ORDO/Orphanet_29073,D009101,Q467635,,Q467635
1414,Vincristine sulphate liposomes,EU/3/08/555,Treatment of acute lymphoblastic leukaemia,NDA Regulatory Science Ltd,08/07/2008,,,acute lymphoblastic leukemia,http://purl.obolibrary.org/obo/DOID_9952,http://purl.obolibrary.org/obo/HP_0006721,http://www.orpha.net/ORDO/Orphanet_513,D054198,Q180664,Q180664,Q6708277
1415,Viral vector containing DNA encoding the human SMN protein,EU/3/11/876,Treatment of 5q spinal muscular atrophy,University of Sheffield,21/06/2011,,,5q spinal muscular atrophy,,,,,,,
1416,Voclosporin,EU/3/12/1085,Treatment of non-infectious uveitis,Granzer Regulatory Consulting & Services,06/12/2012,,Q7939256,noninfectios uveitis,,,,,,,
1417,Volanesorsen sodium,EU/3/16/1711,Treatment of familial partial lipodystrophy,Ionis USA Limited,14/07/2016,,Q27265010,familial partial lipodystrophy,http://purl.obolibrary.org/obo/DOID_0050440,,http://www.orpha.net/ORDO/Orphanet_98306,D052496,Q5432945,Q5432945,Q5432945
1418,Volasertib,EU/3/14/1255,Treatment of acute myeloid leukaemia,Boehringer Ingelheim International GmbH,26/03/2014,,Q7939986,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1419,Vosaroxin,EU/3/12/990,Treatment of acute myeloid leukaemia,Sunesis Europe Ltd,26/04/2012,,Q18395775,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1420,Xenon,EU/3/15/1483,Treatment of perinatal asphyxia,Neuroprotexeon Ltd,24/04/2015,,Q1106,perinatal asphyxia,,,,,,,
1421,Xenon,EU/3/16/1768,Treatment of ischaemia reperfusion injury associated with cardiac arrest,Neuroprotexeon Ltd,14/10/2016,,Q1106,ischemia reperfusion injury associated with cardiac arrest,,,,,,,
1422,Yttrium (90Y) antiferritin polyclonal antibodies,EU/3/03/162,Treatment of Hodgkin lymphoma,Mablife,02/10/2003,,,hodgkin lymphoma,http://purl.obolibrary.org/obo/DOID_8567,http://purl.obolibrary.org/obo/HP_0012189,http://www.orpha.net/ORDO/Orphanet_98293,D006689,Q209369,Q209369,Q18557991
1423,Yttrium (90Y) edotreotide,EU/3/08/589,Treatment of gastro-entero-pancreatic neuroendocrine tumours,Molecular Insight Limited,04/12/2008,,,gastroenteropancreatic neuroendocrine tumors,,,,,,,
1424,Yttrium (90Y)-DOTA-radiolabelled humanized monoclonal antibody against mucin 1,EU/3/08/608,Treatment of pancreatic cancer,Immunomedics GmbH,06/02/2009,,,pancreatic cancer,http://purl.obolibrary.org/obo/DOID_1793,http://purl.obolibrary.org/obo/HP_0002894,,D010190,Q212961,,Q212961
1425,Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10,EU/3/12/994,Treatment of soft tissue sarcoma,"Laboratoires OncoTherapy Science France, S.A.R.L",25/05/2012,,,soft tissue sarcoma,,http://purl.obolibrary.org/obo/HP_0030448,http://www.orpha.net/ORDO/Orphanet_3394,D012509,,,Q18975788
1426,"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide",EU/3/14/1313,Treatment of acute myeloid leukaemia,Karyopharm Europe GmbH,22/08/2014,,,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
1427,"(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide",EU/3/14/1317,Treatment of diffuse large B-cell lymphoma,Karyopharm Europe GmbH,22/08/2014,,,diffuse large bcell lymphoma,http://purl.obolibrary.org/obo/DOID_0050745,,http://www.orpha.net/ORDO/Orphanet_544,,Q2626074,,
1428,Zanolimumab,EU/3/07/438,"Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",TenX Biopharma Ltd,20/03/2007,,Q8066254,"peripheral tcell lymphoma (nodal, other extranodal and leukemic/disseminated)",,,,,,,
1429,Zinc gluconate,EU/3/16/1793,Treatment of facioscapulohumeral muscular dystrophy,Université de Montpellier,18/11/2016,,Q3822815,facioscapulohumeral muscular dystrophy,http://purl.obolibrary.org/obo/DOID_11727,,http://www.orpha.net/ORDO/Orphanet_269,D020391,Q1399182,,Q1399182
1430,Zoledronic acid,EU/3/13/1192,Treatment of complex regional pain syndrome,Axsome Therapeutics Limited,07/10/2013,,Q218507,complex regional pain syndrome,http://purl.obolibrary.org/obo/DOID_3223,,http://www.orpha.net/ORDO/Orphanet_83452,,Q1066311,,
1431,Zoledronic acid,EU/3/16/1735,Treatment of glioma,Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A.,29/08/2016,,Q218507,glioma,http://purl.obolibrary.org/obo/DOID_3070,http://purl.obolibrary.org/obo/HP_0009733,http://www.orpha.net/ORDO/Orphanet_182067,D005910,Q1365309,Q1365309,Q18556612
1432,Zosuquidar trihydrochloride,EU/3/06/355,Treatment of acute myeloid leukaemia,"Kanisa Europe Limited, Mofo Notices Limited, C/Morrison & Foerster MNP",17/02/2006,,Q27269191,acute myeloid leukemia,http://purl.obolibrary.org/obo/DOID_9119,http://purl.obolibrary.org/obo/HP_0004808,http://www.orpha.net/ORDO/Orphanet_519,D015470,Q264118,,Q264118
